Cover Page for Protocol 
Sponsor name:  [CONTACT_3454] A/S 
NCT number [STUDY_ID_REMOVED] 
Sponsor trial ID: NN1218-4113 
Official title of study: Efficacy and Safety of Fast-acting Insulin Aspart Compared to 
NovoRapidÂ® both in Combination with Insulin Degludec with 
or without Metformin in Adu lts with Type 2 Diabetes  
(onsetÂ® 9) 
Document date: 20 June 2019 
/LQN
/LQN/LQN
/LQN
/LQN
/LQN
/LQN/LVWRIFRQWHQWV
3URWRFROYHUVLRQ  
3URWRFROYHUVLRQ  
$SSHQGL[$ 9HUVLRQ  
$SSHQGL[$ 9HUVLRQ  
$WWDFKPHQW,DQG,,  
3URWRFRODPHQGPHQW  
3URWRFRODPHQGPHQW  &21),'(17,$/'DWH 1RYR1RUGLVN
9HUVLRQ
6WDWXV)DVWDFWLQJLQVXOLQDVSDUW
7ULDO,'11&OLQLFDO7ULDO5HSRUW
$SSHQGL[-XQH

)LQDO
3URWRFRODQGSURWRFRODPHQGPHQWVCONFIDENTIAL
 
 
 
 
 
Redacted protocol 
Includes redaction of personal identifiable information only. 
 
 
 
. 
 
 
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 1 of 113
Protocol
Trial ID:NN1218-[ADDRESS_1187224]-acting Insulin Aspart Compared to 
NovoRapidÂ®both in Combination with Insulin Degludec with or 
without Metformin in Adults with Type 2 Diabetes (onsetÂ®9)
Trial phase: 3b
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187225] of abbreviations.......................................................................................................... ...............................6
1 Summary....................................................................................................................... .............................8
2 Flow chart .................................................................................................................... ............................11
3 Background information and rationale for the trial............................................................................ 14
3.1 Background information...................................................................................................... ........14
3.1.1 Therapeutic Area........................................................................................................14
3.1.2 NovoRapidÂ® (Insulin aspart) ......................................................................................[ADDRESS_1187226]-acting insulin aspart ...........................................................................................15
3.1.4 Insulin degludec.........................................................................................................1 6
3.2 Rationale for the trial ..................................................................................................... ..............17
4 Objectives and endpoints...................................................................................................... ..................18
4.1 Objectives .................................................................................................................. ..................18
4.2 Endpoints ................................................................................................................... ..................18
4.2.1 Primary endpoint........................................................................................................18
4.2.2 Secondary endpoints..................................................................................................18
[IP_ADDRESS] Confirmatory seconda ry endpoints .....................................................18
[IP_ADDRESS] Supportive seconda ry endpoints..........................................................[ADDRESS_1187227] replacement......................................................................................................... ............29
6.9 Rationale for trial population.............................................................................................. .........29
7 Milestones.................................................................................................................... .............................30CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 3 of 113
8 Methods and a ssessments ....................................................................................................... ................31
8.1 Visit procedures ............................................................................................................ ...............31
8.1.1 Screening (Visit 1).....................................................................................................31
8.1.2 Run-in .................................................................................................................... ....32
8.1.3 Randomisation ...........................................................................................................33
8.1.4 Phone contacts ...........................................................................................................3 3
8.1.5 Fasting visits ............................................................................................................ ..33
8.1.6 Rescheduled visits......................................................................................................33
8.1.7 End of treatment.........................................................................................................3 3
8.1.8 Follow-up period........................................................................................................34
8.1.9 Premature discontinuation of trial products...............................................................34
8.1.10 Withdrawal from trial ................................................................................................36
[IP_ADDRESS] Lost to follow-up.................................................................................[ADDRESS_1187228] related infor mation/assessments ..................................................................................... 37
8.2.1 Demography...............................................................................................................3 7
8.2.2 Diabetes history and diabetes complications .............................................................38
8.2.3 Hypoglycaemia una wareness.....................................................................................38
8.2.4 Concomitant illness a nd medical history ...................................................................38
8.2.5 Concomitant medication............................................................................................39
8.2.6 Concomitant medication (diabetes) ...........................................................................[ADDRESS_1187229]................................................................................................................. ....40
8.3.2 Self-measured plasma glucose...................................................................................44
8.3.3 Insulin dose.............................................................................................................. ..46
8.4 Safety assessments........................................................................................................... ............46
8.4.1 Adverse events...........................................................................................................4 6
[IP_ADDRESS] Medication error..................................................................................47
[IP_ADDRESS] Adverse events requiring additional data collection ...........................47
8.4.2 Hypoglycaemic epi[INVESTIGATOR_1841] ...........................................................................................48
8.4.3 Eye examination ........................................................................................................51
8.4.4 Electrocardiogram â€“ [ADDRESS_1187230] compliance.......................................................................................................... ............57
9 Trial supplies ................................................................................................................ ...........................58
9.1 Trial products.............................................................................................................. .................58CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 4 of 113
9.2 Labelling ................................................................................................................... ...................58
9.3 Storage ..................................................................................................................... ....................59
9.4 Drug accountability and destruction ......................................................................................... ...59
9.5 Auxiliary supplies.......................................................................................................... ..............60
10 Interactive voice/web response system ........................................................................................ ..........61
11 Randomisation procedure and b reaking of blinded codes ..................................................................62
11.1 Breaking of blinded codes .................................................................................................. .........62
12 Adverse events, technical comp laints and pregnancies .......................................................................63
12.1 Definitions ................................................................................................................ ...................63
12.1.1 Adverse event ............................................................................................................ 63
12.1.2 Serious adverse event.................................................................................................64
12.1.3 Non-serious adverse event .........................................................................................65
12.1.4 Medication errors.......................................................................................................6 5
12.1.5 Adverse events requiring additional data collection..................................................65
12.1.6 Technical complaints .................................................................................................66
12.2 Reporting of adverse events................................................................................................ .........66
12.3 Follow-up of adverse events ................................................................................................ ........68
12.4 Technical complaints and tec hnical complaint samples ..............................................................69
12.4.1 Reporting of technical complaints .............................................................................69
12.4.2 Collection, storage and shipment of technical complaint samples ............................70
12.5 Pregnancies in female subjects ............................................................................................. .......71
12.6 Precautions and/or overdose ................................................................................................ ........72
12.7 Committees related to safety............................................................................................... .........73
12.7.1 Novo Nordisk sa fety committee ................................................................................73
13 Case report forms............................................................................................................ ........................74
13.1 Corrections to cas e report forms........................................................................................... .......74
13.2 Case report form flow...................................................................................................... ............75
14 Monitoring procedures ........................................................................................................ ...................75
15 Data management.............................................................................................................. ......................76
16 Computerised systems......................................................................................................... ....................76
17 Statistical considerations ................................................................................................... .....................78
17.1 Sample size calculation.................................................................................................... ............80
17.2 Definition of analysis sets................................................................................................ ............82
17.3 Primary endpoint........................................................................................................... ...............82
17.4 Secondary endpoints........................................................................................................ ............86
17.4.1 Confirmatory sec ondary endpoints............................................................................86
17.4.2 Supportive secondary endpoints ................................................................................88
[IP_ADDRESS] Efficacy endpoints...............................................................................88
[IP_ADDRESS] Safety endpoints ..................................................................................92
18 Ethics ....................................................................................................................... .................................98
18.1 Benefit-risk assessment of the trial....................................................................................... .......98
18.2 Informed consent ........................................................................................................... ............100
18.3 Data handling.............................................................................................................. ...............101
18.4 Information to sub jects during trial....................................................................................... .....101CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 5 of 113
18.5 Premature termination of the trial and/or trial site.....................................................................10 1
19 Protocol compliance.......................................................................................................... ....................102
19.1 Protocol deviations ........................................................................................................ ............102
19.2 Prevention of missing data................................................................................................. ........102
20 Audits and inspections ....................................................................................................... ...................103
21 Critical documents ........................................................................................................... .....................103
22 Responsibilities ............................................................................................................. .........................104
23 Reports and publications..................................................................................................... .................106
23.1 Communication of results................................................................................................... .......106
23.2 Investigator access to data and review of results .......................................................................107
24 Retention of clinical trial documentation.................................................................................... ........108
24.1 Retention of clinical trial documentation.................................................................................. .108
25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities............[ADDRESS_1187231] of key staff and relevant departments, if applicable for the individual country
Table of Figures
Page
Figure 5â€“1 Trial Design. ........................................................................................................ ...................21
Figure 12â€“1 Reporting of AEs.................................................................................................... ................67
Figure 17â€“1 Novo Nordisk classification of hypoglycaemia......................................................................94
Figure 17â€“2 ADA classification of hypoglycaemia................................................................................. ...95
Table of Tables
Page
Table 8â€“[ADDRESS_1187232] schedule.................................................................................................... ...............42
Table 8â€“2 7-point SMPG profiles with  additional 9-point SMPG profile...............................................45
Table 9â€“1 Trial products........................................................................................................ ..................58
Table 9â€“2 Storage conditions .................................................................................................... ..............59
Table 17â€“1 Specifications assumed  for sample size calculations..............................................................81
Table 17â€“2 Sensitivity of sample size to power .................................................................................. ......81CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187233] aspartate aminotransferase
BG Blood glucose
CRF case report form
DUNdispensing unit number
ECG electrocardiogram
eCRF electronic case report form
eDiary electronic diary FAS full analysis setFDA U.S. Food and Drug AdministrationFPG fasting plasma glucoseGCP Good Clinical PracticeGLP-1 glucagon-like peptide-1HbA
1c glycosylated haemoglobin
IB Investigatorâ€™s BrochureICH International Conference on 
Harmonisation of Technical 
Requirements for Registration of 
Pharmaceuticals for Human Use
IEC independent ethics committeeCONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187234]
IWRSinteractive voice/web response 
system
LPLV last patient last visit
NIMPnon-investigational medicinal 
product
OAD oral antidiabetic drug
PG plasma glucose
PPG postprandial glucose
PP per protocolSAE serious adverse event
SmPC summary of product characteristics
SMPG self-measured plasma glucose
S[LOCATION_003]Rsuspected unexpected serious adverse 
reaction
T1DM Type 1 diabetes mellitusT2DM Type 2 diabetes mellitus
TEAE Treatment Emergent Adverse Event 
TMM Trial Materials Manual
UTN Universal Trial NumberCONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 8 of 113
1 Summary
Objective(s) and endpoint(s):
Primary objective
To confirm the effect in terms of glycaemic control of treatment with fast-acting insulin aspart 
compared to NovoRapidÂ®both in combination with insulin degludec with or without metformin in 
adults with type [ADDRESS_1187235]-acting insulin aspart compared to NovoRapidÂ®both in combination 
with insulin degludec with or without metformin in adults with type 2 diabetes mellitus treated with 
a basal-bolus regimen in terms of:
!Postprandial glucose regulation 
!Overall glycaemic control 
!Postprandial glucose excursions 
To compare the safety of fast-acting insulin aspart to NovoRapidÂ®both in combination with insulin 
degludec with or without metformin in adults with type 2 diabetes mellitus treated with a basal-
bolus regimen.
Primary endpoint
Change from baseline in HbA 1c16 weeks after randomisation
Key secondary endpoints
Confirmatory secondary endpoints:
!Change from baseline in 1-hour postprandial glucose increment 16 weeks after 
randomisation (meal test)
!Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation
Trial design:
This is a phase 3b, 16-week, multicentre, multinational, 1:[ADDRESS_1187236]-acting insulin aspart to NovoRapidÂ®both in combination with insulin degludec with 
or without metformin in subjects with type 2 diabetes mellitus treated with a basal-bolus regimen. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187237]-acting insulin aspart and mealtime 
NovoRapidÂ®.
Trial population:
A total of 1803 subjects with Type 2 diabetes mellitus are planned to be screened and 1072 are 
planned to be randomised.
Key inclusion criteria:
!Male or female, age â‰¥ 18 years at the time of signing informed consent.
!Diagnosed with type 2 diabetes mellitus â‰¥ 10 years prior to screening (Visit 1).
!Treated with a basal-bolus insulin regimen â‰¥ 1 year prior to the day of screening (Visit 1). A 
basal-bolus insulin regimen is defined as basal insulin once or twice daily and bolus insulin 
analogue taken with meals at least 3 times daily. Treatment with premixed insulin or soluble 
insulin combination is not considered a basal-bolus regimen.
!Treated with or without oral antidiabetic drugs including extended release formulations. 
HbA 1c7.0-10.0% (both inclusive) as assessed by [CONTACT_21922] (Visit 1).
Key exclusion criteria:
!Any of the following: myocardial infarction, stroke, hospi[INVESTIGATOR_826623] 180 days prior to the day of screening (Visit 1). 
!Subjects presently classified as being in [LOCATION_001] Heart Association (NYHA) Class IV. 
!Planned coronary, carotid or peripheral artery revascularisation known on the day of 
screening (Visit 1).
!Treatment with injectable GLP-1 receptor agonists in a period of 90 days prior to screening 
(Visit 1). 
!Anticipated initiation or change in concomitant medications (for more than 14 consecutive 
days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid 
hormones, or corticosteroids).
Randomisation criterion:
!HbA 1câ‰¤ 9.0% measured by [CONTACT_23258] 13 (week -1).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 10 of 113
Key Assessments:
!HbA 1c
!Postprandial glucose increment (meal test)
!1,5-anhydroglucitol 
!Hypoglycaemic epi[INVESTIGATOR_1841]
!Adverse events
Trial product(s):
Investigational medicinal products:
!Test products: 
oFast-acting insulin aspart, 100 U/mL solution for subcutaneous injection, 3 mL 
PDS290 pen injector (blinded) 
oInsulin degludec, 100U/mL solution for subcutaneous injection, 3 mL PDS290 pen 
injector 
!Reference therapy: 
oInsulin aspart (NovoRapidÂ®), 100 U/mL solution for subcutaneous injection, 3 mL 
PDS290 pen injector (blinded)
Other medicinal products: 
!Rapid acting insulin analogues (NovoRapidÂ®or marketed formulations of insulin lispro or 
insulin glulisine) during run-in period
!Metformin, tablets for oral useCONFIDENTIAL
Protocol UTN: U1111-1180-0636 Date: 28 March 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN1218-[ADDRESS_1187238] no.: 2016-000878-38 Version: 2.0 Page: [ADDRESS_1187239]
End of treatment
Premature 
discontinuation
Follow-up 1
Follow-up 2
Visit (V)
Phone contact (P)V1 V2P3
P4V5P6
P7
P8V9P10
P11
P12V13 V14 P15 V16 P17 V18P19
P20
P21V22P23
P24
P25V26P27
P28
P29V30 V30A V31 P32
Time of visit (weeks) -14 -12-11
-10-9-8
-7
-6-5-4
-3
-2-1 0 1 2 3 45
6
789
10
111213
14
1516+7 
days+30
days
Visit window (days) +10 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 0 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 +10 +[ADDRESS_1187240] RELATED INFO/ASSESSMENTS
Informed consent 18.2 X
In/exclusion criteria 6.[ADDRESS_1187241] 8.3.1 X X X
4-point profile (SMPG) 8.3.2 X XXXXXX X X X X X X X X X X X X
7-9-7-point profile (SMPG) 8.3.2 X X X X
1,5-anhydroglucitol 8.5.1 X X X X X X
Fasting plasma glucose 8.5.1 X X X X
Protocol UTN: U1111-1180-0636 Date: 28 March 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN1218-[ADDRESS_1187242] no.: 2016-000878-38 Version: 2.0 Page: [ADDRESS_1187243]
End of treatment
Premature 
discontinuation
Follow-up 1
Follow-up 2
Visit (V)
Phone contact (P)V1 V2P3
P4V5P6
P7
P8V9P10
P11
P12V13 V14 P15 V16 P17 V18P19
P20
P21V22P23
P24
P25V26P27
P28
P29V30 V30A V31 P32
Time of visit (weeks) -14 -12-11
-10-9-8
-7
-6-5-4
-3
-2-1 0 1 2 3 45
6
789
10
111213
14
1516+7 
days+30
days
Visit window (days) +10 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 0 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 +10 +5
HbA 1c 8.5.1 X XXX X X X X X X
Fasting C-peptide 8.5.1 X
Lipi[INVESTIGATOR_805] 8.5.1 X X X X X
SAFETY
Adverse events8.4.1 , 
12XXXXXXXX X X X X X XXX XXXX X X
Injection site reactions [IP_ADDRESS] XXXXXXX X X X X X XXX XXXX X
Hypoglycaemic epi[INVESTIGATOR_1841] 8.4.[ADDRESS_1187244] 8.5.2 X X X X
TRIAL MATERIAL
Dispensing visit 9.4 X XXX X X X X X
New (prescribed) dose of trial insulin 8.3.3 X XXXX X X X X X X X X X X X X
Dosing (Start/stop date of trial insulin) 8.3.3 X X X X X
Insulin dose of basal and bolus insulin each day 8.3.3 X XXXXXX X X X X X X X X X X X X
Drug accountability 9.4 X XXX X X X X X X X
Protocol UTN: U1111-1180-0636 Date: 28 March 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN1218-[ADDRESS_1187245] no.: 2016-000878-38 Version: 2.0 Page: [ADDRESS_1187246]
End of treatment
Premature 
discontinuation
Follow-up 1
Follow-up 2
Visit (V)
Phone contact (P)V1 V2P3
P4V5P6
P7
P8V9P10
P11
P12V13 V14 P15 V16 P17 V18P19
P20
P21V22P23
P24
P25V26P27
P28
P29V30 V30A V31 P32
Time of visit (weeks) -14 -12-11
-10-9-8
-7
-6-5-4
-3
-2-1 0 1 2 3 45
6
789
10
111213
14
1516+7 
days+30
days
Visit window (days) +10 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 0 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 +10 +[ADDRESS_1187247] mealtime insulin 
dose adjustment guide8.3.3 X
eDiary collection 8.6.3 X
End of treatment 8.1.7 X X
End of trial X
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187248] of 
the clinical trial at a trial site.
3.1 Background information
Improvement in long-term glucose control, as obtained with intensified insulin therapy, may reduce 
the incidence of complications and delay the progression of existing complications in people with 
Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM).3, 4Postprandial 
hyperglycaemia contributes significantly to the glycosylated haemoglobin (HbA 1c) level and its 
control is thus essential for achieving the HbA 1ctarget level.5Postprandial hyperglycaemia is 
associated with increased risk of micro- and macro-vascular complications.6Lowering of 
postprandial hyperglycaemia may reduce the progression of atherosclerosis and cardiovascular 
events in patients with T2DM.[ADDRESS_1187249] possible extent. For that purpose, rapid-acting insulin analogues were developed 
to more effectively control the postprandial glucose (PPG) excursions than subcutaneously injected 
human regular insulin, primarily through offering a faster onset and shorter duration of action.
[ADDRESS_1187250] within prandial insulin therapy for people with diabetes. The current insulin analogues are not able to match the speed of the normal physiological postmeal insulin 
secretion, leading to suboptimal control of blood glucose (BG), and exogenous insulin with a faster 
glucose lowering effect is needed for tighter PPG control. In addition, a faster glucose lowering 
effect is also likely to offer greater flexibility in the time of dosing around meals thus increasing 
convenience for the patients and may allow the patients to better match the insulin taken to the 
meal.
9
For an assessment of benefits and risks of the trial, see Section 18.1
3.1.1 Therapeutic Area
Due to the progressive nature of T2DM, many patients are likely to be candidates for intensified 
insulin therapy. Prandial insulin supplementation is recommended by [CONTACT_853249] (EASD)/American Diabetes Association (ADA) guidelines10for treatment 
intensification in patients with T2DM who do not reach HbA 1ctarget below 7.0% on oral 
antidiabetic drugs (OADs) and basal insulin alone. The recommendation is a stepwise addition of 
bolus insulin when significant PPG excursions occur. A trial investigating step-wise addition of 
bolus insulin (basal-plus regimen) showed that around 75% of patients enrolled in the trial needed CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187251] 
of the total prandial insulin dose is delivered with each meal in the majority of patients achieving 
HbA1c â‰¤7.0%.12When used as part of a basal-bolus regimen in patients with T2DM who had 
previously received other insulin and/or OAD regimens, insulin aspart in combination with insulin 
degludec was a safe, well tolerated and effective treatment associated with clinically relevant 
reductions in hyperglycaemia.13
3.1.2 NovoRapidÂ® (Insulin aspart)
Insulin aspart is currently marketed worldwide as NovoRapidÂ®(in US it is NovoLogÂ®) and is a 
rapid-acting insulin analogue indicated for the treatment of diabetes. In the remainder of this 
protocol the name [CONTACT_853319]Â®will be applied for the marketed formulation of insulin aspart.
Insulin aspart is homologous to human insulin, with the exception of the substitution of proline with 
aspartic acid at position B28. The rapid action of insulin aspart is related to a weakened tendency of 
the insulin molecules to self-associate due to this modification and thereby [CONTACT_853250]. Compared with human insulin, NovoRapidÂ®
has a faster onset and a shorter duration of action, resulting in superior postmeal glucose control by [CONTACT_853251] a meal, both in subjects with T1DM
3, 14, 15and 
in subjects with T2DM.16-18This also allows NovoRapidÂ®to be injected immediately before a meal, 
in contrast to regular human insulin which should be injected 30 minutes prior to the meal.
For further details, please refer to the current version of the NovoRapidÂ®EU Summary of Product 
Characteristics19(SmPC) and the U.S. NovoLogÂ®Label Information20.
3.1.[ADDRESS_1187252]-acting insulin aspart (faster aspart) (markedet as FiaspÂ®) is insulin aspart in a new formulation. 
Faster aspart is being developed with the objective of achieving an increased early absorption of 
insulin aspart compared to NovoRapidÂ®thereby [CONTACT_1541] a faster insulin action. Faster aspart aims 
at approaching the physiological prandial insulin secretion pattern better than currently available 
treatment and thereby [CONTACT_853252] a better PPG
control and increased flexibility in the time of dosing around meals compared with NovoRapidÂ®. 
Results from clinical pharmacology trials in adults comparing pharmacokinetic and pharmacodynamic properties of faster aspart and NovoRapid
Â®have shown that faster aspart resulted 
in an earlier onset of appearance and a greater early exposure to insulin aspart than NovoRapidÂ®in 
subjects with T1DM, with the largest difference found within the first [ADDRESS_1187253] than NovoRapidÂ®, but no 
statistically significant difference between faster aspart and NovoRapidÂ®in total glucose-lowering 
effect.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 16 of 113
In a therapeutic confirmatory basal-bolus trial in adult subjects with T1DM, faster aspart taken with 
the meal in combination with LevemirÂ®effectively improved glycaemic control and the reduction in 
HbA 1cwas statistically significantly larger than with NovoRapidÂ®. Mealtime faster aspart provided 
superior PPG control compared to NovoRapidÂ®based on 2-hour PPG increment during a meal test. 
A statistically significant difference was also demonstrated for 1-hour PPG increment (meal test) in 
favour of mealtime faster aspart. No statistically significant difference was seen in overall rate of 
severe or BG confirmed hypoglycaemic epi[INVESTIGATOR_853201]Â®. 
The rate during the first one hour after start of a meal, constituting a smaller fraction of all severe or 
BG confirmed hypogly caemic epi[INVESTIGATOR_1841], was statistically significantly higher for faster aspart 
compared to NovoRapidÂ®. The overall safety profile for faster aspart and NovoRapidÂ®was similar 
and as expected for insulin aspart.
In a therapeutic confirmatory basal-bolus trial in adult subjects with T2DM, adding and titrating 
mealtime faster aspart in combination with insulin glargine also effectively improved glycaemic 
control and non-inferiority to NovoRapidÂ®regarding HbA 1cchange from baseline was confirmed. A 
statistically significant benefit in 2-hour PPG increment (meal test) could not be confirmed for 
faster aspart compared to NovoRapidÂ®. A statistically significant difference was demonstrated for 
1-hour PPG increment (meal test) in favour of faster aspart compared to NovoRapidÂ®. No 
statistically significant difference was seen in overall rate of severe or BG confirmed 
hypoglycaemic epi[INVESTIGATOR_853202]Â®. The rate during the first two hours 
after start of a meal, constituting a small fraction of all severe or BG confirmed hypoglycaemic 
epi[INVESTIGATOR_1841], was statistically significantly higher for faster aspart compared to NovoRapidÂ®. The 
overall safety profile for faster aspart and NovoRapidÂ®was similar and as expected for insulin 
aspart.
The safety profile of faster aspart is expected to be similar to that of NovoRapidÂ®. The insulin aspart 
molecule has a well-known safety profile based on more than 15 years of clinical experience. 
Compared to NovoRapidÂ®faster aspart contains excipi[INVESTIGATOR_853203] a faster initial 
absorption of insulin aspart following subcutaneous injection. The added excipi[INVESTIGATOR_853204] U.S. Food and Drug Administrationâ€™s (FDA) list for approved drug products for injections, and no toxicological concerns have been predicted from subcutaneous use in humans at the proposed 
concentrations. For further details, please refer to the current version of the Fiasp
Â®SmPC21. If not 
approved in the country of interest detailed information for faster aspart is available in the current edition of the Investigatorâ€™s Brochure (IB)
22and any updates hereof.
At the time of this protocol issuance, faster aspart is approved in EU and Canada among others.
3.1.4 Insulin degludec
Insulin degludec (marketed as TresibaÂ®) is a basal insulin with an ultra-long duration of action for 
once-daily subcutaneous administration at any time of the day, preferably at the same time every CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187254]. The duration of action of insulin degludec is beyond 42 
hours within the therapeutic dose range.
For further details please refer to the current version of the TresibaÂ®SmPC23. If not approved in the 
country of interest detailed information for insulin degludec is available in the current edition and 
any updates of the IB24.
At the time of this protocol issuance, insulin degludec is approved in more than [ADDRESS_1187255] and compare safety of faster aspart compared to 
NovoRapid
Â®both in combination with insulin degludec with or without metformin in subjects with 
T2DM treated with a basal-bolus regimen. This trial will provide new information in subjects with 
T2DM already treated with a basal-bolus regimen as this was not studied in the phase 3a
programme.
In the European Medicines Agency (EMA) and FDA note for guidance on clinical investigation of 
medicinal products for the treatment of diabetes, HbA 1cis considered the most widely accepted 
measure of overall, long-term glucose control. Consequently, HbA 1cwill be included as the primary 
endpoint.25, 26
The trial is intended to confirm that administration of faster aspart gives overall glycaemic control non-inferior to NovoRapid
Â®and to confirm that faster aspart, with its faster onset of action, is
capable of demonstrating superior control of postprandial glucose regulation and excursions as well 
as a greater reduction in HbA 1cin subjects with T2DM.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187256] in terms of glycaemic control of treatment with faster aspart compared to 
NovoRapidÂ®both in combination with insulin degludec with or without metformin in adults with 
T2DM treated with a basal-bolus regimen, using a non-inferiority approach.
Secondary objectives
To confirm superiority of faster aspart compared to NovoRapidÂ®both in combination with insulin 
degludec with or without metformin in adults with T2DM treated with a basal-bolus regimen in 
terms of:
!Postprandial glucose regulation
!Overall glycaemic control 
!Postprandial glucose excursions 
To compare the safety of faster aspart to NovoRapidÂ®both in combination with insulin degludec 
with or without metformin in adults with T2DM treated with a basal-bolus regimen.
4.2 Endpoints
Baseline is defined as randomisation (Visit 14) 
4.2.1 Primary endpoint
Change from baseline in HbA 1c16 weeks after randomisation
4.2.2 Secondary endpoints
[IP_ADDRESS] Confirmatory secondary endpoints
!Change from baseline in 1-hour PPG increment 16 weeks after randomisation (meal test)
!Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisationCONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 19 of 113
[IP_ADDRESS] Supportive secondary endpoints
Supportive secondary efficacy endpoints
!Change from baseline in fasting plasma glucose (FPG) 16 weeks after randomisation
!If a subject achieves HbA 1ctargets 16 weeks after randomisation:
oHbA1c < 7.0% 
oHbA1c < 7.0% without severe hypoglycaemia
!Change from baseline in 30- minutes, 1- hour,  2- hour, 3- hour and 4- hour PPG and 30-
minutes, 2- hour, 3- hour and 4- hour PPG increment 16 weeks after randomisation (meal 
test)
!Change from baseline in endpoints derived from the 7-9-7-point self-measured plasma 
glucose (SMPG) profile 16 weeks after randomisation:
oMean of the 7-9-7-point profile
oPostprandial glucose and PPG increment (mean, breakfast, lunch, main evening meal)
oFluctuation in 7-9-7-point profile
oChange in the nocturnal SMPG measurements
!If a subject achieves PPG target (overall mean of daily PPG measurements in 7-9-7-point 
SMPG profile) 16 weeks after randomisation:
oOverall PPG (1 hour) â‰¤7.8 mmol/L [140 mg/dL]
oOverall PPG (1 hour) â‰¤7.8 mmol/L [140 mg/dL] without severe hypoglycaemia
!Insulin dose (Units/day and Units/kg/day; total basal, total bolus and individual meal insulin 
dose) 16 weeks after randomisation
!Change from baseline in lipi[INVESTIGATOR_805]-lipoproteins profile 16 weeks after randomisation (total 
cholesterol, high density lipoproteins (HDL) cholesterol, low density lipoproteins (LDL) 
cholesterol)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 20 of 113
Supportive secondary safety endpoints
!Number of treatment emergent adverse events (AEs) during 16 weeks after randomisation
!Number of treatment emergent injection site reactions during 16 weeks after randomisation
!Number of treatment emergent hypoglycaemic epi[INVESTIGATOR_853205] 16 weeks after randomisation
oOverall
oDaytime hypoglycaemic epi[INVESTIGATOR_853206] (00:01-05:59 â€“ inclusive)
oHypoglycaemic epi[INVESTIGATOR_853207] 1, 2, 4 hours and from 2 hours 
(exclusive) to 4 hours (inclusive) after start of meal
!Change from baseline in clinical evaluations 16 weeks after randomisation:
oPhysical examination
oVital signs (diastolic blood pressure, systolic blood pressure and pulse)
oElectrocardiogram 
oFundoscopy/fundus photography
!Change from baseline in central laboratory assessments 16 weeks after randomisation:
oHaematology (erythrocytes, haematocrit, haemoglobin, leucocytes, thrombocytes)
oBiochemistry (alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
albumin, alkaline phosphatase, creatinine, potassium, sodium, total bilirubin)
!Change from baseline in body weight and body mass index 16 weeks after randomisationCONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 21 of 113
5 Trial design
5.1 Type of trial
This is a phase 3b, 16-week, multicentre, multinational, 1:[ADDRESS_1187257] and 
safety of faster aspart to NovoRapidÂ®both in combination with insulin degludec with or without 
metformin in subjects with T2DM treated with a basal-bolus regimen. 
Figure 5â€“1 Trial Design.
The trial design is summarised in Figure 5â€“1 . The total duration of the trial is approximately 34 
weeks divided into the following periods:
!An approximately 2-week screening period
!A 12-week run-in period primarily for optimisation of the basal insulin and subject training
!A 16-week treatment period
!A 30-day follow-up period: FU1; 7 days after end of treatment and FU2; 30 days after end 
of treatment 
The trial includes a screening period followed by [CONTACT_413846]/phone contacts during the trial. At 
Visit 2, all eligible subjects will be enrolled in a 12-week run-in period. After the run-in period, 
subjects eligible for randomisation (HbA 1câ‰¤ 9.0% measured at Visit 13) will be randomised (1:1) to 
receive double blinded treatment with either faster aspart or NovoRapidÂ®both in combination with 
once daily insulin degludec with or without metformin.     -14    -12 weeks                            0                                                            16 weeks +7d+30d   Screening RandomisationFaster aspart + insulin degludec Â± metformin
NovoRapidÂ®+ insulin degludec Â± metformin 
End of 
treatment
Basal titration Bolus titrationBolus insulin analogue + insulin 
degludec Â± metforminFU1   FU2
12-week run-in period 16-week treatment 
periodHbA1câ‰¤9.0 % CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187258] at baseline (Visit 14 before randomisation) and at 
end of treatment (Visit 30). The meal test will be described in more details in section 8.3.[ADDRESS_1187259] a 30-day safety follow-up period.
5.2 Rationale for trial design
The 12-week run-in period has been included to ensure the subjects are being trained in the trial 
procedures and that the basal insulin titration is optimised. A 16-week treatment period is needed to 
obtain valid and adequate efficacy and sa fety data. 
The rational for the simple carbohydrate counting (carbohydrate awareness) is to ensure that 
subjects are able to better control the carbohydrate amount of their meals aiming at a similar 
carbohydrate intake between days as a supplement to the algorithm based titration.
The rationale for the meal test is to evaluate PPG regulation after a standardised meal when 
injecting faster aspart compared to NovoRapidÂ®.
The treat-to-target approach, and thereby [CONTACT_853253], has been chosen in 
order to ensure optimal titration of faster aspart and NovoRapidÂ®.
The 7-day follow-up visit and 30-day follow up contact [CONTACT_853254]-up period.
5.2.1 Rational for choice of non-inferiority margin 
In a recently finalised faster aspart trial (NN1218-4049, data on file) with a bolus insulin naÃ¯ve 
T2DM adult population comparing a basal insulin treatment in addition to metformin to a full basal-
bolus insulin treatment in addition to metformin the estimated treatment effect in change from 
baseline HbA 1cwas - 0.94% [-1.17; -0.72]. In this trial the addition of 3 times daily faster aspart led 
to a reduction in HbA 1cof 1.16% after 18 weeks of treatment. In a similar phase 4 trial27
investigating the stepwise addition of NovoRapidÂ®to a full basal-bolus regimen in bolus naÃ¯ve 
T2DM adults the observed reduction in HbA 1cafter 21 weeks of treatment was 1.15% (data ANA-
3786, data on file) with 3 times daily NovoRapidÂ® added to basal insulin. This gives some 
indication that the effect of NovoRapidÂ®versus placebo would be close to the 0.94% observed in 
trial NN1218-4049. Thus using a non-inferiority margin of 0.4%, one of the suggested margins in 
the FDA guidance26, an improvement of approximately 0.54% would have been preserved using the 
0.4% non-inferiority margin.
5.[ADDRESS_1187260] CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187261] be stopped at Visit 2. For subjects treated with metformin prior to the trial, they should continue with their pre-trial dose of metformin. The dose and dosing frequency of metformin should not be changed at any time during the trial, unless due to safety concerns. Initiation of any other diabetes treatment is not allowed during the screening, run-in or treatment period and must be 
reported (see section 8.2.6 ).This includes metformin for subjects not treated with metformin prior 
to the trial. During the run-in period, the investigator will focus on optimising the basal insulin treatment using a treat-to-target approach following the titration guideline ( Appendix A ). The bolus 
insulin will not be titrated during the run-in period unless the investigator finds it necessary to adjust the bolus insulin for safety reasons. All subjects will receive dietary training regarding simple carbohydrate counting (carbohydrate awareness) in the run-in period.
All subjects should consume 3 main meals (breakfast, lunch and dinner) daily throughout the trial.
In the treatment period, eligible subjects must discontinue their pre-trial bolus insulin analogue and 
will receive double blinded treatment with either faster aspart or NovoRapid
Â®both in combination 
with once daily insulin degludec with or without metformin. The investigator should focus on optimising the bolus insulin treatment following the bolus dosing algorithm as described in the 
titration guideline ( Appendix A ). Surveillance of insulin titration will be performed by [CONTACT_49753].
The maximum duration of treatment will be 28 weeks. No maximum dose is specified. Doses are 
adjusted according to SMPG values ( Appendix A ).
Use of flash glucose monitoring or a real time continuous glucose monitoring system is not allowed 
throughout the trial.
5.[ADDRESS_1187262] and long half-life of insulin 
degludec.
5.5 Rationale for treatment
Based on the currently available pharmacokinetic data on faster aspart, it is anticipated that 
treatment with faster aspart as a mealtime insulin will enable insulin therapy to more closely 
approach a physiologic insulin secretory pattern. Consequently, the PPG excursions may be more 
effectively controlled. For further details, please refer to the current version of the faster aspart 
SmPC21or IB.22CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 24 of 113
NovoRapidÂ®will be used as a comparator to faster aspart in order to compare the effect and safety 
of faster aspart to the currently marketed insulin aspart formulation. As this is a double-blind trial, 
NovoRapidÂ®and faster aspart will be titrated following the same recommendations.
Insulin degludec has been chosen as the basal insulin because it is a once-daily basal insulin and as 
effect and safety has been confirmed in adult subjects. The flat and stable glucose-lowering effect of 
insulin degludec makes it optimal when assessing the properties of bolus insulin (faster aspart 
compared to NovoRapidÂ®).
Combination of insulin treatment with metformin is associated with better glycaemic control, fewer 
hypoglycaemic events, and less weight gain than treatment with insulin alone, therefore metformin 
should be continued when type 2 patients are on insulin therapy.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 25 of 113
6 Trial population
6.1 Number of subjects 
Number of subjects planned to be screened: 1803
Number of subjects planned to be included in the run-in period: 1262
Number of subjects planned to be randomised: 1072
A screening failure rate of approximately 30% and a run-in failure rate of approximately 15% are 
anticipated for this trial.
6.[ADDRESS_1187263] be answered â€œyesâ€. 
1. Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability 
for the trial. 
2. Male or female, age â‰¥ 18 years at the time of signing informed consent.
3. Diagnosed with type 2 diabetes mellitus â‰¥ 10 years prior to screening (Visit 1).
4. Treated with a basal-bolus insulin regimen â‰¥ 1 year prior to the day of screening (Visit 1). A 
basal-bolus insulin regimen is defined as basal insulin once or twice daily and bolus insulin 
analogue taken with meals at least 3 times daily. Treatment with premixed insulin or soluble 
insulin combination is not considered a basal-bolus regimen.
5. Treated with or without oral antidiabetic drugs including extended release formulations. 
6. HbA 1c7.0-10.0% (both inclusive) as assessed by [CONTACT_21922] (Visit 1).
7. Able and willing to adhere to the protocol including performance of SMPG profiles and 
meal test.
8. Able and willing to consume 3 main meals (breakfast, lunch and dinner) daily throughout 
the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187264] be answered â€œnoâ€. 
1. Known or suspected hypersensitivity to trial product(s) or related products.
2. Previous participation in this trial. Participation is defined as signed informed consent. 
3. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measure 
as required by [CONTACT_17993]).
For Bulgaria, Czech Republic, [LOCATION_013], Greece, Italy, Poland, Romania and Spain: The 
following contraceptive measures are considered adequate: 
ocombined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation (oral, transdermal or intravaginal)
oprogestogen-only hormonal contraception associated with inhibition of ovulation
(oral, injectable or implantable)
ointrauterine device
ointrauterine hormone-releasing system
osexual abstinence
ovasectomised partner
odouble barrier method (a combination of male condom with either cap, diaphragm or 
sponge with spermicide)
4. Participation in any clinical trial of an approved or non-approved investigational medicinal 
product within 30 days before screening (Visit 1). Clinical trials do not include non-
interventional studies.
5. Any disorder, except for conditions associated with type 2 diabetes mellitus, which in the 
investigatorâ€™s opi[INVESTIGATOR_36174]â€™s safety or compliance with the protocol.
6. Any of the following: myocardial infarction, stroke, hospi[INVESTIGATOR_826623] 180 days prior to the day of screening (Visit 1). 
7. Subjects presently classified as being in [LOCATION_001] Heart Association (NYHA) Class IV. 
8. Planned coronary, carotid or peripheral artery revascularisation known on the day of 
screening (Visit 1).
9. Inadequately treated blood pressure defined as Grade 3 hypertension or higher (Systolic 
â‰¥180 mmHg or diastolic â‰¥110 mmHg) at screening (Visit 1).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 27 of 113
10. Treatment with injectable GLP-1 receptor agonists in a period of 90 days prior to screening 
(Visit 1). 
11. Anticipated initiation or change in concomitant medications (for more than 14 consecutive 
days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid 
hormones, or corticosteroids).
12. Proliferative retinopathy or maculopathy requiring acute treatment. Verified by [CONTACT_853255] [ADDRESS_1187265] 5 years prior to the day of 
screening (Visit 1). Basal and squamous cell skin cancer and any carcinoma in-situ is 
allowed. 
14. For subjects treated with metformin: Any contraindications or restrictions to use of 
metformin (according to local labelling) at investigatorâ€™s discretion.
6.[ADDRESS_1187266] be withdrawn from the trial during the run-in period if the following applies after 
screening (Visit 1), and before or at randomisation (Visit 14): 
1. Included in the trial in violation of the inclusion and/or exclusion criteria.
2. Pregnancy
3. Intention of becoming pregnant
4. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product.
5. Any of the following: myocardial infarction, stroke, hospi[INVESTIGATOR_853208].
6. Planned coronary, carotid or peripheral artery revascularisation.
7. Any disorder which in the investigatorâ€™s opi[INVESTIGATOR_36174]â€™s safety.
8. Inability or lack of willingness to adhere to the protocol, based on the investigatorâ€™s 
judgement.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187267] be answered â€œyesâ€.
1. HbA 1câ‰¤ 9.0% measured by [CONTACT_23258] 13 (week -1).
6.[ADDRESS_1187268] with the site 
in relation to the trial will be considered as withdrawn from the trial (see Section 6.7).
The subject may be prematurely discontinued from trial products at the discretion of the investigator 
due to a safety concern.
The subject must be prematurely discontinued from trial products if the following applies after 
randomisation:
1. Included in the trial in violation of the inclusion and/or exclusion criteria and/or randomised 
in violation of the randomisation criterion.
2. Pregnancy 
3. Intention of becoming pregnant
4. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product.
See Section 8.1.[ADDRESS_1187269] is considered withdrawn from trial if the following applies before Visit 30:
!Subject is lost to follow up (see Section 8.1.10 ))
!Subject withdraws consent 
!Death
Subjects withdrawing from trial before randomisation are considered screening or run-in failures.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187270] 365 days, but are not optimally controlled as demonstrated by [CONTACT_361996] 1c
â‰¥ 7.0%, and may benefit from intensified insulin titration using a treat-to-target approach. The 
subjects need to have had T2DM for at least [ADDRESS_1187271] been adequately educated and are familiar 
with using the intensive regimen required in this trial. This will also help to avoid including newly 
diagnosed patients that could enter in the metabolic remission period.
Subjects with an HbA 1c> 10% are not included in this trial. This is because the trial protocol 
requires strict adherence and good subject compliance and a likely cause of elevated HbA 1c> 10% 
in a diabetic subject is poor compliance with treatment regimens or an atypi[INVESTIGATOR_853209]. The upper HbA 1climit is also expected to select a population that can achieve adequate 
basal insulin coverage in the 12-week run-in basal insulin titration period. Subjects in good 
glycaemic control defined as HbA 1c<7.0 % may not benefit from this trial and hence the lower cut-
off value has been chosen. Subjects with an HbA 1c> 9% are not eligible to be randomised into the 
treatment period of the trial. This is because the trial protocol requires strict adherence and good 
subject compliance, a likely cause of HbA 1c> 9% after 12-week basal insulin titration period is poor 
compliance with treatment regimens or an atypi[INVESTIGATOR_853210].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 30 of 113
7 Milestones
Planned duration of recruitment period: [ADDRESS_1187272] visit (LPLV).
Recruitment:
The screening and randomisation rate will be followed closely via the interactive voice/web 
response system (IWRS) in order to estimate when to stop screening. All investigators will be 
notified immediately when the recruitment period ends, after which no further subjects may be 
screened and the IWRS will be closed for further screening. All subjects screened during the 
recruitment period and found eligible for randomisation can be randomised within the timelines 
specified in the flow chart (see Section 2).
Trial registration:
Information of the trial will be disclosed at clinicaltrials.gov and novonordisk-trials.com . According 
to the Novo Nordisk Code of Conduct for Clinical Trial Disclosure28, it will also be disclosed 
according to other applicable requirements such as those of the International Committee of Medical 
Journal Editors (ICMJE)29, the FDA Amendment Act (FDAAA)30, European Commission 
Requirements31, 32and other relevant recommendations or regulations. If a subject requests to be 
included in the trial via the Novo Nordisk e-mail contact [CONTACT_36283], Novo Nordisk may 
disclose the investigatorâ€™s contact [CONTACT_18026]. As a result of increasing requirements for 
transparency, some countries require public disclosure of investigator names and their affiliations.
Primary Completion Date is the last assessment of the primary endpoint, and is for this protocol last 
subject first visit + [ADDRESS_1187273] is withdrawn/dropout 
early the Primary Completion Date is the date when the last subject would have completed Visit 30. 
The Primary Completion Date determines the deadline for results disclosure at clinicaltrials.gov
according to FDAAA.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 31 of 113
8 Methods and assessments
8.1 Visit procedures
The following sections describe the assessments and procedures. These are also included in the flow 
chart (see Section 2).
8.1.1 Screening (Visit 1)
Informed consent must be obtained before any trial related activity, see Section 18.2.
All subjects must be provided with a copy of their own signed and dated informed consent form.
Subjects will continue on their current diabetes treatment until start of run-in period (Visit 2) and 
they will not be supplied with any trial products until then.
The investigator must keep a subject screening log, a subject identification code list and a subject 
enrolment log. Only subjects who have signed the informed consent form should be included on the 
logs. The subject screening log and subject enrolment log may be combined in one log.
At screening, subjects will be provided with a card stating that they are participating in a trial and 
giving contact [CONTACT_49761](es) and telephone number(s) of relevant trial site staff. Subjects should be 
instructed to return the card to the investigator at the last trial visit or to destroy the card after the 
last visit.
Each subject will be assigned a unique 6-digit subject number which will remain the same 
throughout the trial. A screening session must be performed in the IWRS.
Screening failures
For screening failures the screening failure form in the electronic case report form (eCRF) must be 
completed with the reason for not continuing in the trial. Serious AEs (SAEs) from screening 
failures must be transcribed by [CONTACT_215546]. Follow-up on SAEs must be carried 
out according to Section 12.
A screening failure session must be made in the IWRS. When data has been monitored and queries 
have been resolved the case book must be signed.
Re-screening is NOT allowed if the subject has failed one of the inclusion, exclusion or 
randomisation criteria, this includes re-sampling if the subject has failed one of the inclusion,
exclusion or randomisation criteria related to laboratory parameters.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187274] not be ticked â€œYesâ€ or â€œNoâ€ in the eCRF before source data is 
available. In case source data is not available â€œResult pendingâ€ must be chosen. This is particularly 
relevant for lab samples and in some cases the ECG (electrocardiogram) and eye examination 
result. The results of all the screening assessments must be available (including central laboratory 
results) and must have been reviewed by [CONTACT_853256]-in 
period.
At start of the run-in period (Visit 2), the subject will receive the basal insulin trial product (Insulin 
degludec). The subjects must be trained in how to handle the insulin pen injectors (see section 
8.6.2 ). Training may be repeated during the trial if necessary. First date of trial product (basal 
insulin) must be recorded in the eCRF.
A run-in dispensing session must be performed in the IWRS. A drug accountability session 
confirming dispensing of allocated trial product should also be performed when dispensing trial 
product.
The BG meter and electronic diary (eDiary) should be provided to the subjects at Visit 2. Subjects 
must be trained in the BG meter and eDiary and complete a practise eDiary training, before the 
eDiary can be used.
Run-in failures
If the subject is not eligible to be randomised (i.e. has met one of the run-in period exclusion 
criteria, has not met the randomisation criterion or withdraw from trial before randomisation) then 
the subject will be considered a run-in failure. Consequently, a run-in failure session must be made 
in the IWRS system and a run-in failure form must be completed in the eCRF together with the 
reason for not continuing in the trial. The last date of trial product must be captured in the eCRF. 
No follow-up visit should take place and no additional assessments are needed.
The eDiary must be returned to the site. For Argentina, Russia, Serbia and Ukraine: The BG meter should also be collected by [CONTACT_1275].
SAEs and non-serious AEs from run-in failures must be recorded by [CONTACT_56276]. 
Follow-up of AEs must be carried out according to section 12.3.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187275] (bolus insulin) must be recorded in the eCRF.
The subject must attend randomisation visit fasting. For definition of fasting, please see section 
8.1.[ADDRESS_1187276] subjects
how to self-titrate (section 8.3.3 and Appendix A ).
8.1.[ADDRESS_1187277] attend the visits specified in the flowchart (section 2) in a fasting condition. 
Fasting is defined as at least eight hours without drink or food intake prior to the visit except for 
water.
Insulin dosing (including basal insulin) and medication which should be taken with or after a meal 
should be withheld until blood sampling has been performed. If a subject attends the visit non-
fasting, then the subjectâ€™s blood samples, meal test and body weight measurement must be re-
scheduled within the visit window and at Visit [ADDRESS_1187278] the actual date of the rescheduled 
assessment (i.e. the actual visit date will differ from the assessment date under the same visit).
8.1.[ADDRESS_1187279] be recorded in eCRF.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187280] be recorded on the concomitant medication (diabetes) form in eCRF, as described 
in section 8.2.6 .
8.1.8 Follow-up period
The follow-up visit 1 (FU1) is a site visit and must take place 7-[ADDRESS_1187281] 2 (FU2) is a phone contact [CONTACT_853257] 30-35 days after the end of 
treatment visit.
Follow-up visit 1
The following data will be collected:
!AEs 
!Concomitant medication
!Current diabetes medication
!Hypoglycaemic epi[INVESTIGATOR_1841]
!Additional information on injection site reactions
Follow-up contact 2
The following data will be collected:
!AEs
!Concomitant medication
!Current diabetes medication
!Hypoglycaemic epi[INVESTIGATOR_1841]
8.1.[ADDRESS_1187282] prematurely discontinues trial products after randomisation (Visit 14), the investigator 
must undertake procedures similar to those for Visit 30 as soon as possible, also called Visit 30A 
(see flowchart section 2). 
Premature discontinuation of trial products must be registered in the eDiary webportal. This must be 
performed at least [ADDRESS_1187283] is switched to. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187284] at the discretion of the investigator. 
The medication should be recorded on the concomitant medication (diabetes) form in the eCRF, as 
described in section 8.2.[ADDRESS_1187285] should also complete the follow-up visits  (FU1 and FU2) [ADDRESS_1187286]. Visit 31 (FU1) can be converted into a phone contact [CONTACT_853258].
In addition, subjects prematurely discontinued from trial products should continue with the per 
protocol planned visits at 4 (Visit 18), 8 (Visit 22), 12 (Visit 26), 16 (Visit 30) weeks after 
randomisation depending on when the subject discontinues trial products. The meal test at Visit 30
should be done with the subjectsâ€™ currently prescribed insulin treatment with the same bolus insulin 
dose as at baseline. 
The following assessments are not applicable for subjects that prematurely discontinue trial 
products: [ADDRESS_1187287]:
!If Visit 30A is within 2 weeks of one of the per protocol planned visits, only Visit 30A 
should be performed
!If any per protocol planned visit and the windows of a follow-up visit are overlappi[INVESTIGATOR_853211], only the per protocol planned visit should be performed
It should be documented in the medical records if subject refuses to attend a visit from Visit 30A 
and onwards.
The eDiary must be returned to the site at the last site visit (Visit 30). 
A subject that permanently discontinues trial product before the End of Treatment visit (V30), will 
be considered to be a treatment non-completer. 
For Argentina, Russia, Serbia and Ukraine: The BG meter should be collected by [CONTACT_853259] (Visit 30).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 36 of 113
eDiary records after premature discontinuation of trial products:
Date, actual clock time and value of the SMPG measurements performed as part of the 7-9-7-point 
profiles on the three consecutive days prior Visit 30A, Visit 22 and Visit 30 will be transferred to 
the eDiary, where each measurement should be assigned to the corresponding time point.
For hypoglycaemic epi[INVESTIGATOR_153555] a reduced amount of information should be recorded from one 
day after Visit 30A and to Visit 30 (see section 8.4.2 ):
8.1.[ADDRESS_1187288] aim to perform the follow up visits (FU1 and FU2) [ADDRESS_1187289] is not obliged to give his/her reason(s) for withdrawing consent, the investigator 
must make a reasonable effort to ascertain the reason(s), while fully respecting the subjectâ€™s rights. 
Where the reasons are obtained, the primary reason for withdrawing consent must be specified in 
the eCRF.
A subject that is withdrawn from trial before the End of Treatment Visit (V30), will be considered 
to be a treatment non-completer and a trial non-completer. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 37 of 113
[IP_ADDRESS] Lost to follow-up
The following actions must be taken in relation to a subject who fails to attend the site for a 
required visit:
!The site must attempt to contact [CONTACT_49878]
!The site must re-train the subject in the importance of maintaining the scheduled visits 
In cases in which the subject is deemed lost to follow-up the investigator must make every effort to 
regain contact [CONTACT_1155] (e.g. telephone calls to friends or family members, e-mails or 
certified letter to the subject as applicable). These contact [CONTACT_853260]â€™s medical records. Should the subject continue to be unreachable, only then will he/she be 
considered to have withdrawn from the trial with the primary reason being â€œlost to follow-upâ€.
8.1.[ADDRESS_1187290]â€™s medical record.
If clarification of entries or discrepancies in the eDiary is needed, the subject must be questioned 
and a conclusion made in the subjectâ€™s medical record. Care must be taken not to bias the subject.
Any discrepancies or missing data points available elsewhere related to a 7-9-[ADDRESS_1187291] related information/assessments 
8.2.1 Demography
Demography will be recorded at screening and consists of:
!Date of birth (according to local regulation)
!Sex
!Ethnicity (according to local regulation)
!Race (according to local regulation)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 38 of 113
8.2.2 Diabetes history and diabetes complications 
Diabetes history and diabetes complications will be recorded at screening and consists of:
!Date of diagnosis of T2DM 
!
!Information regarding diabetes complications including date of onset
â€“ Diabetic retinopathy
â€“ Diabetic neuropathy
â€“ Diabetic nephropathy
â€“ Macroangiopathy (including peripheral vascular disease)
8.2.3 Hypoglycaemia unawareness 
Information on hypoglycaemia unawareness will be recorded at screening according to Clarkeâ€™s 
questionnaire, question 8.[ADDRESS_1187292]: â€œTo what extent can you tell by [CONTACT_41122]?â€ The subject can answer never, rarely, sometimes, often 
or always.
Subjects answering â€˜never, rarely or sometimesâ€™ are considered as having impaired awareness of 
hypoglycaemia.
8.2.4 Concomitant illness and medical history
â€“A  concomitant illness is any illness that is present at the start of the trial (i.e. at the first 
visit (Visit 1)) or found as a result of a screening procedure or other trial procedures 
performed before exposure to trial product. 
T2DM and diabetes complications should be reported separately in the Diabetes History/Diabetes 
Complications Form in the eCRF.
Medical history is a medical event that the subject has experienced in the past. Only relevant 
medical history, as judged relevant by [CONTACT_093], should be reported. 
The information collected for concomitant illness and medical history should include diagnosis, 
date of onset and date of resolution or continuation, as applicable.
Any change to a concomitant illness should be recorded during the trial. A clinically significant 
worsening of a concomitant illness must be reported as an AE.
It must be possible to verify the subjectâ€™s medical history in source documents such as subjectâ€™s 
medical record. If a subject is not from the investigators own practice; the investigator must make CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187293]â€™s medical record from relevant party e.g. primary 
physician. The investigator must document any attempt to obtain external medical information by 
[CONTACT_18031](s) when information was requested and who has been contact[INVESTIGATOR_530].
8.2.[ADDRESS_1187294](s), which is taken during 
the trial, including the screening, run-in, treatment and follow-up periods.
Details of any concomitant medication must be recorded at Visit 1. Changes in concomitant 
medication must be recorded at each visit as they occur. 
The information collected for each concomitant medication includes trade name [CONTACT_18058], 
indication, start date and stop date or continuation. 
If a change is due to an AE, then this must be reported according to Section 12. If the change 
influences the subjectâ€™s eligibility to continue in the trial, the monitor must be informed.
8.2.6 Concomitant medication (diabetes)
Any diabetes medication other than the trial product(s) which is taken during the trial, including the 
screening, run-in, treatment and follow-up periods must be recorded in a separate concomitant 
medication (diabetes) form in the eCRF including the trade name [CONTACT_18058], total daily dose, 
frequency, start date and stop date or continuation. For subjects treated with metformin it is the start 
date and dose of last stable metformin dose which should be reported.
At the run-in visit (Visit 2) basal insulin and all OADs except for metformin must be discontinued 
and a stop date recorded. For subjects treated with metformin, investigator should at each weekly 
contact (visit or phone contact), confirm with the subject that dose and frequency of metformin has 
been unchanged. This should be documented in the medical records. 
At the randomisation visit (Visit 14) pre-trial bolus insulin must be discontinued and a stop date 
recorded.
It is important to ensure subjects adhere to treatment. Therefore, during the treatment period the 
investigator must also at each weekly contact (visit or phone contact), evaluate if the subject has 
taken any ancillary treatment since last contact. Ancillary treatment is defined as any diabetes 
medication - other than randomised treatment (trial products in the basal-bolus regimen with or without metformin) initiated in case of unsatisfactory glycaemic control. It should be registered as 
such on the concomitant medication (diabetes) form in the eCRF. For subjects not treated with 
metformin prior to the randomisation, initiation of long term use of metformin is considered as 
ancillary treatment. A medication error (Section [IP_ADDRESS] ) is as such not considered as ancillary 
treatment.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187295] be instructed to use adequate 
contraceptive methods throughout the trial and until 1 week after end of treatment.
Female of non-childbearing potential is defined as:
!Female who has undergone a hysterectomy, bilateral oophorectomy or bilateral tubal 
ligation 
!Postmenopausal defined as no menses for 12 months without an alternative medical cause
!Other medical reasons preventing childbearing potential 
8.2.[ADDRESS_1187296] one 
cigarette or equivalent daily. 
Smoking status:
!Never smoked
!Previous smoker
!Current smoker
8.[ADDRESS_1187297] at two visits (see flowchart section 2) and 
will have their [ADDRESS_1187298] is 
expected to be up to 6 hours including preparations. During that time 6 blood samples will be 
drawn, as specified in the Table 8â€“1 . CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187299] should be instructed to: 
!Follow normal routine regarding eating and exercise habits on the day prior to the meal test
!Refrain from intake of alcohol and use of medications that affect motility (i.e. prokinetics, 
anticholinergics, tricyclic antidepressants) on the day prior to the meal test, unless the subject was on this medication at trial entry and does not change the product or product dose
!Remember to bring their current/trial bolus and basal insulin, eDiary and BG meter to the 
meal test visits
!Attend the meal test visits in a fasting condition. For definition of fasting, please refer to 
section 8.1.[ADDRESS_1187300]
!Achieve an SMPG value within a range of 4.0-8.8 mmol/L [71-160 mg/dL] before 
beginning the meal test. The SMPG value should be verified at the site before starting the 
meal test.
The meal test should be re-scheduled within the visit window and at Visit [ADDRESS_1187301] in case:
!any hypoglycaemic epi[INVESTIGATOR_853212] 
!the subject is not fasting or 
!the SMPG value is outside the range.
At Visit 14 (randomisation visit) the investigator must evaluate if the subject is eligible to continue 
in the trial before the meal test is performed. Only subjects eligible for randomisation should have the Visit [ADDRESS_1187302], the bolus insulin dose should be calculated by [CONTACT_853261] a calculated insulin:carbohydrate ratio. The 
insulin:carbohydrate ratio in this trial is calculated by [CONTACT_60875] 500 by [CONTACT_853262] (taken 
from the day before) of both basal and bolus insulin. The calculated dose should be rounded to the 
nearest whole unit. 
Same bolus insulin dose will be used for the meal test at end of treatment. The insulin should be 
administered subcutaneously in the abdomen in accordance with Table 8â€“1 .CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187303]â€™s body weight must  be measured before start and a blood sample must be drawn two 
minutes before intake of the standardised meal. 
For the meal test at Visit [ADDRESS_1187304] both at Visit 30A and again at Visit 30; the meal test at Visit [ADDRESS_1187305] consumed the required volume of the standardised liquid meal in the eCRF.
Table 8â€“[ADDRESS_1187306] schedule
Time point 
(minutes)Blood 
sample SMPG 
values Standardised meal Bolus insulin injection
Before start 
of meal testX (within target 
range 4.0-8.8 
mmol/L [71-160 
mg/dL])
-2X
0
X (as appropriate 
to ensure 
subjectâ€™s safety)XX
Insulin injection at the start of the meal
30X
60X
120X
180X
240X
End of meal 
testX (for subjectâ€™s 
safety)
Conduct of meal test
The subject should stay in the clinic to have the blood samples drawn after 30 minutes, 1, 2, 3 and 4 
hours from the start of the standardised meal, as detailed in Table 8â€“1 . The samples will be 
analysed by [CONTACT_2237].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187307], except for water consumption which is allowed two 
hours after intake of the standardised meal.
If SMPG values â‰¤3.9 mmol/L [70 mg/dL] are measured, then the hypoglycaemia should be treated 
with glucose rescue treatment according to local practice and the meal test should continue 
according to the investigatorâ€™s discretion. The hypoglycaemic epi[INVESTIGATOR_853213]. Please see 
section 8.4.[ADDRESS_1187308]: 
!Fasting status
!SMPG value measured before the meal test and within allowed ranges and the time of the 
measurement
!Actual clock start and end time of standardised meal
!Volume of meal consumed
!Confirmation that the subject consumed the required volume of the standardised meal
!Batch number of the standardised meal consumed
!Actual clock time and dose of bolus insulin 
!Actual clock time of blood samples
!Hypoglycaemic epi[INVESTIGATOR_1841], if relevant
oSMPG value, time of intervention and amount of glucose rescue treatment and 
hypoglycaemic epi[INVESTIGATOR_853214]. The meal test results will not be provided to the investigator until after LPLV in order to 
keep the blinding of the subject and investigator.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187309] strips calibrated to plasma values. Therefore, all measurements performed 
with capi[INVESTIGATOR_36191], which will be 
shown on the display. 
Only the BG meter provided by [CONTACT_156056]. 
For Argentina, Russia, Serbia and Ukraine: The BG meter should be collected by [CONTACT_853263]1 (Visit 31).
Subjects must be instructed in how to transfer the results of the SMPG values daily into the 
eDiaries.
4-point self-measured plasma glucose profile 
The 4-point SMPG profile will be recorded for insulin titration purposes. Subjects will be instructed 
to perform 4-point profiles every day from Visit 2 to Visit 30 for titration purposes. The 
measurements should be performed at the following time points:
!Before breakfast
!Before lunch
!Before main evening meal (dinner)
!At bedtime
For SMPG measurements actual clock time, date and value should be transferred to the eDiary, 
where each measurement should be assigned to the corresponding time point.
SMPG values measured before breakfast, lunch, main evening meal, and at bedtime should be 
performed before any injection of bolus insulin and just before the start of the meal (breakfast, 
lunch or main evening meal). SMPG values measured before breakfast should be performed in a 
fasting condition. The 4-point profile is part of the 7- or 9-point profiles which are measured prior 
to selected site visits.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187310] before selected visits as outlined in the flowchart in section 2. See Table 8â€“2 (7-point profiles 
indicated as X and the 9-point profile indicated as âˆš). 
Table 8â€“[ADDRESS_1187311] X âˆ€âˆ€ âˆ€ #X)a 
60 minutes after the start of 
breakfastX âˆ€ X
Before lunch X âˆ€ X
60 minutes after the start of 
lunchX âˆ€ X
Before main evening meal X âˆ€ X
60 minutes after the start of 
main evening mealX âˆ€ X
At bedtime X âˆ€ X
At 4 am âˆ€ 
aThe last SMPG in the 9-point profile and the first SMPG of the 7-point profile on day-[ADDRESS_1187312] before the start of the meal (breakfast, lunch or main 
evening meal). SMPG values measured before breakfast should be performed in a fasting condition.
The measurements will be used to evaluate the glucose profile.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187313] should be instructed to report the following concerning dosing of trial products in the 
eDiary:
!Date, actual clock time and dose of basal and bolus insulin on a daily basis from Visit 2 to 
Visit 30.
!Date, actual clock time, and dose for other (extra) bolus insulin administration as well as 
time and type of previous main meal and reason for the extra bolus from Visit 2 to Visit 30.
Dosing and dose adjustment (new dose)
The recommended insulin doses will be calculated in the eDiary webportal based on 
recommendations from the Insulin Titration Guideline (see Appendix A ). At each visit/phone 
contact [CONTACT_853264]. 
Investigator must hand out the subject mealtime insulin dose adjustment guide at Visit [ADDRESS_1187314] subjects to perform self-titrati on of bolus (mealtime) trial insulin between the 
scheduled visits/phone contacts from Visit [ADDRESS_1187315] the following in the eDiary webportal:
!Prescribed doses of trial products
!Reason for deviating in dose adjustments from the titration guideline, if applicable
The subject should report the following in the eDiary: 
!Dose adjustment of bolus trial insulin 
8.[ADDRESS_1187316] be 
reported as an AE.
8.4.1 Adverse events
Adverse events (AEs) must be reported at each visit in accordance with the procedures outlined in 
Section 12.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 47 of 113
[IP_ADDRESS] Medication error
If a medication error is observed during the trial, the following information is required and a 
specific event form must be completed in the eCRF in addition to the AE form:
!Trial product(s) involved
!Classification of medication error
!Whether the subject experienced any hypoglycaemic epi[INVESTIGATOR_36192]/or AEs as a result of the 
medication error
!Suspected primary reason for the medication error
For definition of medication errors, see Section 12.1.4 .
[IP_ADDRESS] Adverse events requiring additional data collection
For some AEs additional data collection is required and specific event forms must be completed in 
the eCRF in addition to the AE form. 
In case any of these events fulfil the criteria for a SAE, please report accordingly, see Section 12.
Injection site reaction
If an event of injection site reaction is observed the following additional information must be 
obtained if available on the injection site reaction form:
!Type of reaction â€“ local or generalised
!Symptoms associated with the event
!Treatment given for the event
!Association with the trial product(s)
!Relevant risk factors associated with the event
The investigator has to evaluate whether further actions are needed (e.g. extra visits, supervised 
injection, premature discontinuation of trial products, dermatologist consultation).
If any injection site reactions occur after Visit 31 they should still be recorded as AEs, but the 
additional data collection on the specific event form in the eCRF is not required.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 48 of 113
8.4.2 Hypoglycaemic epi[INVESTIGATOR_688133] a hypogl ycaemic epi[INVESTIGATOR_36190]. 
All plasma glucose (PG) values:
!â‰¤ 3.9 mmol/L (70 mg/dL) or 
!> 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms 
should be reported in the eDiary by [CONTACT_248463] 2 to Visit 31 (FU1) and in the eCRF by 
[CONTACT_853265]1 to FU2 according to the instructions below . However, only a reduced 
amount of information will be collected for hypoglycaemic epi[INVESTIGATOR_853215]* in 
this section in the following periods:
!During the run-in period from Visit 2 to Visit 14 
!One day after Visit 30 to FU2
!For subjects discontinuing trial products prematurely: One day after Visit 30A to Visit [ADDRESS_1187317] is recommended to measure PG every 15 
minutes until the SMPG value is >3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved in 
accordance to current guidelines.34
A SMPG value â‰¤3.9 mmol/L (70 mg/dL) or hypoglycaemic symptoms  must trigger a 
hypoglycaemic epi[INVESTIGATOR_36197]. Repeated SMPG measurements and/or 
symptoms, occurring within a period of 60 minutes after onset on a hypoglycaemic epi[INVESTIGATOR_1865], will by 
[CONTACT_156095][INVESTIGATOR_41106] a succeeding SMPG value is >3.9 
mmol/L (70 mg/dL) and/or symptoms have been resolved and should be reported on one 
hypoglycaemic epi[INVESTIGATOR_215510]. SMPG measurements â‰¤3.9 mmol/L (70 mg/dL) or hypoglycaemic 
symptoms after the [ADDRESS_1187318] to fill out a new hypoglycaemic epi[INVESTIGATOR_708719] a succeeding 
measurement is >3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved.
In case of several low SMPG values within the [ADDRESS_1187319] SMPG value and/or symptom.
The eDiary will automatically link multiple values within 60 minutes to the same hypoglycaemic 
epi[INVESTIGATOR_853216].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187320] should include the following information:
!Start date and time of the hypoglycaemic epi[INVESTIGATOR_1865]*
!The PG level before treating the epi[INVESTIGATOR_1865] (if available) and any follow up measurements.*
The lowest value measured during the hypoglycaemic epi[INVESTIGATOR_36201], the remaining values will be kept as source data in the eDiary.
!Whether the epi[INVESTIGATOR_36202] (Yes/No)*
A hypoglycaemic epi[INVESTIGATOR_36203]. The subject is therefore to be questioned 
whether there are changes to symptoms for each low SMPG value within the [ADDRESS_1187321] has confirmed that the hypoglycaemic epi[INVESTIGATOR_853217].
!Whether the subject was able to treat him/herself*
If the severity of a hypoglycaemic epi[INVESTIGATOR_1865] a ggravates, only one hypoglycaemic epi[INVESTIGATOR_853218]. The subject is therefore to be 
questioned whether he/she is able to self-treat for each low SMPG value within the [ADDRESS_1187322] respond that he/she is not able to self-treat.
!Date, time and dose of last bolus insulin administration prior to the epi[INVESTIGATOR_1865] 
!Date, time and dose of last basal administration prior to the epi[INVESTIGATOR_1865] 
!Date and time of last main meal (not including snacks) prior to the epi[INVESTIGATOR_1865]
!Whether the epi[INVESTIGATOR_36205]
!Change in any concomitant illness
!Any sign of fever and/or other acute disease 
!Whether the subject was asleep when the epi[INVESTIGATOR_36206]
â€“ If yes, whether the symptoms of the epi[INVESTIGATOR_513399]: "Was the subject able to treat him/herself?" must be answered "No" for 
an epi[INVESTIGATOR_36208], glucagon, or 
take other corrective actions. Plasma glucose concentrations may not be available during an event, 
but neurological recovery following the return of PG to normal is considered sufficient evidence 
that the event was induced by a low PG concentration.[ADDRESS_1187323] is unconscious.
If the question "Was the subject able to treat him/herself?" is answered "No", the following 
information should be recorded by [CONTACT_423]:
!Who assisted in the treatment of the hypoglycaemic epi[INVESTIGATOR_1865] (i.e. medical person or non-
medical person)?
!Where the treatment was administered (in clinic/emergency room/hospi[INVESTIGATOR_36209]. If the 
subject was treated in clinic/emergency room/hospi[INVESTIGATOR_307], whether they were transported in an 
ambulance or not)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 50 of 113
!Type of treatment provided by [CONTACT_19015] (i.e. oral carbohydrates, glucagon, IV glucose 
or other)
!Were symptoms alleviated after administration of treatment?*
!Factors contributing to the epi[INVESTIGATOR_1865] (i.e. physical activity, missed meal, diet change, 
medication error (i.e. overdose, mix-up between products, incorrect use of device), 
miscalculation of dose of antidiabetic medication, other factors not listed or unknown)
!Did the subject experience seizure?*
!Was the subject unconscious/comatose?*
!Did the subject experience any of the following symptoms35(layman term used in the
eDiary is specified in brackets if different from the protocol term)? 
â€“ Autonomic: sweating, trembling, hunger or palpi[INVESTIGATOR_814] (rapid or irregular heart beat)
â€“ Neuroglycopenic: confusion, drowsiness, speech difficulty, visual disturbances, odd 
behaviour, impaired balance or incoordination (reduced ability to coordinate movement)
â€“ General malaise: headache or malaise (feeling discomfort/unease)
!Other symptoms 
The investigator must review the eDiary data for correct reporting of SMPGs and hypoglycaemic 
epi[INVESTIGATOR_1841]. In case of incomplete or incorrect data in the eDiary, the subject must be questioned 
whether there have been any severe hypoglycaemic epi[INVESTIGATOR_111388], i.e. any 
hypoglycaemic epi[INVESTIGATOR_853219]-treat. Any severe hypoglycaemic 
epi[INVESTIGATOR_826632]. 
Low SMPG values for non-severe hypoglycaemic epi[INVESTIGATOR_36212] a hypoglycaemic epi[INVESTIGATOR_36213] [ADDRESS_1187324] be re-trained in how to report  hypoglycaemic epi[INVESTIGATOR_36214] e investigator identifies 
unreported hypoglycaemic epi[INVESTIGATOR_1841].
If the hypoglycaemic epi[INVESTIGATOR_853220] a safety 
information form (SIF) must also be filled in the eCRF, see Section 12. One AE-form and SIF can 
cover several hypoglycaemic epi[INVESTIGATOR_853221].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 51 of 113
8.4.3 Eye examination
Fundus photography/pharmacologically dilated fundoscopy must be performed by [CONTACT_093], 
a local ophthalmologist, or an optometrist according to local practice. The result of the fundus 
photography/pharmacologically dilated fundoscopy must be interpreted locally by [CONTACT_093]. 
To document this, the investigator must sign and date the result page or write the interpretation in 
the subjectâ€™s medical records. 
The evaluation must follow the categories:
!Normal
!Abnormal
â€“ Was the result clinically significant? (Yes/No)
Abnormal and clinically significant findings must be recorded as described in Section 8.4.
If a fundus photography/pharmacologically dilated fundoscopy has been performed within [ADDRESS_1187325]â€™s medical records that this procedure was not performed in relation to the trial.
The eye examination must be performed prior to administration of bolus trial insulin at Visit 14 (the 
results do not need to be available for randomisation). An eye examination performed within 14 
days prior to randomisation is acceptable.
Eye examination obtained within 21 days prior to Visit 30 is acceptable if the result is available at 
the visit.
For subjects prematurely discontinued trial products: eye examination performed 21 days in 
advance of Visit 30A are acceptable if the results are available at the scheduled visits. However eye 
examination performed at Visit 14 cannot be accepted for the Visit 30A.
8.4.4 Electrocardiogram â€“ 12 lead
An electrocardiogram (ECG)-[ADDRESS_1187326]â€™s medical records.
The evaluation must follow the categories:
!Normal
!Abnormal
â€“ Was the result clinically significant? (Yes/No)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187327] be recorded as described in Section 8.4
If an ECG-12 lead has already been performed within 21 days before screening (Visit 1), and if the 
results are available at the screening visit, the procedure does not need to be repeated. If performed 
before the subject consents to participate in the trial it must also be stated in the subjectâ€™s medical 
records that this procedure was not performed in relation to the trial.
ECGs performed 21 days in advance of Visit 14 and Visit 30 are acceptable if the results are 
available at the scheduled visits.
For subjects prematurely discontinued trial products: ECGs performed 21 days in advance of Visit 
30A are acceptable if the results are available at the scheduled visits. However ECGs performed at 
Visit 14 cannot be accepted for the Visit 30A.
8.4.5 Body measurements
Height (without shoes) will be measured at site in centimetres (cm) or inches (in) and recorded to 
one decimal place in the eCRF.
Body weight should be measured in kilograms (kg) or pounds (lb) without overcoat and shoes, and 
wearing only light clothing. Body weight must be measured prior to the start of the meal test at 
Visit [ADDRESS_1187328]. The body weight should be assessed on the 
same weighing scale equipment throughout the trial, if possible. 
BMI will automatically be calculated by [CONTACT_51084].
8.4.6 Physical examination
Physical examination will include examination of:
!the respi[INVESTIGATOR_2133]
!the cardiovascular system
!the central and peripheral nervous system
!the gastrointestinal system, including the mouth
!the musculoskeletal system
!the skin
!the head, ears, eyes, nose, throat and neck
The results must be transcribed to the eCRF as:CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 53 of 113
!Normal
!Abnormal
â€“ Was the result clinically significant? (Yes/No)
Abnormal and clinically significant findings must be recorded as described in Section 8.[ADDRESS_1187329] is using antihypertensive medication to 
control the blood pressure, then the medication should be taken as usual prior to assessing vital 
signs. 
At screening (Visit 1) blood pressure needs to be measured three times and all values should be 
recorded in the eCRF. The mean value will be calculated by [CONTACT_51084], and must be used to assess 
the relevant exclusion criterion; please see section 6.3.
Abnormal and clinically significant findings must be recorded as described in Section 8.4
8.5 Laboratory assessments
Except for urine pregnancy testing, which will be performed locally, all laboratory analyses will be 
performed by a central laboratory contracted by [CONTACT_3454]. The central laboratory will provide 
all laboratory supplies for the sampling and transportation of all blood and urine samples taken 
during the trial.
A detailed description of the procedures for obtaining the samples, handling, storage, and shipment 
of the samples are specified in a trial-specific laboratory manual provided to the sites by [CONTACT_11378]. Information regarding laboratory materials such as tubes and labels are also described. 
Laboratory samples can be drawn on another day than on the day of the actual visit, as long as it is 
within the visit window, as stated in the flowchart in section 2. 
If laboratory samples need to be retaken due to missing result(s) (e.g. haemolysed, sample leaked 
during transit, sample not being conclusive, lost in transit, etc.), the subject should be called in for 
resampling. Please see the laboratory manual for further guidance.
Samples will be coded in order to keep subjectâ€™s identity anonymous. 
The laboratory provides results to the trial sites in the units preferred by [CONTACT_135545].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187330] be documented either on the documents and/or in the subject's medical 
record.
Only laboratory samples specified in the protocol must be sent to the central laboratory for analysis; 
if additional laboratory sampling is needed, e.g. to follow up on AEs, this must be done at a local 
laboratory.
Laboratory samples will be destroyed on an ongoing basis and no later than at finalisation of the 
clinical trial report.
8.5.[ADDRESS_1187331] attend these visits fasting. 
For definition of fasting, see Section 8.1.5 .
A FPG result â‰¤3.9 mmol/L (70 mg/dL) should not be reported as a hypoglycaemic epi[INVESTIGATOR_36189] a 
clinical laboratory AE (CLAE) at the discretion of the investigator (see Section 12.1.1 ). 
The level of 1,5-anhydroglucitol (GlycoMark) is measured in order to evaluate post prandial 
glucose excursions. 
Blood samples will be drawn to determine the HbA 1clevel in order to evaluate metabolic control. 
Fasting C-peptide is measured at randomisation in order to reflect endogenous insulin secretion.
Lipi[INVESTIGATOR_853222]:
!Total cholesterol
!High density lipoprotein (HDL) cholesterol
!Low density lipoprotein (LDL) cholesterolCONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 55 of 113
8.5.2 Laboratory assessments for safety
Biochemistry
Blood samples for biochemistry will be analysed to determine:
!ALT
!AST
!albumin
!alkaline phosphatase
!creatinine
!potassium
!sodium
!total bilirubin
!total protein
!eGFR(estimated glomerular filtration rate) at screening
eGFR will be calculated by [CONTACT_167808]-EPI 
[INVESTIGATOR_853223] 15 according to local label.33
Haematology
Blood samples for haematology will be analysed to determine:
!erythrocytes
!haematocrit
!haemoglobin
!leucocytes
!thrombocytes 
Pregnancy testing
For females of childbearing potential (see section 8.2.7 ), a blood human Chorion Gonadotropin 
(hCG) pregnancy test will be performed at the visits indicated in the flowchart in section 2. In 
addition, urine pregnancy tests will be performed locally during the trial if pregnancy is suspected
or if required by [CONTACT_1769]. A positive urine test should be followed by a confirmatory serum-hCG 
(central laboratory).
The central laboratory will provide the pregnancy kits for urine testing performed locally at the site.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187332] dietary training regarding simple carbohydrate 
counting (e.g. sessions with a diabetes educator, dietician or qualified site staff) to improve 
subjectâ€™s carbohydrate awareness and understanding of their eating habits effect on their diabetes. It 
is the investigatorâ€™s responsibility to ensure that the subject is adequately trained and has a 
satisfactory knowledge in:
!Recognition of carbohydrates in commonly eaten foods 
!Ability to count the carbohydrate content in typi[INVESTIGATOR_853224]
!Ability to interpret a nutrition label for carbohydrate content 
!Glycaemic targets 
!Preventing and treating hypoglycaemia using carbohydrate foods
!Ability to sum the carbohydrate content of a meal [ADDRESS_1187333] prior to the visits indicated in the 
flowchart (Section 2) in order to evaluate the subjectâ€™s ability to count the carbohydrate content of 
the meal. The meal records will not be collected by [CONTACT_456].
8.6.[ADDRESS_1187334] be repeated according to flowchart (Section 2) in order to ensure correct use of the 
pen injector. The following should be emphasised:
!Always use a new needle for each injection as this will prevent contamination and blocked 
needles
!Remember to prime the pen to ensure product flow 
!The needle should be kept in the skin while counting slowly to [ADDRESS_1187335] been delivered.
!Always check that the correct insulin pen is used (bolus or basal) e.g. by [CONTACT_853266]. Use the pen differentiation guide as a reference.
!In-use time and storage conditions of pen-injectors (Section 9.3).
8.6.3 eDiary
At the run-in visit (Visit 2) the subjects will be provided with an eDiary device. The investigator 
must carefully instruct the subject in how to use the eDiary. All data entered in the eDiary is 
considered source data, as described in sections 8.3.2 , 8.3.3 and 8.4.2 .CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187336] the following administrative information in the eDiary/webportal:
!Subject ID
!7-9-7-point profile scheduling and confirmation
!Visit confirmation 
!Hypoglycaemic epi[INVESTIGATOR_826637]
!Premature discontinuation of trial products, if applicable
All data entered by [CONTACT_853267]. 
Investigator must review data for the subjects belonging to the site through the eDiary webportal. 
The review of hypoglycaemic epi[INVESTIGATOR_853225]â€™s 
medical record, while review of remaining data must be documented in the subjectâ€™s medical 
record. The review of data must be performed before or during each visit/phone contact.
Selected titration data (e.g. certain SMPGs and dose data) will only be used during the trial for 
central titration surveillance, to ensure compliance with the titration guideline ( Appendix A ), and 
will not be reported in the CTR. All data will be stored by [CONTACT_3454] (Section 24).
The eDiary should be collected by [CONTACT_771507]1 (Visit 31).The subject should be provided 
with a paper diary for collecting hypoglycaemic epi[INVESTIGATOR_853226]. The 
paper diary will not be returned to site by [CONTACT_853268]2 is a phone contact. Consequently, 
source data for FU2 (Phone Contact 32) is the notes written in subjectâ€™s medical record.
8.[ADDRESS_1187337] compliance will be assessed by 
[CONTACT_853269], please refer to the flow chart (Section 2). The 
unused amount of investigational medicinal product (IMP) will be assessed against the dispensed 
amount and, in case of discrepancies, the subject must be asked to clarify.
If a subject is found to be non-compliant, the investigator will remind the subject of the importance 
of following the instructions given including taking the trial products as prescribed.
The investigator will at each weekly contact (visit or phone contact) assess the subjectâ€™s compliance 
by [CONTACT_222680], adherence to treatment and the visit schedule and completion 
of the subjectâ€™s eDiary including the SMPG profiles, dose and hypoglycaemia reporting.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 58 of 113
9 Trial supplies
Trial supplies comprise trial products and auxiliary supplies. Additional details regarding trial 
supplies can be found in the Trial Materials Manual (TMM).
Trial products must not be dispensed to any person not included in the trial.
Trial product must not be used, if it does not appear clear and colourless.
9.1 Trial products
The following trial products will be provided by [CONTACT_3454] A/S, Denmark:
Table 9â€“[ADDRESS_1187338] Strength Dosage formRoute of 
administrationContainer/
delivery device
Faster aspart, (IMP), test product
100 U/ml Solution for 
injectionSubcutaneously3 ml prefilled 
pen
Insulin aspart 
(NovoRapidÂ®)
(IMP), reference therapy
Insulin degludec
(IMP), test product100 U/mlSolution for 
injectionSubcutaneously3 ml prefilled 
pen
The following non-investigational medicinal products (NIMP) will not be provided by [CONTACT_49753]. However, they will be reimbursed if required according to local regulations.
!Rapid acting insulin analogues (NovoRapidÂ®or marketed formulations of insulin lispro or 
insulin glulisine) in the run-in period
!Metformin, tablets for oral use
The comparator and active drug are visually identical.
9.2 Labelling
The trial products will be labelled in accordance with Annex 1338, local regulations and trial 
requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187339] dispensing visit (Visit 2). Additionally, the pen differentiation guide must be provided to 
subjects at randomisation (Visit 14). Direction for use and pen differentiation guide can be provided 
as needed at the following dispensing visits.
9.3 Storage 
Table 9â€“2 Storage conditions
Trial productStorage conditions
(not-in-use)In-use conditions In-use timea
Faster aspartStore in refrigerator
(2Â°C â€“ 8Â°C)
Do not freeze
Protect from lightStore below 30Â°C
Do not refrigerate
Do not freeze
Protect from lightUse within 4 
weeks Insulin aspart
(NovoRapidÂ®)
Insulin degludec Store in refrigerator
(2Â°C â€“ 8Â°C)
Do not freeze
Protect from lightDo not store above 30Â°C
Protect from light
Can be stored in refrigerator 
(2Â°C â€“ 8Â°C)
Do not freezeUse within [ADDRESS_1187340] has been stored outside specified conditions (e.g. outside temperature range). Additional 
details regarding handling of temperature deviations can be found in the TMM.
Trial product that has been stored improperly must not be dispensed to any subject before it has 
been evaluated and approved for further use by [CONTACT_3454]. The investigator must take 
appropriate action to ensure correct storage.
9.[ADDRESS_1187341] (used/partly used and/or unused), expi[INVESTIGATOR_135522]-allocated trial product.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 60 of 113
Non-allocated trial products (expi[INVESTIGATOR_5697], damaged and available) must be accounted as unused at the 
latest at closure of the trial site.
Subjects are instructed to return all used, partly used and unused trial product at each dispensing 
visit after Visit 2. Please refer to the flowchart (section 2) for timing of the dispensing visits.
Destruction of trial products can be performed on an on-going basis and will be done according to 
local procedures after accountability is finalised and reconciled by [CONTACT_853270]. 
Destruction of products must be documented in the IWRS.
9.5 Auxiliary supplies
The following will be provided by [CONTACT_3454]:
!Direction for use for the prefilled pens
!Novo Nordisk needles
!Standardised liquid meal (for the meal test)
!MyGlucoHealth Wireless Meter (CE approved) and strips, lancets and control solution for 
BG meters
!eDiary
Only needles provided by [CONTACT_215572].The BG meter has not been approved in Argentina, Russia, Serbia and Ukraine and will be labelled 
for investigational use only. The BG meter has been selected in order to have automatic transfer of SMPG data to the eDiary and thereby [CONTACT_826694]. It is expected that the 
better accuracy in SMPG data will facilitate an improvement in the insulin titration efforts during 
the trial. 
Please refer to the TMM for further auxiliary details.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 61 of 113
10 Interactive voice/web response system
A trial-specific IWRS will be set up which can be accessed at any time via the internet or telephone. 
Access to the IWRS must be restricted to and controlled by [CONTACT_36301]. 
IWRS is used for:
!Medication arrival
!Screening
!Screening failure
!Run-in dispensing
!Run-in failure
!Randomisation
!Dispensing
!Dispensing Verification (when barcode scanner is used)
!Treatment discontinuation 
!Completion
!Code break
!Drug accountability
!Data change
IWRS user manuals will be provided to each trial site.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 62 of 113
11 Randomisation procedure and breaking of blinded codes
At randomisation (Visit 14) the subject will be randomised to either faster aspart or NovoRapidÂ®, 
both in combination with once daily insulin degludec with or without metformin.
The randomisation will be carried out in a 1:1 manner to the 2 different treatment possibilities 
described below using the IWRS:
!Faster aspart and insulin degludec with or without metformin
!NovoRapidÂ®and insulin degludec with or without metformin
The investigator, subject and sponsor will be blinded to the bolus treatment.
11.1Breaking of blinded codes
The IWRS will notify Novo Nordisk (monitor and the Global Safety department) immediately after 
the code is broken.
The code for a particular subject may be broken in a medical emergency if knowing the actual 
treatment would influence the treatment of the subject. Whenever a code is broken the person breaking the code must print the Code Break Confirmation Notification generated by [CONTACT_8784], record the reason, and sign and date the document.
When the code is broken, the treatment allocation will be accessible to the investigator and the 
Novo Nordisk Global Safety department. If IWRS is not accessible at the time of code break the 
IWRS helpdesk should be contact[INVESTIGATOR_530]. Contact [CONTACT_136758] I.
If the code has been broken by [CONTACT_1697], the subject must discontinue treatment with trial 
product and a treatment discontinuation session must be completed in IWRS.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 63 of 113
12 Adverse events, technical complaints and pregnancies
12.1 Definitions
12.1.1 Adverse event 
An adverse event (AE) is any untoward medical occurrence in a subject administered a medicinal 
product, and which does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with the use of a product, whether or not 
considered related to the product. 
An AE includes:
!A clinically significant worsening of a concomitant illness.
!A clinical laboratory AE (CLAE): a clinical laboratory abnormality which is clinically 
significant, i.e. an abnormality that suggests a disease and/or organ toxicity and is of a 
severity that requires active management. Active management includes active treatment or 
further investigations, for example change of medicine dose or more frequent follow-up due 
to the abnormality.
The following should not be reported as AEs:
!Pre-existing conditions, including those found as a result of screening or other trial 
procedures performed before exposure to trial product (pre-existing conditions should be 
reported as medical history or concomitant illness).
!Pre-planned procedures unless the condition for which the procedure was planned has 
worsened from the first trial related activity after the subject has signed the informed 
consent.
!Non-serious hypoglycaemia is an AE, but is reported on a hypoglycaemic epi[INVESTIGATOR_135524], see Section 8.4.2 .
The following three definitions are used when assessing an AE:
!Severity 
â€“Mild â€“ no or transient symptoms, no interference with the subjectâ€™s daily activities.
â€“Moderate â€“ marked symptoms, moderate interference with the subjectâ€™s daily activities.
â€“Severe â€“ considerable interference with the subjectâ€™s daily activities; unacceptable.
!Causality 
Relationship between an AE and the relevant trial product(s): 
â€“Probable - Good reason and sufficient documentation to assume a causal relationship.
â€“Possible - A causal relationship is conceivable and cannot be dismissed.
â€“Unlikely - The event is most likely related to aetiology other than the trial product.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 64 of 113
â€¢Final outcome
â€“Recovered/resolved - The subject has fully recovered, or by [CONTACT_36303]-related activity after the 
subject signed the informed consent.
â€“Recovering/resolving - The condition is improving and the subject is expected to recover 
from the event. This term is only applicable if the subject has completed the trial or has died 
from another AE.
â€“Recovered/resolved with sequelae - The subject has recovered from the condition, but 
with lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an 
SAE criterion, the AE must be reported as an SAE.
â€“Not recovered/not resolved - The condition of the subject has not improved and the 
symptoms are unchanged, or the outcome is not known.
â€“Fatal - This term is only applicable if the subject died from a condition related to the 
reported AE. Outcomes of other reported AEs in a subject before he/she died should be 
assessed as â€œrecovered/resolvedâ€, â€œrecovering/resolvingâ€, â€œrecovered/resolved with 
sequelaeâ€ or â€œnot recovered/not resolvedâ€. An AE with fatal outcome must be reported as 
an SAE.
â€“Unknown - This term is only applicable if the subject is lost to follow-up.
12.1.2 Serious adverse event
A serious adverse event (SAE) is an experience that at any dose results in any of the following:
!Death.
!A life-threateningaexperience.
!In-patient hospi[INVESTIGATOR_36220].
!A persistent or significant disability or incapacityc.
!A congenital anomaly or birth defect.
!Important medical events that may not result in death, be life threateningaor require 
hospi[INVESTIGATOR_36221] - based on appropriate medical judgement 
- they may jeopardise the subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in the definition of SAEd. 
a.The term â€œlife threateningâ€ in the definition of SAE refers to an event in which the subject was at 
risk of death at the time of the event. It does not refer to an event which hypothetically might have 
caused death if it was more severe.
b.The term â€œhospi[INVESTIGATOR_11956]â€ is used when a subject: 
â€“ Is admitted to a hospi[INVESTIGATOR_36222]-patient, irrespective of the duration of physical stay, or â€“ Stays at the hospi[INVESTIGATOR_36223] [ADDRESS_1187342] should be 
regarded as a hospi[INVESTIGATOR_11956]. Hospi[INVESTIGATOR_17957], trial related and social purposes do CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187343]â€™s ability to conduct normal life functions (e.g. following the 
event or clinical investigation the subject has significant, persistent or permanent change, 
impairment, damage or disruption in his/her body function or structure, physical activity and/or 
quality of life).
d.For example intensive treatment in an emergency room or at home of allergic bronchospasm, 
blood dyscrasia or convulsions that do not result in hospi[INVESTIGATOR_11956], or development of drug 
dependency or drug abuse.
The following AEs must always be reported as an SAE using the important medical event criterion 
if no other seriousness criteria are applicable:
!suspi[INVESTIGATOR_36225] 
!risk of liver injury defined as ALT or AST >3 x UNL and total bilirubin >2 x UNL, where 
no alternative aetiology exists (Hy's law).
12.1.3 Non-serious adverse event
A non-serious AE is any AE which does not fulfil the definition of an SAE.
12.1.4 Medication errors
A medication error concerning trial products is defined as:
!Administration of wrong drug. 
Note: Use of wrong dispensing unit number (DUN) is not considered a medication error unless 
it results in administration of wrong drug.
!Wrong route of administration, such as intramuscular instead of subcutaneous.
!Administration of an overdose with the intention to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product.
!Accidental administration of a lower or higher dose than intended. The administered dose 
must deviate from the intended dose to an extent where clinical consequences for the trial subject were likely to happen as judged by [CONTACT_093], although they did not 
necessarily occur.
Medication errors must be reported on an AE form and a specific event form, see Section [IP_ADDRESS] .
12.1.[ADDRESS_1187344].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 66 of 113
In this trial the following AEs require the completion of specific event forms in the eCRF
!Injection site reaction
For details, see Section [IP_ADDRESS] .
12.1.[ADDRESS_1187345] 
(medicine or device) defects. The technical complaint may be associated with an AE, but does not 
concern the AE itself.
Examples of technical complaints:
!The physical or chemical appearance of trial products (e.g. discoloration, particles or 
contamination)
!All packaging material including labelling
!Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push 
button or interface between the pen and the needle)  
12.[ADDRESS_1187346]-treatment follow-up period (FU2). For subjects discontinuing trial products prematurely 
this also includes events after the post-treatment follow-up period until the last contact (Visit 30). 
The events must be recorded in the applicable eCRF forms in a timely manner, see timelines below 
and Figure 12â€“[ADDRESS_1187347] be asked about AEs and technical 
complaints, for example by [CONTACT_7939]: â€œHave you experienced any problems since the last contact?â€
All AEs, either observed by [CONTACT_36305], must be reported by [CONTACT_36306].
All AEs must be recorded by [CONTACT_49738]. The investigator should report the 
diagnosis, if available. If no diagnosis is available, the investigator should record each sign and 
symptom as individual AEs using separate AE forms.
For SAEs, a safety information form must be completed in addition to the AE form. If several 
symptoms or diagnoses occur as part of the same clinical pi[INVESTIGATOR_1103], one safety information form can 
be used to describe all the SAEs. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187348].
Timelines for initial reporting of AEs:
The investigator must complete the following forms in the eCRF within the specified timelines:
!SAEs: The AE form within 24 hours and the safety information form within 5 calendar
days of the investigatorâ€™s first knowledge of the SAE. Both forms must be signed within 7 
calendar days from the date the information was entered in the eCRF. 
For SAEs requiring reporting on a specific event form : In addition to the above the 
specific event form within 14 calendar days from the investigatorâ€™s first knowledge of the 
AE.
If the eCRF is unavailable, the concerned AE information must be reported on a paper AE form and 
sent to Novo Nordisk by [CONTACT_6791], e-mail or courier within the same timelines as stated above. When the 
eCRF becomes available again, the investigator must enter the information on the form into the 
eCRF.
Contact [CONTACT_8972] (fax, telephone, e-mail and address) are provided in the investigator trial master file. 
AE identifiedDoes the AE require 
a specific event 
form?
AE  form < 24 hours
SIF < 5 calendar da ys
Specific event form  
For SAEs: 
< 14 calendar da ys
Is the Adverse Event 
serious or non-
serious?
AE formNon-seriousSerious
NoYes
Queries and follow-up 
requests to be resolved 
< 14 calendar days
Timelines are for the completion of forms from the time of investigatorâ€™s awareness.
AEs requiring specific event forms are descibed in Section 12.1.4 and 12.1.5 .
No additional action
AE: Adverse Event   SIF: Safety Information form
Figure 12â€“1 Reporting of AEs CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 68 of 113
Novo Nordisk assessment of AE expectedness: 
Novo Nordisk assessment of expectedness is performed according to the following reference 
documents:
!Faster aspart IB22current version and any updates thereto.
!Insulin degludec Company Core Data Sheet current version and any updates thereto.
!NovoRapidÂ®, Company Core Data Sheet current version and any updates thereto.
Reporting of trial product-related S[LOCATION_003]Rs by [CONTACT_3454]:
Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious 
adverse reactions (S[LOCATION_003]Rs) in accordance with local requirements and ICH GCP.1In addition, the 
investigator will be informed of any trial-related SAEs that may warrant a change in any trial procedure.
In accordance with regulatory requirements, Novo Nordisk will inform the regulatory authorities, 
including EMA, of trial product-related S[LOCATION_003]Rs. In addition, Novo Nordisk will inform the 
IRBs/IECs of trial product-related S[LOCATION_003]Rs in accordance with local requirement and ICH GCP
1, 
unless locally this is an obligation of the investigator.
Novo Nordisk and non-Novo Nordisk products used as concomitant medication or non-
investigational medicinal product:
If an AE is considered to have a causal relationship with a non-Novo Nordisk and Novo Nordisk 
marketed product used as NIMP (NovoRapidÂ®in run-in period) and metformin or concomitant 
medication in the trial, it is important that the suspected relationship is reported to Novo Nordisk, 
e.g. in the alternative aetiology section on the safety information form. Novo Nordisk may need to 
report this AE to relevant regulatory authorities.
12.[ADDRESS_1187349] be reported to Novo Nordisk according to the following:
!SAEs: All SAEs must be followed until the outcome of the event is â€œrecovered/resolvedâ€, 
â€œrecovered/resolved with sequelaeâ€ or â€œfatalâ€, and until all queries have been resolved. 
Cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to 
another AE) may be closed with the outcome â€œrecovering/resolvingâ€ or â€œnot recovered/not 
resolvedâ€. Cases can be closed with the outcome of â€œrecovering/resolvingâ€ when the subject 
has completed the follow-up period and is expected by [CONTACT_36308].
The SAE follow-up information should only include new (e.g. corrections or additional) 
information and must be reported within 24 hours of the investigatorâ€™s first knowledge of the CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 69 of 113
information. This is also the case for previously non-serious AEs which subsequently become 
SAEs. 
!Non-serious AEs: Non-serious AEs must be followed until the outcome of the event is 
â€œrecovering/resolvingâ€, â€œrecovered/resolvedâ€ or â€œrecovered/resolved with sequelaeâ€ or until 
the end of the follow-up period stated in the protocol, whichever comes first, and until all 
queries related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs 
ongoing at time of death (where death is due to another AE) may be closed with the 
outcome â€œrecovering/resolvingâ€ or â€œnot recovered/not resolvedâ€. Cases can be closed with 
the outcome of â€œrecovering/resolvingâ€ when the subject has completed the follow-up period 
and is expected by [CONTACT_36308].
The investigator must ensure that the recording of the worst case severity and seriousness of an 
event is kept throughout the trial. A worsening of an unresolved AE must be reported as follow up 
with re-assessment of severity and/or seriousness of the event.
Queries or follow-up requests from Novo Nordisk must be responded to within [ADDRESS_1187350].
SAEs after end of trial: If the investigator becomes aware of an SAE with a suspected causal 
relationship to the IMP occurring to a subject after the subject has ended the trial, the investigator 
should report this SAE within the same timelines as for SAEs during the trial. 
12.4 Technical complaints and technical complaint samples
12.4.1 Reporting of technical complaints
For Novo Nordisk Products
All technical complaints on any of the following products:
!Faster aspart, 100 U/mL solution for subcutaneous injection, 3 mL PDS290 pen injector 
(blinded)
!NovoRapidÂ®, 100 U/mL solution for subcutaneous injection, 3 mL PDS290 pen injector 
(blinded)
!Insulin degludec, 100U/mL solution for subcutaneous injection, 3 mL PDS290 pen injector 
(open)
!Novo Nordisk Needles
which occur from the time of first usage of the product until the time of the last usage of the 
product, must be collected and reported to Customer Complaint Center, Novo Nordisk.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187351] details (fax, e-mail and address) are provided in Attachment I to the protocol.
The investigator must assess whether the technical complaint is related to any AEs and/or SAEs. 
Technical complaints must be reported on a separate technical complaint form:
!One technical complaint form must be completed for each affected DUN
!If DUN is not available, a technical complaint form for each batch, code or lot number must
be completed
The investigator must complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint:
!Technical complaint assessed as related to an SAE within 24 hours
!All other technical complaints within [ADDRESS_1187352] enter the information on the technical complaint form in the 
eCRF.
Only technical complaints related to AEs will be reported in the clinical trial report.
For BG meters, strips, lancets and control solution 
All Technical Complaints on BG meter, strips, lancets and control solution should be reported
directly to the supplier using the supplier reporting form within the following timelines: 
!Technical complaint assessed as related or potential related to an SAE within 24 hours
!All other technical complaints within [ADDRESS_1187353] details (e-mail and address) are provided in Attachment I  to the protocol. 
12.4.[ADDRESS_1187354] coordinate the shipment to 
Customer Complaint Center, Novo Nordisk (the address is provided in Attachment I ) and ensure 
that the sample is sent as soon as possible. A copy of the technical complaint form must be included 
in the shipment of the sample. If several samples are returned in one shipment, the individual sample and the corresponding technical complaint form must be clearly separated.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187355].
For BG meters strips, lancets and control solution 
The investigator must collect the technical complaint sample and send it to the supplier using the 
contact [CONTACT_853271] I.
12.5Pregnancies in female subjects 
Female subjects must be instructed to notify the investigator immediately if they become pregnant 
during the trial. The investigator must report any pregnancy in subjects who have received trial product(s).
The investigator must follow the pregnancy until the pregnancy outcome and the newborn infant is 
one month of age.
The investigator must report information about the pregnancy, pregnancy outcome, and health of 
the newborn infant(s), as well as AEs in connection with the pregnancy, and AEs in the foetus and newborn infant.
The following must be collected and reported by [CONTACT_136760] 
(e.g. in PDF format), or by [CONTACT_36310]:
1. Reporting of pregnancy information
Information about the pregnancy and pregnancy outcome/health of the newborn infant(s) has to
be reported on Maternal Form 1A and 1B, respectively.
When the pregnancy outcome is abnormal (i.e. congenital anomalies, foetal death including 
spontaneous abortion and/or any anomalies of the foetus observed at gross examination or 
during autopsy), and/or when a congenital anomaly is diagnosed within the first month, further 
information has to be reported for the female subject on Maternal Form 2. In addition, 
information from the male partner has to be reported on the Paternal Form, after an informed consent has been obtained from the male partner.
Initial reporting and follow-up information must be reported within 14 calendar days of the 
investigatorâ€™s first knowledge of initial or follow-up information.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 72 of 113
2. Reporting of AE information
The investigator has to report AEs in connection with the pregnancy as well as in the foetus and 
newborn infant(s). The SAEs that must be reported include abnormal outcome, such as foetal 
death (including spontaneous abortion), and congenital anomalies (including those observed at 
gross examination or during autopsy of the foetus), as well as other pregnancy complications 
fulfilling the criteria of an SAE.
Forms and timelines for reporting AEs:
Non-serious AEs: 
!AE formawithin 14 calendar days of the investigatorâ€™s first knowledge of the initial or 
follow-up information to the non-serious AE.
SAEs: 
!AE formawithin 24 hours of the investigatorâ€™s first knowledge of the SAE.
!Safety information form within 5 calendar days of the investigatorâ€™s first knowledge of the 
SAE.
!SAE follow-up information to the AE form and/or safety information form within 24 
hours of the investigatorâ€™s first knowledge of the follow-up information.
a It must be clearly stated in the AE diagnosis field on the AE form if the event occurred in 
the subject, foetus or newborn infant. If the AE occurred in the foetus or newborn infant, the AE 
can only be reported on paper AE and safety information form.
Any queries or follow-up requests from Novo Nordisk to non-serious AEs, SAEs and pregnancy 
forms must be responded to by [CONTACT_19452] [ADDRESS_1187356].
12.6 Precautions and/or overdose
During treatment with insulin, there is a risk of hypoglycaemia (see section 8.4.2 ). Symptoms of 
hypoglycaemia usually occur suddenly and may include cold sweat, nervousness or tremor, anxious 
feelings, unusual tiredness, confusion, difficulty in concentration, excessive hunger, temporary 
vision changes, headache, nausea, and palpi[INVESTIGATOR_332]. Prolonged or severe hypoglycaemia can lead to a 
loss of self-control, spasms, and/or unconsciousness and, in extreme cases, death.
Asymptomatic hypoglycaemia and symptoms of hypoglycaemia should be treated with 
carbohydrates. Mild to moderate symptoms can be treated by [CONTACT_826697] (for 
example, juice). Severe hy pogly caemia resulting in the loss of consciousness should be treated with 
parenteral glucose, glucagon or dextrose.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 73 of 113
For further details, please refer to the current version of faster aspart IB22, Insulin degludec IB24and 
for NovoRapidÂ®, please refer to the current versions of the SmPC19or U.S. NovologÂ®Label 
Information.20
12.7 Committees related to safety
12.7.1 Novo Nordisk safety committee
Novo Nordisk will constitute an internal faster aspart safety committee to perform ongoing safety 
surveillance. The faster aspart safety committee may recommend unblinding of any data for further 
analysis, and in this case an independent ad hoc group will be established in order to maintain the
blinding of the trial personnel.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187357] or an 
assessment has not been done and will not be available, or if the question is irrelevant (e.g. is not 
applicable), indicate this according to the data entry instructions.
The following will be provided as paper case report forms (CRFs):
!Pregnancy forms
The following will be provided as paper CRFs to be used when access to the eCRF is revoked or if 
the eCRF is unavailable:
!AE forms 
!Safety information forms
!Technical complaint forms (also to be used to report complaints that are not subject related 
(e.g. discovered at trial site before allocation)
On the paper CRF forms print legibly, using a ballpoint pen. Ensure that all questions are answered, 
and that no empty data blocks exist. Ensure that no information is recorded outside the data blocks. If a test/assessment has not been done and will not be available, indicate this by [CONTACT_565] â€œNDâ€ (not 
done) in the appropriate answer field in the CRF. If the question is irrelevant (e.g. is not applicable) 
indicate this by [CONTACT_565] â€œNAâ€ (not applicable) in the appropriate answer field. Further guidance can 
be obtained from the instructions in the CRF.
The investigator must ensure that all information is consistent with the source documentation. By 
[CONTACT_36321], the investigator confirms that the information in 
the eCRF and related forms is complete and correct.
13.1 Corrections to case report forms 
Corrections to the eCRF data may be made by [CONTACT_36322]â€™s delegated staff. 
An audit trail will be maintained in the eCRF application containing as a minimum: the old and the 
new data, identification of the person entering the data, date and time of the entry and reason for the 
correction.
If corrections are made by [CONTACT_093]â€™s delegated staff after the date the investigator has signed 
the case book, the case book must be signed and dated again by [CONTACT_093].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187358] ensure that data is recorded in the eCRF as soon as possible, preferably
within 5 days after the visit. Once data has been entered, it will be available to Novo Nordisk for 
data verification and validation purposes.
Site specific eCRF data (in an electronic readable format) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site.
[ADDRESS_1187359] visit at the trial site and no later than 4 
weeks after. The monitoring visit intervals will depend on the outcome of the centralised
monitoring of the eCRFs (remote assessment of data by [CONTACT_3454]), the trial site's recruitment 
rate and the compliance of the trial site to the protocol and GCP, but will not exceed [ADDRESS_1187360] access to all source documents (original documents, data and 
records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are important to the evaluation of the trial. If the electronic medical record does 
not have a visible audit trail, the investigator must provide the monitor with signed and dated 
printouts. In addition the relevant trial site staff should be available for discussions at monitoring 
visits and between monitoring visits (e.g. by [CONTACT_756]).
All data must be verifiable in source documentation other than the eCRF. Data entered by [CONTACT_853272]. All data entered in the eDiary 
device will be automatically transferred to a database, where it is kept as a certified copy of the 
source data. Data entered in the device will upon confirmation of a successful back-up be deleted 
from the device. Hence the certified copy in the database is regarded as source data. For data 
entered by [CONTACT_853273], the database is regarded as source data.
For all data recorded the source document must be defined in a source document agreement at each 
trial site. There must only be one source defined at any time for any data element.
Source data generated by [CONTACT_36323]; any correction must be explained, signed and dated 
by [CONTACT_36324].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 76 of 113
The monitor will ensure that the eCRFs are completed and that paper CRFs are collected.
The following data will be source data verified for screening failures: 
!Date for obtaining informed consent. 
!Screen failure date and reason
!Date of visit
!Demography (date of birth, sex and race (according to local regulation))
!Eligibility criteria
!SAE
Monitors will review the subjectâ€™s medical records and other source data to ensure consistency 
and/or identify omissions compared to the eCRF. If discrepancies are found, the investigator must 
be questioned about these.
[ADDRESS_1187361] research organisation (CRO).
Appropriate measures, including encryption of data files containing person identifiable data, will be 
used to ensure confidentiality of subject data, when they are transmitted over open networks.
Data from central laboratories will be transferred electronically. In cases where data is transferred 
via non-secure electronic networks, data will be encrypted during transfer.
The subject and any biological material obtained from the subject will be identified by [CONTACT_36325]. Appropriate measures such as encryption or leaving out certain identifiers will 
be enforced to protect the identity of subjects in all presentations and publications as required by 
[CONTACT_5737], regional and national requirements.
[ADDRESS_1187362] Operating Procedures and IT architecture documentation. The use and 
control of these systems are documented.
Investigators working on the trial may use their own electronic systems to capture source data.
The eDiary software and hardware implementation are compliant with the requirements of FDA 21 
CFR Part 11 and ICH E6 (EU directive for personal data protection). After trial finalisation, each 
site will be supplied with long-life DVDs. These DVDs will contain site-specific subject records 
including the subjectâ€™s eDiary data and audit trail as well as any data additions and corrections CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 77 of 113
made on each form. The eDiary vendor will furthermore retain and securely store copi[INVESTIGATOR_434856] 50 years or as required by [CONTACT_56325]. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 78 of 113
17 Statistical considerations
If necessary, a statistical analysis plan may be written in addition to the protocol, including a more 
technical and detailed elaboration of the statistical analyses. The statistical analysis plan will be 
finalised before database lock.
General considerations
In general, for endpoints evaluated as a change from baseline and/or where a baseline adjustment is 
made, baseline is defined as information collected at randomisation (Visit 14). In case a 
measurement is not available at randomisation, the most recent measurement prior to randomisation 
will be used as baseline. 
Two observation periods are defined, â€œin-trialâ€ and â€œon-treatmentâ€, and it will be specified which 
period each analysis will use.
!In-trial: The observation period from date of randomisation and until last trial-related 
subject-site contact. The in-trial observation period includes data collected after treatment 
discontinuation.
!On-treatment: The observation period from date of first dose of randomised 
NovoRapidÂ®/faster aspart and to [ADDRESS_1187363] occurrence of:
oThe day of last dose of randomised NovoRapidÂ®/faster aspart
oThe day before initiation of ancillary treatment
All efficacy endpoints will be summarised and analysed using the full analysis set (FAS), unless 
otherwise stated. Safety endpoints will be summarised using the safety analysis set and analysed 
using the FAS. The FAS is defined in section 17.2.
Presentation of results from a statistical analysis will include the estimated mean treatment effects 
(LSMeans) for change from baseline, if applicable. Estimated mean treatment differences (or ratios) 
will be presented together with two-sided 95% confidence interval (CI) for all endpoints analysed 
statistically. 
Data collected before randomisation (Visit 14) will only be summarised descriptively.
The primary objective of the trial is to confirm the effect of treatment with faster aspart compared to 
NovoRapidÂ®, both in combination with insulin degludec with or without metformin in adults with 
T2DM in terms of glycaemic control, using a non-inferiority approach. 
More specifically the upper limit of the 95% confidence interval for the difference between faster
aspart and NovoRapidÂ®should be compared to a non-inferiority margin of 0.4%. If it is below or 
equal to 0.4% non-inferiority will be considered established and effect demonstrated. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 79 of 113
The trial also aims to confirm superiority of treatment with faster aspart for a number of secondary 
confirmatory endpoints. The family-wise type I error rate will be controlled in the strong sense 
using a hierarchical (fixed sequence) testing procedure. This is based on a priority ordering of the 
null-hypotheses, and testing them in this order using the two-sided 95% confidence interval 
approach until an insignificant result appears. The effect is that rejection of a null hypothesis only 
will be considered for analyses where all previous null-hypotheses have been rejected in favour of 
faster aspart. 
The steps in the hierarchical testing procedure are as follows:
Step 1 (Primary analysis) :  HbA 1cnon-inferiority of faster aspart versus NovoRapidÂ®
Step 2 : 1-hour PPG increment (meal test) superiority of faster aspart versus NovoRapidÂ®
Step 3 : HbA 1csuperiority of faster aspart versus NovoRapidÂ®
Step 4 : 1,5-anhydroglucitol superiority of faster aspart versus NovoRapidÂ®
Estimands
Primary estimand
The primary estimand is defined as the treatment difference between subjects randomised to faster
aspart and NovoRapidÂ® both in combination with insulin degludec with or without metformin, in 
adults with T2DM not optimally controlled with a basal-bolus regimen assessed by [CONTACT_853274] 1c16 weeks after randomisation for all randomised subjects regardless of treatment 
discontinuation or use of ancillary treatment.  
The primary estimand assesses the expected benefit a future population with T2DM can achieve if 
prescribed to faster aspart as compared to NovoRapidÂ®. By [CONTACT_853275], this estimand aims at a difference as close as possible to the one that can be 
expected in real-world clinical practice, provided that the treatment adherence and use of ancillary 
treatment reflects clinical practice. Thereby [CONTACT_853276] a treatment difference 
for clinicians concerning the glycaemic effect of faster aspart compared to NovoRapidÂ® in the day 
to day life in subjects with T2DM in an adult population.
Secondary estimand
A secondary estimand is defined as the treatment difference in change from baseline in HbA 1c16 
weeks after randomisation between treatment with faster aspart and treatment with NovoRapidÂ®
both in combination with insulin degludec with or without metformin in adult subjects with T2DMCONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 80 of 113
not optimally controlled with a basal-bolus regimen if all subjects had adhered to randomised 
treatment and did not receive ancillary treatment.  
The condition â€˜adhered to randomised treatment and did not receive ancillary treatmentâ€™ should be 
interpreted as the exclusion of information collected after initiation of antidiabetic treatment that 
can mask or exaggerate the effect of the initially randomised treatment. Only data collected prior to 
discontinuation of trial product or initiation of ancillary treatment is used to draw inference. This 
avoids confounding effects of ancillary treatment.
The two estimands will be repeated for the confirmatory endpoints
!Change from baseline in 1-hour PPG increment (meal test) 16 weeks after randomisation
!Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation
17.1 Sample size calculation
The sample size is determined to ensure a sufficient power for step 1 and step 2 in the hierarchical 
testing procedure for the primary estimand presented in section 17. The power for step 3 and 4 in 
the hierarchical testing procedure will also be presented. The sample size is determined using a non-
inferiority limit of 0.4% in step 1, which was chosen as described in section 5.2.[ADDRESS_1187364] 
been high. Therefore it will be expected that treatment discontinuation might be as low as 10% 
where trial discontinuation constitutes half of these and with similar withdrawal reasons in the 
treatment arms.
Power for the non-inferiority step (Step 1) is based on a t-statistic under the assumption of a one-
sided test of size 2.5% for the FAS. A mean treatment difference of -0.1% for the comparison 
between faster aspart and NovoRapidÂ®in favour of faster aspart is expected. As trials in this 
population where data from treatment withdrawn subjects is retrieved is limited, a conservative 
estimate of the standard deviation (SD) in change from baseline in HbA 1c of 0.8% was chosen. The 
power for superiority in step 3 will be calculated using the same assumptions as for step 1 but 
without the non-inferiority margin. 
For determination of power in step 2 in the hierarchical testing, where change from baseline in 1-
hour PPG increment 16 weeks after randomisation is compared between faster aspart and 
NovoRapidÂ®a t-statistic with a two-sided test of size 5% is used, where the treatment difference is 
expected to be at least 0.6 mmol/L [11 mg/dL]. The SD=3.5 mmol/L [63 mg/dL] in change from 
baseline in 1-hour PPG increments [ADDRESS_1187365] will be considered reasonable based on trials NN1218-3852 and 
NN1218-3853.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 81 of 113
The power in step 4, where superiority of faster aspart over NovoRapidÂ®in change from baseline in 
1,5-anhydroglucitol [ADDRESS_1187366] of size 
5% is used. The mean treatment difference is expected to be at least 0.2 Î¼g/mL and an SD of 
3.5Î¼g/mL will be used based on trials NN1218-3852 and NN1218-3853.
The power calculations are done using proc power in SAS 9.4. Please refer to Table 17â€“1 for 
assumptions for the sample size calculation.
Table 17â€“[ADDRESS_1187367] One-sided 2.5 % FAS 0.4 % (absolute) 0.8 % -0.1 % 1:[ADDRESS_1187368] Two-sided 5.0% FAS NA 3.5 mmol/L 0.6 mmol/L 1:[ADDRESS_1187369] Two-sided 5.0% FAS NA 0.8 % -0.1 % 1:1Step [ADDRESS_1187370] Two-sided 5.0% FAS NA 3.5 Î¼g/mL 0.2 Î¼g/mL 1:1
In Table 17â€“2 the sensitivity of the sample size to the power shown for three different sizes of FAS. 
Three different choices of the mean difference are used to calculate the power in step 2.
Table 17â€“[ADDRESS_1187371] 
per 
armStep 
1Step 2 Step 
3Step 4
FAS FAS Mean 
diff
(%)SD
(%)Power 
(%)Mean 
diff
(mmol/L)SD
(mmol/L)Power 
(%)Mean 
diff
(%)SD
(%)Power 
(%)Mean
diff
(Î¼g/mL)SD
(Î¼g/mL)Power 
(%)
-0.1 0.8 >99.9 0.5 3.5 58.1 -0.1 0.8 47.4 0.2 3.5 13.9
920 460 -0.1 0.8 >99.9 0.6 3.5 73.8 -0.1 0.8 47.4 0.2 3.5 13.9
-0.1 0.8 >99.9 0.7 3.5 85.8 -0.1 0.8 47.4 0.2 3.5 13.9
-0.1 0.8 >99.9 0.5 3.5 64.7 -0.1 0.8 53.4 0.2 3.5 15.5
1072 536 -0.1 0.8 >99.9 0.6 3.5 80.1 -0.1 0.8 53.4 0.2 3.5 15.5
-0.1 0.8 >99.9 0.7 3.5 90.5 -0.1 0.8 53.4 0.2 3.5 15.5
-0.1 0.8 >99.9 0.5 3.5 70.4 -0.1 0.8 58.9 0.2 3.5 17.0
1224 612 -0.1 0.8 >99.9 0.6 3.5 85.0 -0.1 0.8 58.9 0.2 3.5 17.0
-0.1 0.8 >99.9 0.7 3.5 93.8 -0.1 0.8 58.9 0.2 3.5 17.0CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 82 of 113
In conclusion, 1072 subjects in the FAS (536 subjects per group) will ensure a marginal power of 
>99.9% to show non-inferiority in step 1, given that the actual treatment difference is -0.1%, and a 
marginal power of 80.1% to show superiority in step 2, given that the actual treatment difference is 
0.6 mmol/L.
Assuming a screening failure rate of 30% and run-in failure rate of 15%, 1803 subjects should be 
screened for inclusion in the trial.
17.2 Definition of analysis sets
The following analysis sets are defined in accordance with the ICH-E9 guidance39.
!Full Analysis Set (FAS) includes all randomised subjects. In exceptional cases, randomised 
subjects may be excluded from the FAS. In such cases, the reason for exclusion will be 
justified and documented. Subjects in the FAS will contribute to the evaluation â€œas 
randomisedâ€
!Per Protocol (PP) Analysis Set includes all subjects in the FAS, excluding subjects who:
oHave violated any inclusion criteria
oHave fulfilled any exclusion criteria
Subjects in the PP analysis set will contribute to the evaluation â€œas treatedâ€ 
!Safety Analysis Set includes all subjects receiving at least one dose of randomised 
treatment. Subjects in the safety analysis set will contribute to the evaluation â€œas treatedâ€. 
Randomised subjects who are lost to follow-up, and where no exposure information of the trial 
product or its comparator is available after randomisation, will be handled as unexposed.
Before data are released for statistical review, a blinded review of all data will take place to identify 
serious non-adherence to the protocol that may potentially affect the results. Furthermore, extreme 
values and outliers will be identified by [CONTACT_853277],
according to ICH-E9.39This will be performed by [CONTACT_2329] a fake randomisation.
The subjects or observations to be excluded, and the reasons for their exclusion must be documented and signed by [CONTACT_36331]. The subjects and observations 
excluded from analysis sets, and the reason for this, will be described in the clinical trial report.
17.3 Primary endpoint
The primary endpoint is change from baseline in HbA
1c16 weeks after randomisation. 
Primary analysis:
1) The primary estimand will be addressed by [CONTACT_853278]-trial observation period. Note that if subjects withdraw CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187372]-randomisation measurements 
contribute to the analysis, as the missing values will be imputed. The analysis will be 
implemented as follows: 
!In the first step, intermittent missing values are imputed using a Markov Chain 
Monte Carlo method, in order to obtain a monotone missing data pattern. This 
imputation is done for each group separately and 100 copi[INVESTIGATOR_853227]. 
!In the second step, for each of the 100 copi[INVESTIGATOR_136691], an analysis of variance 
model with region and metformin use at baseline (Yes/No) as factors and baseline 
HbA 1cas covariate is fitted to the change in HbA 1cfrom baseline to week 4 for each 
treatment group separately. The estimated parameters, and their variances, from 
these models are used to impute missing values at week 4 for subjects in each 
treatment group, based on region, metformin use at baseline (Yes/No) and baseline 
HbA 1c.
!In the third step, for each of the [ADDRESS_1187373] as for week 4. The imputations are based on an analysis of variance model with region and metformin use at baseline (Yes/No) as factors and 
baseline HbA
1cand change from baseline in HbA 1cat week 4 as covariates.
!This stepwise procedure is then repeated sequentially for week 12 and 16.
!For each of the complete data sets, the change from baseline to week 16 is analysed 
using an analysis of variance model with treatment, region and metformin use at 
baseline (Yes/No) as factors, and baseline HbA 1cas a covariate. 
!The estimates and standard deviations for the [ADDRESS_1187374] deviation using Rubinâ€™s formula:
m  =1
100 m 			   
   CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 84 of 113
SD  = 1
100 SD     
   + 1[PHONE_4579]  1
100âˆ’1  (m âˆ’m  )    
   
where m iand SD iare the estimated means and standard deviations for the 100 copi[INVESTIGATOR_853228], and m MIand SD MIare the pooled estimates.
!From m MI  and  SD MI, the 95% confidence interval for the treatment differences is 
calculated. 
Non-inferiority of faster aspart will be considered confirmed if the upper boundary of the two-sided 
95% confidence interval is below or equal to 0.4% or equivalent if the p-value for the one-sided test 
of
H0: D > 0.4%    against   H A: D â‰¤ 0.4%
is less than or equal to 2.5%, where D is the mean treatment difference (faster aspart minus 
NovoRapidÂ®).
Note that as the anticipated number of subjects discontinuing treatment, but not trial is low, multiple 
imputations based on such subjects is not expected to be suitable.
Provided that the hierarchical testing allows, the evaluation of superiority will be based on the same 
statistical model, as the primary analysis 1). The associated sensitivity analysis that follows will 
investigate the robustness of non-inferiority and superiority (analysis 3b and 3c) as well.
Sensitivity analysis for the primary analysis addressing the primary estimand
All sensitivity analyses for the primary analysis addressing the primary estimand will use the in-trial 
observation period.
2) First the primary analysis in 1) will be repeated, but excluding all factors except from 
treatment in the model. This analysis will explore the influence of the different factors.
3) The primary analysis approach chosen for this trial relies on the assumption that missing data 
is missing at random (MAR). This assumption implies that the HbA 1cfor subjects leaving the 
trial, after their withdrawal, develops in a similar way as the HbA 1cfor similar subjects that 
remain in the trial (not necessarily on treatment) and had similar development of HbA 1c 
before withdrawal. The MAR assumption may be questionable for subjects withdrawing at own will. Therefore the statistical models using multiple imputation will be repeated with the 
following alteration:CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 85 of 113
a) Imputations will be done from the treatment arm that the subject was randomised to and 
a value of 0.4% (non-inferiority margin) is added to the change from baseline in HbA 1c
at week 16 for subjects randomised to faster aspart who withdrew from the trial.40
b) Imputations will be done from the comparator arm (NovoRapidÂ®). This will serve as a 
supplementary sensitivity analysis for the superiority analysis. It does not rely on the 
MAR assumption, but assumes that all subjects who withdraw from the trial in the faster
aspart arm shift to NovoRapidÂ®. The imputation will be done conditional on observed 
information for subjects that withdraw from the faster aspart arm such that the treatment 
effect diminishes gradually after trial discontinuation (copy reference/conditional 
imputation). The analysis will use data from the in-trial observation period.
c) Imputation will be done from the comparator arm (NovoRapidÂ®). This will serve as a 
supplementary sensitivity analysis for the superiority analysis. It does not rely on the 
MAR assumption, but it is assumed that all subjects who withdraw from the trial in the 
faster aspart arm respond at week [ADDRESS_1187375] been treated with NovoRapidÂ®for 
the entire trial. That is, all collected post-randomisation data for subjects who withdraw 
from the trial in the faster aspart arm will be set to missing. The analysis will use data 
from the in-trial observation period.
Analyses addressing the secondary estimand
All analyses addressing the secondary estimand will use the on-treatment observation period.
4) The secondary estimand will be analysed using the same statistical model using multiple 
imputations as the primary analysis in 1) except using the on-treatment observation period. 
5) A tippi[INVESTIGATOR_853229] a statistical model using multiple imputation model similar 
to 1), using the on-treatment observation period, will be made. In this analysis observations 
for subjects that discontinue randomised treatment are imputed based on the treatment arm 
they were randomised to and subjects discontinuing treatment in the faster aspart group are 
given a penalty. This is done to investigate the robustness of the conclusion in the primary 
analysis with respect to the MAR assumption and mimics a scenario where the HbA 1cof the 
subjects discontinuing treatment in the faster aspart groups evolve less favourably than predicted. As a first step imputations will be done without penalty assuming MAR in the 
treatment group. Second, the imputed values for week 16 in the faster aspart group will be 
added a penalty. This is done repeatedly, gradually increasing the penalty until the 
conclusion from the non-inferiority analysis no longer holds. This will serve as a sensitivity 
analysis for the non-inferiority analysis and the specific value of the penalty that changes the 
conclusion will be used to evaluate the robustness of the conclusion of the non-inferiority 
analysis.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 86 of 113
6) A tippi[INVESTIGATOR_853229] a statistical model using multiple imputation, similar to 5) 
but with the modification that subjects discontinuing treatment due to non-eligibility 
(Subjects discontinuing randomised treatment prematurely due to criteria 1, 2, 3, and 4, 
which are defined in section 6.6) in the faster aspart group will not have a penalty added. 
These analyses are motivated by [CONTACT_853279]-eligibility can reasonably be assumed to be missing 
completely at random. 
7) The same statistical model using multiple imputations as the analysis in 4), but using the PP 
analysis set and analysed using the on-treatment observation period. This analysis will 
investigate the situation that subjects might have deviated from the inclusion and exclusion 
criteria and will serve as sensitivity analysis for the non-inferiority analysis.
17.[ADDRESS_1187376] of treatment with faster aspart for a number of secondary confirmatory 
endpoints using a hierarchical (fixed sequence) testing procedure as described in section 17
(General consideration). This is based on a priority ordering of the null-hypotheses, and testing 
them in this order using the two-sided 95% confidence interval approach until an insignificant result 
appears. The effect is that rejection of the null hypothesis only, will be confirmed for endpoints 
where all previous null-hypotheses have been rejected in favour of faster aspart.
The confirmatory secondary endpoints are:
!Change from baseline in 1-hour PPG increment 16 weeks after randomisation (meal test)
!Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation
The steps in the hierarchical testing procedure are as follows:
Step 1 (Primary analysis) :  HbA 1cnon-inferiority of faster aspart versus NovoRapidÂ®
Step 2 : 1-hour PPG increment (meal test) superiority of faster aspart versus NovoRapidÂ®
Step 3 : HbA 1csuperiority of faster aspart versus NovoRapidÂ®
Step 4 : 1,5-anhydroglucitol superiority of faster aspart versus NovoRapidÂ®
The primary estimand for the primary endpoint will be repeated for the confirmatory secondary 
endpoints, change from baseline in 1-hour PPG increment (meal test) and change from baseline in 
1,5-anhydroglucitol 16 weeks after randomisation. The analyses related to these estimands are CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 87 of 113
defined below and will be used for the decisions to continue or not, throughout the hierarchical 
testing procedure. These analyses will be based on the FAS and use the in-trial observation period.
As sensitivity analysis the secondary analysis 4) will also be repeated for the confirmatory 
secondary endpoints. The analyses will be based on the FAS and using the on-treatment observation 
period.
Change from baseline in 1-hour PPG increment 16 weeks after randomisation (meal test) 
(step 2)
As the second step of the hierarchical testing procedure changes from baseline in 1-hour PPG 
increment (meal test) 16 weeks after randomisation will be tested for superiority of faster aspart 
compared to NovoRapidÂ®.
The 1-hour PPG increment will be analysed based on the laboratory measured values in the meal 
test.
The 1-hour PPG increment endpoint will be analysed using the FAS and the in-trial observation 
period based on a multiple imputation technique where the change from baseline in 1-hour PPG 
increment at week 16 for subjects withdrawn from trial are imputed based on data from trial 
completers in the NovoRapidÂ®arm. Multiple copi[INVESTIGATOR_014] (100 copi[INVESTIGATOR_014]) of the full dataset will be 
generated by [CONTACT_853280]: 
!An analysis of variance model with region and metformin use at baseline (Yes/No) as 
factors and baseline 1-hour PPG increment as covariate is fitted to the change from baseline 
in 1-hour PPG increment at week 16 for the NovoRapidÂ®group only. The estimated 
parameters, and the variance, from this model are used to impute missing values using 
stochastic simulation at week 16 for subjects in both treatment groups in order to generate 
100 complete datasets.
!For each of the complete data sets, the change from baseline to week 16 is analysed using an 
analysis of variance model with treatment, region and metformin use at baseline (Yes/No) as 
factors, and baseline 1-hour PPG increment as covariate.
!The estimates and standard deviations for the [ADDRESS_1187377] deviation using Rubins formula. From this, the pooled estimates and 
95% confidence interval for the treatment difference is calculated.
The superiority will be assessed by [CONTACT_30357] 95% CI to 0. If the upper 95% 
CI is below 0 then superiority will be confirmed.
Change from baseline in HbA 1c16 weeks after randomisation (step 3)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187378] of treatment with faster aspart compared to NovoRapidÂ®. 
Superiority will be based on the same 95% CI that was used for addressing the primary analysis. 
Superiority will be confirmed if the upper boundary of the two-sided 95% confidence interval of the 
mean treatment difference (faster aspart minus NovoRapidÂ®) is below 0%.
Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation (step 4)
Step [ADDRESS_1187379] of treatment with faster aspart compared 
to NovoRapidÂ®. The endpoint will be analysed based on all planned post baseline measurements 
until or at 16 weeks after randomisation using a model similar to the primary analysis 1), but with 
baseline 1,5-anhydroglucitol as covariate. Superiority will be confirmed if the upper boundary of 
the two-sided 95% confidence interval of the mean treatment difference (faster aspart minus 
NovoRapidÂ®) is below 0.
17.4.2 Supportive secondary endpoints
[IP_ADDRESS] Efficacy endpoints
All endpoints except insulin dose in this section will be assessed using the FAS and the in-trial 
observation period and repeated using the on-treatment observation period. Insulin dose will be 
presented using the safety analysis set and will therefore only use the on-treatment observation 
period.
Change from baseline in FPG [ADDRESS_1187380] baseline measurements until or at 16 weeks after randomisation using a model similar to 1) 
except with baseline FPG as covariate.
If a subject achieves HbA 1ctarget 16 weeks after randomisation
HbA 1c< 7.0%
A dichotomous (responder/non-responder) endpoint will be defined based on whether a Subject has 
met the HbA 1ctarget (HbA 1c<7.0%) 16 weeks after randomisation.  
This responder endpoint will be analysed based on a logistic regression model using treatment,
region and metformin use at baseline (Yes/No) as factors, and baseline HbA 1cas covariate. In 
analysis of the in-trial observation period subjects without an HbA 1cmeasurement at week 16 will 
be treated as non-responders. In the analysis using the on-treatment observation period both subjects
who discontinue randomised treatment or withdraw from trial is included as non-responders.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 89 of 113
HbA 1c< 7.0% without severe hypoglycaemia
A dichotomous (responder/non-responder) endpoint will be defined based on whether a Subject has 
met the HbA 1ctarget (HbA 1c<7.0%) 16 weeks after randomisation without treatment emergent 
severe hypoglycaemic epi[INVESTIGATOR_1841].
This responder endpoint will be analysed based on a logistic regression model using treatment,
region and metformin use at baseline (Yes/No) as factors and baseline HbA 1cas covariate. In the 
analysis of the in-trial observation period subjects without an HbA 1cmeasurement at week 16 will 
be treated as non-responders. In the analysis using the on-treatment observation period both subjects
who discontinue randomised treatment or withdraw from trial will be included as non-responders.
Change from baseline in 30- minutes, 1- hour, 2- hour, 3- hour and 4- hour PPG and 30-
minutes, 2- hour, 3- hour and 4- hour PPG increment 16 weeks after randomisation (meal 
test)
Laboratory measured PG from the meal test will be analysed for 30 minutes, 1-hour, 2-hours, 3-
hours and 4-hours PPG separately. The corresponding PPG increments will be derived separately 
using each PPG measurement minus the pre-prandial PG measurement.
Change from baseline in PPG and PPG increment 16 weeks after randomisation will be analysed 
separately using a model similar to the model used in hierarchical testing procedure step 2 for 1-
hour PPG increment 16 weeks after randomisation (meal test) except with the corresponding 
baseline value as covariate.
Change from baseline in endpoints derived from the 7-9-7-point SMPG profile 16 weeks after 
randomisation
In general, analyses will be based on the entire 7-9-7-point SMPG profile except for the analyses of 
nocturnal endpoints where information in the 9-point SMPG profile will be utilised. 
PPG and PPG increments based on the 7-9-7-point SMPG profiles will be derived separately for PG 
measurements made 1 hour after the meal. In the following section this distinction will be 
considered implicit and without further explanation.
Pre-prandial PG and PPG will be recorded by [CONTACT_853281] 7-9-7-point SMPG profile 
prior to three defined visits. Individual mean mealtime PPG (post-breakfast, post-lunch, post-main evening meal) will be derived from the three profiles. Overall mean PPG will be derived from the 
individual derived mealtime PPG values.
PPG increment for each meal (breakfast, lunch, main evening meal) will be derived from the 7-9-7-
point SMPG profile as the difference between PPG values and the PG value before meal in each 
separate profile. The mean of the derived increments will then be calculated separately for each CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 90 of 113
meal. Mean 1 hour PPG increments over all meals will be derived as the mean of all corresponding 
mean meal increments. 
!Change from baseline in mean of the 7-9-7-point SMPG profile
The mean of the 7-9-7-point SMPG profile is defined as the area under the curve profile 
divided by [CONTACT_36336], and is calculated using the linear trapezoidal technique.
Change from baseline in the mean of the 7-9-7-point SMPG profile [ADDRESS_1187381] baseline measurements until or at 
16 weeks after randomisation using a model similar to 1) except with the corresponding 
baseline value as covariate.
!Change from baseline in PPG and PPG increment (mean, breakfast, lunch and main evening 
meal)
Change from baseline in PPG and PPG increment endpoints [ADDRESS_1187382] baseline measurements until or at 16 weeks after randomisation using a 
model similar to 1) except with the corresponding baseline value as covariate.
!Change from baseline in fluctuation in 7-9-7-point SMPG profile
The fluctuation in the 7-9-7-point SMPG profile is defined as:
1
  |  ( )âˆ’      | 
   
where T, PG(t) and       denotes the length of the profile, the PGvalue at time tand the mean 
of the profile, respectively. It will be calculated using the linear trapezoidal technique.
Fluctuation in the 7-9-7-point SMPG profile will be logarithmically transformed and 
analysed based on all planned post baseline measurements until or at 16 weeks after 
randomisation using a model similar to 1) except with the corresponding log-transformed 
baseline value as covariate. Estimated treatment means and the estimated treatment 
differences with corresponding 95% CI will be back-transformed to the original scale, 
resulting in estimated geometric means, a treatment ration and a 95% CI for the treatment 
ratio.
!Change from baseline in nocturnal SMPG measurementsCONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187383] value 
the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value 
minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value).
Change from baseline in nocturnal SMPG measurements [ADDRESS_1187384] baseline measurements until or at 16 weeks after 
randomisation using a model similar to 1) except with the corresponding baseline values as 
covariate.
If a subject achieves PPG target (based on overall mean of daily PPG measurements in 7-9-7-
point SMPG profile) 16 weeks after randomisation:
Overall PPG (1 hour) âˆƒâˆƒ7.8 mmol/L [140 mg/dL]
A dichotomous (responder / non-responder) endpoint will be defined based on whether a Subject 
has reached an overall mean 1 hour PPG âˆƒ7.8 mmol/L [140 mg/dL] 16 weeks after randomisation, 
where PPG is derived from the 7-9-7-point SMPG profile. 
This responder endpoint will be analysed based on a logistic regression model using treatment, 
region and metformin use at baseline (Yes/No) as factors, and baseline overall 1-hour mean PPG as 
covariate. In analysis of the in-trial observation period subjects without an overall mean 1 hour PPG 
at week 16 will be treated as non-responder. In the on- treatment observation period analysis both 
subjects who discontinue randomised treatment or withdraw from trial will be included as non-
responders.
Overall PPG (1-hour ) âˆƒ7.8 mmol/L [140 mg/dL] without severe hypoglycaemia
A dichotomous (responder / non-responder) endpoint will be defined based on whether a Subject 
has reached an overall 1-hour PPG âˆƒ7.8 mmol/L [140 mg/dL] 16 weeks after randomisation without 
any treatment emergent seve re hypoglycaemic epi[INVESTIGATOR_1841]. 
This responder endpoint will be analysed based on a logistic regression model using treatment,
region and metformin use at baseline (Yes/No) as factors, and baseline mean 1-hour PPG as 
covariate. In analysis of the in-trial observation period subjects without an overall mean 1 hour PPG 
at week 16 will be treated as non-responders. In the on- treatment observation period analysis both 
subjects who discontinue randomised treatment or withdraw from trial will be included as non-
responders. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 92 of 113
Insulin dose (Units/day and Units/kg/day; total basal, total bolus, total daily insulin dose and 
individual meal insulin dose) 16 weeks after randomisation
The insulin doses will be summarised descriptively by [CONTACT_853282], both 
by [CONTACT_853283]/kg (total daily and separately for each 
mealtime dose). Insulin doses will be summarised using the on-treatment observation period and 
using the safety analysis set.
Change from baseline in lipi[INVESTIGATOR_805]-lipoproteins profile 16 weeks after randomisation
Change from baseline in lipid endpoints (total cholesterol, HDL cholesterol, LDL cholesterol) will 
be logarithmically transformed and analysed separately based on all planned post baseline 
measurements until or at 16 weeks after randomisation using a model similar to 1) except with the 
corresponding log-transformed baseline as covariate. Estimated treatment means and the estimated 
treatment difference with corresponding 95% CI will be back-transformed to the original scale, 
resulting in estimated geometric means, a treatment ratio and a 95% CI for the treatment ratio.
[IP_ADDRESS] Safety endpoints
In terms of AEs, as a minimum, SAEs will be tabulated separately using the in-trial observation 
period.
All events in the in-trial observation period will be listed with information about whether it 
appeared in the on-treatment observation period or not.
Number of treatment emergent adverse events
Adverse events (AEs) will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). AEs will be presented based on system organ class and preferred terms.
A Treatment Emergent Adverse Event (TEAE) is defined as an event that has an onset date on or 
after the first day of exposure to randomised treatment, and no later than seven days after the last 
day of exposure to randomised treatment.
TEAEs are summarised descriptively, whereas AEs not defined as treatment emergent are presented 
in listings, including AEs reported in the 30-day follow-up period. The summaries of TEAEs are 
made displaying the number of subjects with at least one event, the percentage of subjects with at 
least one event, the number of events and the event rate per 100 patient years of exposure. These 
summaries are done by [CONTACT_12917], severity, relation to insulin treatment, relation to technical complaint, premature treatment discontinuation due to AEs, AEs leading to withdrawal from trial
and outcome.
Furthermore, summary tables based on system organ class and preferred terms are made for:CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 93 of 113
!All TEAEs
!Serious TEAEs
!Possibly and probably related TEAEs
!Severe TEAEs
!TEAEs with preferred term that are experienced by [CONTACT_2669] 5% of the subjects in any 
treatment arm or by [CONTACT_2669] 5% of all subjects
For AEs where additional information is recorded, this will be listed.
AEs occurring during the run-in period are considered non-treatment emergent and will be 
summarised separately.
Number of treatment emergent injection site reactions
Treatment emergent injection site reactions occurring during the trial will be summarised and listed.
Classification of Hypoglycaemia
Treatment emergent: hypoglycaemic epi[INVESTIGATOR_853230], and no later than 
one day after the last day of exposure to randomised treatment.
Nocturnal hypoglycaemic epi[INVESTIGATOR_1841]: epi[INVESTIGATOR_111378] 00:01 and 05.59 both inclusive.   
Hypoglycaemic epi[INVESTIGATOR_513417] (see Figure 17â€“1 ) and the ADA classification of hypoglycaemia (see Figure 17â€“2 ).
Novo Nordisk classification of hypoglycaemia
In normal physiology, symptoms of hypoglycaemia occur below a PG level of 3.1 mmol/L (56 
mg/dL).41Therefore, Novo Nordisk has included hypoglycaemia with PG levels below this cut-off 
point in the definition of BG confirmed hypoglycaemia.
Novo Nordisk uses the following classification (see Figure 17â€“1 ) in addition to the ADA 
classification: CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 94 of 113
!Severe hypoglycaemia according to the ADA classification.34
!Severe or BG confirmed hypoglycaemia: An epi[INVESTIGATOR_635610]34or BG confirmed by a PG value <3.1 mmol/L (56 mg/dL) with orwithout 
symptoms consistent with hypoglycaemia. 
Hypoglycaemic
epi[INVESTIGATOR_156028] â‰¤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurementPG < 3.1 mmol/L
(56 mg/dL)
with symptoms
PG < 3.1 mmol/L
(56 mg/dL)
without
symptomsSymptomatic BG 
confirmed 
hypoglycaemia
Asymptomatic BG 
confirmed 
hypoglycaemiaYesNo
Severe or 
BG confirmed symptomatic 
hypoglycaemia
BG confirmed 
hypoglycaemia
Severe or BG 
confirmed 
hypoglycaemia
Note: Glucose measurements are performed with capi[INVESTIGATOR_156029]: blood glucose  PG: plasma glucose  SMPG: Self-measured plasma glucose  Subject 
able to 
treat him/
herselfSevere 
hypoglycaemia
(ADA 2013)
Figure 17â€“1 Novo Nordisk classification of hypoglycaemiaCONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 95 of 113
ADA classification34of hypoglycaemia 
!Severe hypoglycaemia: An epis ode requiring assistance of another person to actively 
administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose 
concentrations may not be available during an event, but neurological recovery following 
the return of PG to normal is considered sufficient evidence that the event was induced by a 
low PG concentration.
!Asymptomatic hypoglycaemia: An epi[INVESTIGATOR_36245], but with a measured PG concentration â‰¤ 3.9 mmol/L (70 mg/dL).
!Documented symptomatic hypoglycaemia: An epi[INVESTIGATOR_36246] a measured PG concentration â‰¤ 3.9 mmol/L (70 
mg/dL).
!Pseudo-hypoglycaemia: An epi[INVESTIGATOR_36247] a measured PG concentration > 3.9 mmol/L (70 
mg/dL) but approaching that level.
!Probable symptomatic hypoglycaemia: An epi[INVESTIGATOR_135529] a PG determination but that was presumably caused by a PG concentration â‰¤ 3.9 mmol/L (70 mg/dL).
Hypoglycaemic 
epi[INVESTIGATOR_36249] â‰¤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurementAsymptomatic 
hypoglycaemia
Documented 
symptomatic 
hypoglycaemia
Pseudo-
hypoglycaemia
Probable 
symptomatic 
hypoglycaemiaNo
Yes
No measurement 
with symptomsPG > 3.9 mmol/L 
(70 mg/dL)
with symptomsPG â‰¤3.9 mmol/L 
(70 mg/dL)
with symptomsPG â‰¤3.9 mmol/L 
(70 mg/dL)
without symptoms
NoYes
Note: Glucose measurements are performed with capi[INVESTIGATOR_135530]: plasma glucose  SMPG: Self-measured plasma glucose  Subject 
able to 
treat him/
herselfSevere 
hypoglycaemia
(ADA 2013)
Figure 17â€“2 ADA classification of hypoglycaemiaCONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187385] one event (N), the percentage of subjects with at least one event (%), the number of events 
(E) and the event rate per 100 years of exposure (R). Separate summaries are made by [CONTACT_853284][INVESTIGATOR_1841], nocturnal and daytime epi[INVESTIGATOR_853231]. All epi[INVESTIGATOR_853232], including summaries in relation to time 
since start of meal, as occurring during1, 2, and 4 hours after start of meal, and from 2 hours 
(exclusive) to 4 hours (inclusive) after start of meal, respectively.
The number of treatment emergent severe or BG confirmed hypoglycaemic epi[INVESTIGATOR_1841] (all, daytime, 
nocturnal, 1 hour, 2 hours, 4 hours and from 2 hours (exclusive) to 4 hours (inclusive) after start of 
the meal) will be analysed based on the FAS using a negative binomial regression model with a log-
link function and the logarithm of the time period in which a hypoglycaemic epi[INVESTIGATOR_778992]. The model will include treatment, region and metformin use at 
baseline (Yes/No) as factors. To the extent where data allow, separate analysis will be performed 
for severe hypoglycaemic epi[INVESTIGATOR_1841].
Change from baseline in clinical evaluations 16 weeks after randomisation:
Physical examination
The physical examination parameters (head, ears, eyes, nose, throat, neck, respi[INVESTIGATOR_2133], 
cardiovascular system, gastrointestinal system incl. mouth, musculoskeletal system, central and 
peripheral nervous system, skin), and their change from baseline, will be summarised descriptively
using the on-treatment period. All findings will be listed.
Vital signs
Vital signs include diastolic blood pressure, systolic blood pressure and pulse. The measurements 
will be summarised descriptively using the on-treatment period and both actual values as mean 
change and change from baseline.
Electrocardiogram
ECG findings will be summarised descriptively using the on-treatment period and including 
summaries of the change from baseline. Change from baseline will be summarised as 
normal/abnormal not clinically significant/abnormal clinically significant categorisation in shift tables.
Fundoscopy/fundus photography
Fundoscopy/fundus photography findings will be summarised descriptively using the on-treatment 
period and including summaries of the change from baseline. Change from baseline will be CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 97 of 113
summarised as normal/abnormal not clinically significant/abnormal clinically significant 
categorisation in shift tables.
Change from baseline in clinical laboratory assessments 16 weeks after randomisation
Change from baseline 16 weeks after randomisation in central laboratory assessments:
!Haematology (erythrocytes, haematocrit, haemoglobin, leucocytes, thrombocytes)
!Biochemistry (ALT, AST, albumin, alkaline phosphatase, creatinine, potassium, sodium, 
total bilirubin)
Individual laboratory values will be compared to their relevant reference range (when existing) and 
flagged as being below or above the range. The measurements and their change from baseline will 
be summarised descriptively using the on-treatment period. Change from baseline will be 
summarised both the actual values and the low/normal/high categorisation in shift tables.
Change from baseline in body weight and body mass index [ADDRESS_1187386] baseline 
measurements until or at 16 weeks after randomisation using a statistical model similar to 1) except 
with the corresponding baseline measurement as covariate.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187387] T2DM at a stage where basal-bolus treatment is needed (i.e. subjects must have 
been diagnosed with T2DM for [ADDRESS_1187388] 365 days prior to screening). 
Subjects taking metformin at the enrolment in the trial should continue the metformin treatment 
unchanged. Metformin plus basal/bolus insulin is a recommended treatment for subjects with 
T2DM9and the combination of metformin and basal-bolus insulin therapy with faster aspart or 
NovoRapidÂ®as the bolus insulin was included in the phase 3A faster aspart trials in T2DM. 
The most common side effect of all available insulin preparations is hypoglycaemia. The 
investigator will explain to the subject how they should check their BG with the BG meter provided 
by [CONTACT_853285].
Trial products will be provided by [CONTACT_853286]. When treatment 
with trial products ends, the subject and investigator will decide on the best available treatment on 
the market. Novo Nordisk will not offer any free medications after the completion of the trial.
Summary of clinical pharmacology
The pharmacokinetic and pharmacodynamic profiles of faster aspart consistently demonstrated a 
left shift compared to that of NovoRapidÂ® in subjects with T1DM and the profiles for faster aspart 
and NovoRapidÂ®were similar in overall shape. Faster aspart produced a faster onset of exposure 
and increased initial absorption rate compared to NovoRapidÂ®resulting in a faster onset of action 
and increased early glucose-lowering effect. Overall, the differences in the pharmacokinetic and 
pharmacodynamic properties for faster aspart compared to NovoRapidÂ®were consistent across 
trials.22No safety concerns were raised during any of the trials. 
Similar clinical pharmacology trials have not been performed in subjects with T2DM, however the phase 3A programme for faster aspart included trials in bolus naÃ¯ve T2DM subjects. Non-inferiority 
to NovoRapid
Â®with regard to HbA 1cchange from baseline was demonstrated. In subjects with 
T2DM faster aspart statistically significantly improved control of the 1-hour PPG increment when 
compared to NovoRapidÂ®.22No safety issues for faster aspart have been identified based on data 
from the clinical development programme, and the safety profile is similar to NovoRapidÂ®.22CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187389] and compare safety of faster aspart compared to 
NovoRapidÂ®both in combination with insulin degludec with or without metformin in subjects with 
T2DM treated with a basal-bolus regimen.
For the individual subjects, the personal health-related benefits are related to the medical 
examination and the benefit from an intensified treatment regimen anticipated to be better than or 
equal to the treatment they receive at the time they enter the trial. However, subjects will have to 
spend some extra time monitoring and recording data and on additional visits to the clinic and 
phone contacts.
The very high frequency of contacts between the subject and the investigator and the thorough 
evaluation of SMPG values will provide the opportunity for optimising the titration of basal and 
bolus insulin based on SMPG values and thereby [CONTACT_826708] 1c
results. All subjects will have reinforced dietary training including simple carbohydrate counting.
For the individual subjects, the anticipated risks include hypoglycaemia, hyperglycaemia, systemic 
allergic reactions, injection site reactions, lipodystrophy, and antibody development. The risks will 
be mitigated by [CONTACT_826709].
A consequence of the pharmacodynamics of rapid-acting insulin analogues is that if hypoglycaemia 
occurs, it may occur earlier after an injection than with soluble human insulin. A phase 3A trial with 
faster aspart in T2DM showed a slight shift in distribution of the occurrence of hypoglycaemic 
epi[INVESTIGATOR_853233] a meal when comparing to NovoRapidÂ®. A statistical significant higher rate 
of hypoglycaemic epi[INVESTIGATOR_853234] [ADDRESS_1187390]â€™s safety. 
Lipodystrophy (including lipohypertrophy, lipoatrophy) at the injection site can occur. Continuous rotation of the injection site within the particular injection area may help to reduce the risk of 
developi[INVESTIGATOR_826655].
The blood samples during meal tests might be inconvenient to the subjects, but are not of any safety 
concern.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187391] to mixing up the pens used for basal 
and bolus injection. Subjects will be trained in distinguishing between the pens. It is expected that 
the risk of mixing up basal and bolus insulin in this trial is similar to other clinical trials.
No maximum dose of insulin is specified as doses are titrated individually. All subjects will perform 
4-point profiles on a daily basis throughout the trial for safety purposes and for the purpose of 
insulin titration.
Conclusion
Subjects in this trial will benefit from an intensified insulin treatment in a basal-bolus regimen in a 
treat-to-target setting under close supervision.
The safety profile of insulin aspart is well established from the market use of NovoRapidÂ®. The data 
available for faster aspart in non-clinical and clinical studies taken together with review of the 
additional excipi[INVESTIGATOR_853235].
It is therefore concluded that the clinical benefits from the trial as well as the contribution to the 
development of a new faster aspart outweigh the potential risks of participating in this trial.
18.[ADDRESS_1187392] comply with applicable 
regulatory requirement(s) and adhere to ICH GCP1and the requirements in the Declaration of 
Helsinki.[ADDRESS_1187393] 
before any trial-related activity.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187394]â€™s willingness to continue 
participating in the trial, the investigator must inform the subject in a timely manner, and a revised 
written subject information must be provided and a new informed consent must be obtained.
18.[ADDRESS_1187395]â€™s data will be handled 
as follows:
!Data already collected and any data collected at the end-of-trial visit including follow-up 
visits will be retained by [CONTACT_3454], entered into the database and used for the clinical 
trial report. 
!Safety events will be reported to Novo Nordisk and regulatory authorities according to 
local/national requirements.
If data is used, it will always be in accordance with local regulations and IRBs/IECs.
18.[ADDRESS_1187396] may 
receive a â€œwelcome to the trial letterâ€ and a â€œthank you for your participation letterâ€ after 
completion of the trial. Further the subject may receive letters during the trial.
All written information to subjects must be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_17950].
18.5 Premature termination of the trial and/or trial site
Novo Nordisk, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial 
or a trial site at any time, but agreement on procedures to be followed must be obtained.
If the trial is suspended or prematurely terminated, the investigator must inform the subjects 
promptly and ensure appropriate therapy and follow-up. The investigator and/or Novo Nordisk must 
also promptly inform the regulatory authorities and IRBs/IECs and provide a detailed written 
explanation. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187397] be 
provided to the IRBs/IECs in case it has an impact on the planned follow-up of subjects who have 
participated in the trial. If it has an impact, the actions needed to inform and protect the subjects 
should be described.
[ADDRESS_1187398] be documented and explained in a protocol deviation by [CONTACT_18030], date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the trial database.
Documentation on protocol deviations must be kept in the investigator trial master file and sponsor 
trial master file.
19.[ADDRESS_1187399] be instructed to complete their diary ongoing according to the protocol. Missing 
data will not be recorded retrospectively due to the decreased validity of such data36, 37; however a 7 
daysâ€™ timeline is applied for reporting of missing hypoglycaemic epi[INVESTIGATOR_1865], The subject will be retrained in correct completion of the diary if missing data is identified.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 103 of 113
The investigator will make every effort to ensure that all assessments are performed and data is 
collected. If missing data does occur the reason will be collected via the protocol deviation process, 
see section 19.1. Novo Nordisk will monitor protocol deviations on an on-going basis throughout 
the trial followed by [CONTACT_36340] (e.g. re-training of site staff).
[ADDRESS_1187400] to audits conducted by [CONTACT_36341]/IECs. Audits and inspections may 
take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff 
have an obligation to cooperate and assist in audits and inspections. This includes giving auditors 
and inspectors direct access to all source documents and other documents at the trial site relevant to 
the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are relevant to the evaluation of the trial.
[ADDRESS_1187401] be available to Novo Nordisk:
!Regulatory approval and/or acknowledgement of notification as required 
!Approval/favourable opi[INVESTIGATOR_36254]/IECs clearly identifying the documents reviewed as 
follows: protocol, any protocol amendments, subject information/informed consent form, 
any other written information to be provided to the subject and subject recruitment materials
!List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
!Curricula vitae of investigator and sub-investigator(s) (current, dated and signed - must 
include documented GCP training or a certificate)
!Signed receipt of IB
!Signed and dated Agreement on Protocol
!Signed and dated Agreement on Protocol Amendment, if applicable
!Contract, signed by [CONTACT_1755]/or appropriate parties on behalf of the investigatorâ€™s 
site and Novo Nordisk
!Source document agreement
!Central laboratory certification and normal ranges
!Insurance statement, if applicable
!Financial disclosure form from investigator and sub-investigator(s)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 104 of 113
!For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest
!For US trial sites: FDA form [ADDRESS_1187402] be completed and signed by [CONTACT_237205] 1572:
For US sites:
!Intended for US sites
!Conducted under the Investigational new drug (IND)
!All US investigators, as described above, will sign FDA Form 1572
For sites outside the US:
!Intended for participating sites outside of the US
!Not conducted under the Investigational new drug (IND)
!All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will analyse and report data from all sites together if more than one site is involved in 
the trial.
By [CONTACT_36343], each investigator agrees to comply fully with ICH GCP1,
applicable regulatory requirements and the Declaration of Helsinki.2
By [CONTACT_36343], each investigator also agrees to allow Novo Nordisk to make 
investigatorâ€™s name [CONTACT_36374] [CONTACT_36344].
[ADDRESS_1187403] of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the trial site. If any tasks are delegated, the investigator 
must maintain a log of appropriately qualified persons to whom he/she has delegated specified trial-
related duties. The investigator must ensure that there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigatorâ€™s responsibility to supervise the 
conduct of the trial and to protect the rights, safety, and well-being of the subjects.
A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible 
for all trial-related medical decisions.
The investigator will follow instructions from Novo Nordisk when processing data.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 105 of 113
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data 
produced) in the investigator trial master file. The documents including the subject identification 
code list must be kept in a secure locked facility, so no unauthorized persons can get access to the 
data.
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.
During any period of unavailability, the investigator must delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk.
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187404], if deemed necessary by [CONTACT_3454]. Provided that certain 
conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial to 
researchers who require access for research projects studying the same disease and/or trial product 
studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted clinical trial report for this trial.
One investigator will be appointed by [CONTACT_41170] 
(signatory investigator) on behalf of all participating investigators. The signatory investigator will 
be appointed based upon the criteria defined by [CONTACT_36346].[ADDRESS_1187405] for 
Clinical Trial Disclosure.28
Novo Nordisk reserves the right to defer the release of data until specified milestones are reached, for example when the clinical trial report is available. This includes the right not to release the 
results of interim analyses, because the release of such information may influence the results of the 
entire trial.
At the end of the trial, one or more scientific publications may be prepared collaboratively by [CONTACT_1275](s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to [ADDRESS_1187406] intellectual property.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 107 of 113
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. All authors will be given the relevant 
statistical tables, figures, and reports needed to evaluate the planned publication. In the event of any 
disagreement on the content of any publication, both the investigatorsâ€™ and Novo Nordisk opi[INVESTIGATOR_36255].
Where required by [CONTACT_18038], the investigator from each trial site will be named in an 
acknowledgement or in the supplementary material, as specified by [CONTACT_18038]. 
Novo Nordisk maintains the right to be informed of plans by [CONTACT_36347], presentation, communication or other information concerning the 
investigation described in this protocol. Any such communication must be submitted in writing to 
Novo Nordisk before submission for comments. Comments will be given within four weeks from 
receipt of the planned communication .
Authorship
Authorship of publications should be in accordance with the Uniform Requirements of the 
International Committee of Medical Journal Editors42(sometimes referred to as the Vancouver 
Criteria).
Site-specific publication(s) by [CONTACT_1697](s)
For a multi-centre clinical trial, analyses based on single-site data usually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
subjects, and therefore may not be supported by [CONTACT_3454]. It is a Novo Nordisk policy that 
such individual reports do not precede the primary manuscript and should always reference the 
primary manuscript of the trial.
Novo Nordisk reserves the right to prior review of such publications. Further to allow for the 
primary manuscript to be published as the first, Novo Nordisk asks for deferment of publication of 
individual site results until the primary manuscript is accepted for publication. As Novo Nordisk 
wants to live up to the industry publication policy, submission of a primary publication will take 
place no later than [ADDRESS_1187407] their own research subjects' data, and will be provided with the 
randomisation code after results are available.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187408]â€™s medical records must be kept for the maximum period permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper-
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if 
not otherwise notified. The investigator should not destroy any documents without prior permission 
from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk 
can refer the investigator to an independent archive provider that has a system in place to allow only 
the investigator to access the files.
The investigator must be able to access his/her trial documents without involving Novo Nordisk in 
any way. Site-specific CRFs and other subject data (in an electronic readable format or as paper 
copi[INVESTIGATOR_17951]) will be provided to the investigator before access is revoked to the systems and/or 
electronic devices supplied by [CONTACT_3454]. These data must be retained by [CONTACT_21655]. If the 
provided data (e.g. the CD-ROM) is not readable during the entire storage period, the investigator 
can request a new copy. A copy of all data will be stored by [CONTACT_3454].
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for at least [ADDRESS_1187409].
The files from the trial site/institution must be retained for 15 years after end of trial as defined in 
Section 7, or longer if required by [CONTACT_36348]. In any case trial files cannot 
be destroyed until the trial site/institution is notified by [CONTACT_3454]. The deletion process must 
ensure confidentiality of data and must be done in accordance with local regulatory requirements.  CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 109 of 113
25 Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval or favourable opi[INVESTIGATOR_36256]/IEC prior to commencement of 
the trial.
During the trial, the investigator or Novo Nordisk, as applicable, must promptly report the 
following to the IRB/IEC, in accordance with local requirements: updates to IB, unexpected SAEs 
where a causal relationship cannot be ruled out, protocol amendments according to local
requirements, deviations to the protocol implemented to eliminate immediate hazards to the 
subjects, new information that may affect adversely the safety of the subjects or the conduct of the 
trial (including new benefit-risk analysis in case it will have an impact on the planned follow-up of 
the subjects), annually written summaries of the trial status, and other documents as required by [CONTACT_36349]/IEC.
The investigator must ensure submission of the clinical trial report synopsis to the IRB/IEC.
Protocol amendments must not be implemented before approval or favourable opi[INVESTIGATOR_36257], unless necessary to eliminate immediate hazards to the subjects.
The investigator must maintain an accurate and complete record of all submissions made to the 
IRB/IEC. The records must be filed in the investigator trial master file and copi[INVESTIGATOR_36258].
Regulatory Authorities:
Regulatory authorities will receive the clinical trial application, protocol amendments, reports on 
SAEs, and the clinical trial report according to national requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187410] liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.
Novo Nordisk assumes no liability in the event of negligence, or any other liability of the sites or 
investigators conducting the trial, or by [CONTACT_18033].
Novo Nordisk accepts liability in accordance with:
Poland: Novo Nordisk carries liability for the trial exclusively in the scope defined by [CONTACT_136778] 6 September 
2001 (uniform version Journal of Laws of 2008 No. 45 item 271 with amendments). In order to 
support potential claims for liability attributable to the trial, Novo Nordisk and the investigators are 
covered by [CONTACT_36352].
Russia: Federal law of 12 April 2010 No. 61-FZ â€˜On Medicinal Drugsâ€™ Circulation and Ministry of 
Healthcare of Russian Federationâ€™ order of 01 April 2016 No. 200n â€œApproval of rules of good 
clinical practice.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 111 of 113
27 References
1. International Conference on Harmonisation. ICH Harmonised Tripatite Guideline. Guideline 
for Good Clinical Practise E6(R2), Step 4. [ADDRESS_1187411] of intensive treatment 
of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-86.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes ([LOCATION_006]PDS 33). [LOCATION_006] Prospective Diabetes Study ([LOCATION_006]PDS) Group. Lancet. 1998;352(9131):837-53, Erratum 1999; 354: 602.
5. Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, et al. Impact of fasting 
and postprandial glycemia on overall glycemic control in type 2 diabetes - Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Research and Clinical Practice. 2007;77(2):280-5.
6. International Diabetes Federation Guideline Development G. Guideline for management of 
postmeal glucose in diabetes. Diabetes Res Clin Pract. 2014;103(2):256-68.
7. Leiter LA, Ceriello A, Davidson JA, Hanefeld M, Monnier L, Owens DR, et al. Postprandial 
glucose regulation: New data and new implications. Clin Ther. 2005;27(Suppl B):S42-S56.
8. Brange J, Owens DR, Kang S, Volund A. Monomeric Insulins and Their Experimental and 
Clinical Implications. Diabetes Care. 1990;13(9):923-54.
9. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin 
aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care. 1999;22(5):801-5.
10. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-96.
11. Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. A comparison of two 
intensification regimens with rapid-acting insulin aspart in type 2 diabetes inadequately controlled by [CONTACT_8206]-daily insulin detemir and oral antidiabetes drugs: the STEP-Wise randomized study. Endocr Pract. 2011:727-36.
12. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B, et al. Comparison of insulin 
analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab. 2009;11(1):45-52.
13. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Munoz-Torres M, et al. Insulin 
degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, 
randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498-
507.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 112 of 113
14. Home PD, Lindholm A, Riis A, European Insulin Aspart Study Group. Insulin aspart vs. 
human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet Med. 2000;17(11):762-70.
15. Raskin P, Riis A, Guthrie RA, Jovanovic L, Leiter L. Use of insulin aspart, a fast-acting 
insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23(5):583-8.
16. Gallagher A, Home PD. The effect of improved post-prandial blood glucose control on post-
prandial metabolism and markers of vascular risk in people with Type [ADDRESS_1187412]. 2005;67(3):196-203.
17. Perriello G, Pampanelli S, Porcellati F, Avogaro A, Bosi E, Petrella G, et al. Insulin aspart 
improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial. Diabet Med. 2005;22(5):606-11.
18. Bretzel RG, Arnolds S, Medding J, Linn T. A direct efficacy and safety comparison of 
insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care. 2004;27(5):1023-7.
19. Novo Nordisk A/S. NovoRapid
Â®(insulin aspart), EU Summary of Product Characteristics 
(SmPC). 15 Nov 2016.
20. Novo Nordisk A/S. NovoLog (insulin aspart), US Prescribing Information (PI). [ADDRESS_1187413] 
2016.
21. Novo Nordisk A/S. Fiasp (insulin aspart), EU Summary of Product Characteristics (SmPC). 
03 Feb 2017.
22. Novo Nordisk A/S. Investigator's Brochure, Faster-acting Insulin Aspart (9th Edition). 2016.23. Novo Nordisk A/S. Tresiba
Â®(insulin degludec) EU Summary of Product Characteristics 
(SmPC). August 2015.
24. Novo Nordisk A/S. Investigator's Brochure, insulin degludec (TresibaÂ®), project NN1250, 
(edition 12). 14 Dec 2016.
25. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). 
Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus (CPMP/EWP/1080/00 Rev. 1). Adoption by [CONTACT_13633]. 14 May 2012.
26. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance 
for Industry. Diabetes Mellitus: Developi[INVESTIGATOR_853236], Draft Guidance. 2008.
27. Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensification with 
stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol. 2014;2(1):30-7.
28. Novo Nordisk A/S. http://www.novonordisk-trials.com/website/content/how-we-disclose-
trial-information.aspx.
29. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med. 2004;351(12):1250-1.
30. U.S. Food and Drug Administration. Food and Drug Administration Amendments Act of 
2007 as amended by [CONTACT_43679] "Clinical Trials Registration and Results Information Submission". 21 September 2017.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 113 of 113
31. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Councill of [ADDRESS_1187414] of clinical trials on medicinal products for human use, article 11. Official Journal of the European Communities. 1 May 2001.
32. The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, article 57. Official Journal of the European Communities. 2004.
33. Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced 
awareness of hypoglycemia in  adults with IDDM. A prospective study of hypoglycemic 
frequency and associated symptoms. Diabetes Care. 1995;18(4):517-22.
34. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia 
and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384-95.
35. McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. 
Diabet Med. 2001;18(9):690-705.
36. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance 
for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. December 2009.
37. Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-
reported outcomes: challenges and potential solutions. Curr Med Res Opin. 2009;25(4):929-42.
38. European Commission. The Rules Governing Medicinal Products in the European Union, 
Volume 4, Annex 13, Investigational Medicinal Products. Brussels, February 2010.
39. International Conference of Harmonisation. ICH Harmonised Tripartite Guideline E9. 
Statistical Principles for Clinical Trials, Step 4 Version. 5 Feb 1998.
40. Koch GG. Comments on 'Current issues in non-inferiority trials' by [CONTACT_19617] R. Fleming, 
Statistics in Medicine, DOI: 10.1002/sim.2855. Stat Med. 2008;27(3):333-42.
41. Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of 
glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest. 1987;79(3):777-81.
42. International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals; current version 
available at www.icmje.org .CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 1 of 112
Protocol
Trial ID:NN1218-4113
Updated protocol including:
Protocol, final version 2.[ADDRESS_1187415]-acting Insulin Aspart Compared to 
NovoRapidÂ®both in Combination with Insulin Degludec with or 
without Metformin in Adults with Type 2 Diabetes (onsetÂ®9)
Trial phase: 3b
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 2 of 112
Table of Contents
Page
Table of Contents.............................................................................................................. ..........................2
Table of Figures ............................................................................................................... ...........................5
Table of Tables................................................................................................................ ............................5
1 Summary ............................................................................................................................... ...............8
2 Flow chart .................................................................................................................... ......................11
3 Background information and rationale for the trial .........................................................................14
3.1 Background information ..........................................................................................................14
3.1.1 Therapeutic Area ...................................................................................................14
3.1.2 N ovoRapidÂ® (Insulin aspart) ...................................................................................[ADDRESS_1187416]-acting insu lin aspart........................................................................................15
3.1.4 Insulin degl udec.....................................................................................................17
3.2 Rationale for the trial ...............................................................................................................17
4 Objectives and endpoints ...................................................................................................................18
4.1 Objectives ............................................................................................................................... 18
4.2 Endpoints ............................................................................................................................... .18
4.2.1 Prima ry endpoint ...................................................................................................18
4.2.2 Sec ondary endpoints ..............................................................................................18
[IP_ADDRESS] Confirmatory seco ndary endpoints ...................................................18
[IP_ADDRESS] Supportive sec ondary endpoints .......................................................[ADDRESS_1187417] replacement ................................................................................................................29
6.9 Rationale for trial population ...................................................................................................29
7 Milestones ............................................................................................................................... ............31
8 Methods and assessments ....................................................................................................... ...........32
8.1 Visit procedures ......................................................................................................................32CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 3 of 112
8.1.1 Screening (Vis it 1).................................................................................................32
8.1.2 Run-in ...................................................................................................................3 3
8.1.3 Ra ndomisation .......................................................................................................33
8.1.4 Phone  contacts .......................................................................................................34
8.1.5 Fasting vi sits..........................................................................................................34
8.1.6 Rescheduled visits..................................................................................................34
8.1.7 End of treatment ....................................................................................................34
8.1.8 Follow-up pe riod ...................................................................................................35
8.1.9 Premature discon tinuation of trial products .............................................................35
8.1.10 Withdrawal from trial .............................................................................................36
[IP_ADDRESS] Lost to fo llow-up..............................................................................[ADDRESS_1187418] related information/assessments ..................................................................................38
8.2.1 Dem ography ..........................................................................................................38
8.2.2 Diab etes history and diabetes complications ...........................................................38
8.2.3 H ypoglycaemia unawareness .................................................................................38
8.2.4 Conco mitant illness and medical history .................................................................38
8.2.5 Conco mitant medication ........................................................................................39
8.2.6 Conco mitant medication (diabetes) ........................................................................[ADDRESS_1187419] ................................................................................................................41
8.3.2 Discon tinuation of MyGlucoHealth BG-meter and electronic diary ........................44
8.3.3 Self-meas ured plasma glucose ................................................................................44
8.3.4 Insulin dos e ...........................................................................................................46
8.4 Safety assessments ........................................................................................................... .......47
8.4.1 Adverse even ts.......................................................................................................47
[IP_ADDRESS] Medicati on error ...............................................................................47
[IP_ADDRESS] Adverse events requiring additional data collection ..........................48
8.4.2 H ypoglycaemic epi[INVESTIGATOR_1841] ........................................................................................48
8.4.3 Eye examinat ion ....................................................................................................51
8.4.4 Electrocardiogram â€“ [ADDRESS_1187420] compliance .................................................................................................................57
9 Trial supplies ............................................................................................................................... .......59
9.1 Trial products ..........................................................................................................................59
9.2 Labelling................................................................................................................... ..............59CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 4 of 112
9.3 Storage..................................................................................................................... ...............60
9.4 Drug accountability and destruction ........................................................................................60
9.5 Auxiliary supplies ...................................................................................................................61
10 Interactive voice/web response system ..............................................................................................61
11 Randomisation procedure and breaking of blinded codes................................................................62
11.1 Breaking of bli nded codes .................................................................................................. .....62
12 Adverse events, technical complaints and pregnancies .....................................................................63
12.1 Defi nitions ..............................................................................................................................6 3
12.1.1 Adverse ev ent ........................................................................................................63
12.1.2 Serious advers e event.............................................................................................64
12.1.3 Non-serious adve rse event......................................................................................65
12.1.4 Medica tion errors ...................................................................................................65
12.1.5 Advers e events requiring additional data collection ................................................65
12.1.6 Technical complaints .............................................................................................66
12.2 Reporting of a dverse events .....................................................................................................66
12.3 Follow-up of adve rse events................................................................................................ ....68
12.4 Technical complaints a nd technical complaint samples ............................................................69
12.4.1 Reporti ng of technical complaints ..........................................................................69
12.4.2 Co llection, storage and shipment of technical complaint samples ...........................70
12.5 Pregnancies in female subjects ................................................................................................71
12.6 Precautions and/or overdose ....................................................................................................72
12.7 Committees related to safety ...................................................................................................72
12.7.1 Novo N ordisk safety committee .............................................................................72
13 Case report forms ............................................................................................................ ..................73
13.1 Corrections to case report forms ..............................................................................................73
13.2 Case report form flow .............................................................................................................74
14 Monitoring procedures ........................................................................................................ ..............74
15 Data management ..............................................................................................................................7 5
16 Computerised systems ......................................................................................................... ..............76
17 Statistical considerations ...................................................................................................................77
17.1 Sample size calculation ...........................................................................................................79
17.2 Definition of analysis sets ........................................................................................................81
17.3 Primary endpoint .....................................................................................................................81
17.4 Secondary endpoints ...............................................................................................................85
17.4.1 Confirmatory s econdary endpoints .........................................................................85
17.4.2 S upportive secondary endpoints .............................................................................87
[IP_ADDRESS] Efficacy endpoints ............................................................................87
[IP_ADDRESS] Safety endpoints ...............................................................................91
18 Ethics....................................................................................................................... ...........................97
18.1 Benefit-risk asse ssment of the trial ....................................................................................... ...97
18.2 Informed consent ....................................................................................................................99
18.3 Data handling ........................................................................................................................100
18.4 Informati on to subjects during trial ........................................................................................100
18.5 Premature termination of the trial and/or trial site ..................................................................100CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 5 of 112
19 Protocol compliance .........................................................................................................................101
19.1 Protocol  deviations ................................................................................................................101
19.2 Prevention of mi ssing data ................................................................................................. ...101
20 Audits and inspections ....................................................................................................... ..............102
21 Critical documents........................................................................................................... ................102
22 Responsibilities ............................................................................................................................... ..103
23 Reports and publications ..................................................................................................... ............105
23.1 Communicati on of results ......................................................................................................105
23.2 Investigator access to data and review of results ....................................................................106
24 Retention of clinical trial documentation ........................................................................................107
24.1 Retention of clinical trial documentation ...............................................................................107
25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities ...........[ADDRESS_1187421] of key staff and relevant departments, if applicable for the individual country
Table of Figures
Page
Figure 5â€“1 Trial Design. ......................................................................................................................21
Figure 12â€“1 Reporting of AEs .................................................................................................... ...........67
Figure 17â€“1 Novo Nordisk classification of hypoglycaemia ...................................................................93
Figure 17â€“2 ADA classification of hypoglycaemia .................................................................................94
Table of Tables
Page
Table 8â€“[ADDRESS_1187422] schedule ..............................................................................................................43
Table 8â€“2 7-point SMPG profiles with additional 9-point SMPG profile .............................................46
Table 9â€“1 Trial products .....................................................................................................................59
Table 9â€“2 Storage conditions.................................................................................................... ..........60
Table 17â€“1 Specifications assumed for sample size calculations ...........................................................80
Table 17â€“2 Sensitivity of sample size to power .....................................................................................80CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187423] aspartate aminotransferase
BG Blood glucose
CRF case report form
DUNdispensing unit number
ECG electrocardiogram
eCRF electronic case report form
eDiary electronic diary FAS full analysis setFDA U.S. Food and Drug AdministrationFPG fasting plasma glucoseGCP Good Clinical PracticeGLP-1 glucagon-like peptide-1HbA
1c glycosylated haemoglobin
IB Investigatorâ€™s BrochureICH International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceut icals for Human Use
IEC independent ethics committeeIMP investigational medicinal productCONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187424]
IWRSinteractive voice/web response 
system
LPLV last patient last visit
NIMPnon-investigational medicinal 
product
OAD oral antidiabetic drug
PG plasma glucose
PPG postprandial glucose
PP per protocolSAE serious adverse event
SmPC summary of product characteristics
SMPG self-measured plasma glucose
S[LOCATION_003]Rsuspected unexpected serious adverse 
reaction
T1DM Type 1 diabetes mellitusT2DM Type 2 diabetes mellitus
TEAE Treatment Emergent Adverse Event 
TMM Trial Materials Manual
UTN Universal Trial NumberCONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 8 of 112
1 Summary
Objective(s) and endpoint(s):
Primary objective
To confirm the effect in terms of glycaemic control of treatment with fast-acting insulin aspart 
compared to NovoRapidÂ®both in combination with insulin degludec with or without metformin in 
adults with type [ADDRESS_1187425]-acting insulin aspart compared to NovoRapidÂ®both in combination 
with insulin degludec with or without metformin in a dults with type 2 diabetes mellitus treated with 
a basal-bolus regimen in terms of:
!Postprandial glucose regulation
!Overall glycaemic control 
!Postprandial glucose excursions 
To compare the safety of fast-acting insulin aspart to NovoRapidÂ®both in combination with insulin 
degludec with or without metformin in adults with type 2 diabetes mellitus treated with a basal-bolus regimen.
Primary endpoint
Change from baseline in HbA
1c16 weeks after randomisation
Key secondary endpoints
Confirmatory secondary endpoints:
!Change from baseline in 1-hour postprandial glucose increment 16 weeks after 
randomisation (meal test)
!Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation
Trial design:
This is a phase 3b, 16-week, multicentre, mu ltinational, 1:[ADDRESS_1187426]-acting insulin aspart to NovoRapid
Â®both in combination with insulin degludec with 
or without metformin in subjects with type 2 di abetes mellitus treated with  a basal-bolus regimen. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187427]-acting insulin aspart and mealtime 
NovoRapidÂ®.
Trial population:
A total of 1803 subjects with Type 2 diabetes mellitus are planned to be screened and 1072 are 
planned to be randomised.
Key inclusion criteria:
!Male or female, age â‰¥ 18 years at the time of signing informed consent.
!Diagnosed with type 2 diabetes mellitus â‰¥ 10 years prior to screening (Visit 1).
!Treated with a basal-bolus insulin regimen â‰¥ 1 year prior to the day of screening (Visit 1). A 
basal-bolus insulin regimen is defined as basal insulin once or twice daily and bolus insulin 
analogue taken with meals at least 3 times daily. Tr eatment with premixed insulin or soluble 
insulin combination is not considered a basal-bolus regimen.
!Treated with or without oral antidiabetic drugs including extended release formulations.
!HbA 1c7.0-10.0% (both inclusive) as assessed by [CONTACT_21922] (Visit 1).
Key exclusion criteria:
!Any of the following: myocardial infarcti on, stroke, hospi[INVESTIGATOR_826623] 180 days prior to the day of screening (Visit 1). 
!Subjects presently classified as being in [LOCATION_001] Heart Association (NYHA) Class IV. 
!Planned coronary, carotid or peripheral artery revascularisation known on the day of 
screening (Visit 1).
!Treatment with injectable GLP-1 receptor agonists in a period of 90 days prior to screening 
(Visit 1). 
!Anticipated initiation or change in concomitant medications (for more than 14 consecutive 
days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid 
hormones,  or corticosteroids).
Randomisation criterion:
!HbA 1câ‰¤ 9.0% measured by [CONTACT_23258] 13 (week -1).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 10 of 112
Key Assessments:
!HbA 1c
!Postprandial glucose increment (meal test)
!1,5-anhydroglucitol 
!Hypoglycaemic epi[INVESTIGATOR_1841]
!Adverse events
Trial product(s):
Investigational medicinal products:
!Test products: 
oFast-acting insulin aspart, 100 U/mL solution for subcutaneous injection, 3 mL 
PDS290 pen injector (blinded) 
oInsulin degludec, 100U/mL solution for subcutaneous injection, 3 mL PDS290 pen 
injector 
!Reference therapy: 
oInsulin aspart (NovoRapidÂ®), 100 U/mL solution for subcutaneous injection, 3 mL 
PDS290 pen injector (blinded)
Other medicinal products: 
!Rapid acting insulin analogues (NovoRapidÂ®or marketed formulations of insulin lispro or 
insulin glulisine) during run-in period
!Metformin, tablets for oral useCONFIDENTIAL
Protocol UTN: U1111-1180-0636 Date: 23 February 2018 Status: Final 1RYR1RUGLVN
Trial ID: NN1218-[ADDRESS_1187428] no.: 2016-000878-38 Version: 4.0 Page: [ADDRESS_1187429]
End of treatment
Premature 
discontinuation
Follow-up 1
Follow-up 2
Visit (V)
Phone contact (P)V1 V2P3
P4V5P6
P7
P8V9P10
P11
P12V13 V14 P15 V16 P17 V18P19
P20
P21V22P23
P24
P25V26P27
P28
P29V30 V30A V31 P32
Time of visit (weeks) -14 -12-11
-10-9-8
-7
-6-5-4
-3
-2-1 0 1 2 3 45
6
789
10
111213
14
1516+7 
days+30
days
Visit window (days) +10 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 0 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 +10 +[ADDRESS_1187430] RELATED INFO/ASSESSMENTS
Informed consent 18.2 X
In/exclusion criteria 6.[ADDRESS_1187431] 8.3.1 X X X
4-point profile (SMPG) 8.3.3 X XXXXXX X X X X X X X X X X X X
7-9-7-point profile (SMPG) 8.3.3 X X X X
1,5-anhydroglucitol 8.5.1 X X X X X X
Fasting plasma glucose 8.5.1 X X X X
Protocol UTN: U1111-1180-0636 Date: 23 February 2018 Status: Final 1RYR1RUGLVN
Trial ID: NN1218-[ADDRESS_1187432] no.: 2016-000878-38 Version: 4.0 Page: [ADDRESS_1187433]
End of treatment
Premature 
discontinuation
Follow-up 1
Follow-up 2
Visit (V)
Phone contact (P)V1 V2P3
P4V5P6
P7
P8V9P10
P11
P12V13 V14 P15 V16 P17 V18P19
P20
P21V22P23
P24
P25V26P27
P28
P29V30 V30A V31 P32
Time of visit (weeks) -14 -12-11
-10-9-8
-7
-6-5-4
-3
-2-1 0 1 2 3 45
6
789
10
111213
14
1516+7 
days+30
days
Visit window (days) +10 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 0 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 +10 +5
HbA 1c 8.5.1 X XXX X X X X X X
Fasting C-peptide 8.5.1 X
Lipi[INVESTIGATOR_805] 8.5.1 X X X X X
SAFETY
Adverse events8.4.1 , 
12X XXXXXXX XXXX X X X X XXXX X X
Injection site reactions [IP_ADDRESS] XXXXXXX XXXX X X X X XXXX X
Hypoglycaemic epi[INVESTIGATOR_1841] 8.4.[ADDRESS_1187434] 8.5.2 X X X X
TRIAL MATERIAL
Dispensing visit 9.4 X XXX X X X X X
New (prescribed) dose of trial insulin 8.3.4 X XXXX X X X X X X X X X X X X
Dosing (Start/stop date of trial insulin) 8.3.4 X X X X X
Insulin dose of basal and bolus insulin each day 8.3.4 X XXXXXX X X X X X X X X X X X X
Drug accountability 9.4 X XXX X X X X X X X
Protocol UTN: U1111-1180-0636 Date: 23 February 2018 Status: Final 1RYR1RUGLVN
Trial ID: NN1218-[ADDRESS_1187435] no.: 2016-000878-38 Version: 4.0 Page: [ADDRESS_1187436]
End of treatment
Premature 
discontinuation
Follow-up 1
Follow-up 2
Visit (V)
Phone contact (P)V1 V2P3
P4V5P6
P7
P8V9P10
P11
P12V13 V14 P15 V16 P17 V18P19
P20
P21V22P23
P24
P25V26P27
P28
P29V30 V30A V31 P32
Time of visit (weeks) -14 -12-11
-10-9-8
-7
-6-5-4
-3
-2-1 0 1 2 3 45
6
789
10
111213
14
1516+7 
days+30
days
Visit window (days) +10 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 0 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 Â±3 +10 +5
IWRS call 10 X X XXX X X X X X X X
BG-meter start datea 8.3.2 (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X)
REMINDERS
Handout ID card 8.1.[ADDRESS_1187437] in BG meter usea 8.3.2 , 
8.3.3X (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X)
Handout and instruct in subject mealtime insulin 
dose adjustment guide8.3.4 X
Diary collection 8.6.3 XX X X X X X X X X X
End of treatment 8.1.7 X X
End of trial X
a(X) is only applicable for subjects who have used the glycaemic data collection system (the combination of the MyGlucoHealth Wi reless BG-meter and an electronic 
diary) section 8.3.2 .
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187438] of 
the clinical trial at a trial site.
3.1 Background information
Improvement in long-term glucose control, as obtained  with intensified insulin therapy, may reduce 
the incidence of complications and delay the progression of existing complications in people with 
Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM).3, 4Postprandial 
hyperglycaemia contributes significantly to the glycosylated haemoglobin (HbA 1c) level and its 
control is thus essential for achieving the HbA 1ctarget level.5Postprandial hyperglycaemia is 
associated with increas ed risk of micro- and macro-vascular complications.6Lowering of 
postprandial hyperglycaemia may reduce the progression of atherosclerosis and cardiovascular 
events in patients with T2DM.[ADDRESS_1187439] possible extent. For that purpos e, rapid-acting insulin analogues were developed 
to more effectively control the postprandial glucose (PPG) excursions than subcutaneously injected 
human regular insulin, primarily through offering a faster onset and shorter duration of action.[ADDRESS_1187440] within prandial insulin therapy for people with diabetes. The current 
insulin analogues are not able to match the speed of the normal physio logical postmeal insulin 
secretion, leading to suboptimal control of blood glucose (BG), and exogenous insulin with a faster 
glucose lowering effect is needed for tighter PPG control. In addition, a faster glucose lowering 
effect is also likely to offer greater flexibility in the time of dosing around meals thus increasing convenience for the patients and may allow the patients to better match the insulin taken to the meal.
9
For an assessment of benefits and risks of the trial, see Section 18.1
3.1.1 Therapeutic Area
Due to the progressive nature of T2DM, many patients are likely to be candidates for intensified 
insulin therapy. Prandial insulin supplementation is recommended by [CONTACT_853249] (EASD)/American Diabetes Association (ADA) guidelines10for treatment 
intensification in patients with T2DM who do not reach HbA 1ctarget below 7.0% on oral 
antidiabetic drugs (OADs) and basal insulin alone. The recommendation is a stepwise addition of bolus insulin when significant PPG excursions o ccur. A trial investigating step-wise addition of 
bolus insulin (basal-plus regimen) showed that around 75% of patients enrolled in the trial needed CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187441] 
of the total prandial insulin dose is delivered w ith each meal in the majority of patients achieving 
HbA1c â‰¤7.0%.12When used as part of a basal-bolus regimen in patients with T2DM who had 
previously received other insulin and/or OAD regimens, insulin aspart in combination with insulin 
degludec was a safe, well tolerated and effective treatment associated with clinically relevant 
reductions in hyperglycaemia.13
3.1.2 NovoRapidÂ® (Insulin aspart)
Insulin aspart is currently marketed worldwide as NovoRapidÂ®(in US it is NovoLogÂ®) and is a 
rapid-acting insulin analogue indicated for the treatment of diabetes. In the remainder of this 
protocol the name [CONTACT_853319]Â®will be applied for the marketed formulation of insulin aspart.
Insulin aspart is homologous to human insulin, with the exception of the substitution of proline with 
aspartic acid at position B28. The rapid action of insulin aspart is related to a weakened tendency of the insulin molecules to self-associate due to this  modification and thereby [CONTACT_853250]. Compared with human insulin, NovoRapid
Â®
has a faster onset and a shorter duration of action, resulting in superior postmeal glucose control by 
[CONTACT_853251] a meal, both in subjects with T1DM3, 14, 15and 
in subjects with T2DM.16-18This also allows NovoRapidÂ®to be injected immediately before a meal, 
in contrast to regular human insulin which should be injected 30 minutes prior to the meal.
For further details, please refer to the current version of the NovoRapidÂ®EU Summary of Product 
Characteristics19(SmPC) and the U.S. NovoLogÂ®Label Information20.
3.1.[ADDRESS_1187442]-acting insulin aspart (faster aspart) (markedet as FiaspÂ®) is insulin aspart in a new formulation. 
Faster aspart is being developed with the objectiv e of achieving an increased early absorption of 
insulin aspart compared to NovoRapidÂ®thereby [CONTACT_1541] a faster insulin action. Faster aspart aims 
at approaching the physiolo gical prandial insulin secretion pattern better than currently available 
treatment and thereby [CONTACT_853287] a better PPG
control and increased flexibility in the time of dosing around meals comp ared with NovoRapidÂ®. 
Results from clinical pharmacology trials in adults comparing pharmacokinetic and pharmacodynamic properties of faster aspart and NovoRapid
Â®have shown that faster aspart resulted 
in an earlier onset of appearance and a greater early exposure to insulin aspart than NovoRapidÂ®in 
subjects with T1DM, with the largest differen ce found within the first [ADDRESS_1187443] than NovoRapidÂ®, but no 
statist ically signif icant difference between faster aspart and NovoRapidÂ®in total glucose-lowering 
effect.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 16 of 112
In a therapeutic confirmatory basal-bolus trial in a dult subjects with T1DM, fa ster aspart taken with 
the meal in combination with LevemirÂ®effectively improved glycaemic control and the reduction in 
HbA 1cwas statistically significantly larger than with NovoRapidÂ®. Mealtime faster aspart provided 
superior PPG control compared to NovoRapidÂ®based on 2-hour PPG increment during a meal test. 
A statistically significant difference was also demonstrated for 1-hour PPG increment (meal test) in 
favour of mealtime faster aspart. No  statist ically significant difference was seen in over all rate of 
severe or BG confirmed hypoglycaemic epi[INVESTIGATOR_853237]Â®. 
The rate during the first one hour after start of a meal, constituting a smaller fraction of all severe or BG confirmed hypoglycaemic epi[INVESTIGATOR_1841], was statistically significantly higher for faster aspart 
compared to NovoRapid
Â®. The overall safety profile for faster aspart and NovoRapidÂ®was similar 
and as expected for insulin aspart.
In a therapeutic confirmatory basal-bolus trial in adult subjects with T2DM, adding and titrating 
mealtime fa ster aspart in combination with insulin glargine also effectively improved glycaemic 
control and non-inferiority to NovoRapidÂ®regarding HbA 1cchange from baseline was confirmed. A 
statist ically si gnificant benefit in 2-hour PPG increment (meal test) could not be confirmed for 
faster aspart compared to NovoRapidÂ®. A statistically significant difference was demonstrated for 
1-hour PPG increment (meal test) in favour of faster aspart compared to NovoRapidÂ®. No 
statist ically signif icant difference was seen in overall rate of severe or BG confirmed 
hypoglycaemic epi[INVESTIGATOR_853202]Â®. The rate during the first two hours 
after start of a meal, constituting a small fraction of all severe or BG confirmed hypoglycaemic epi[INVESTIGATOR_1841], was statistically significantly higher for faster aspart co mpared to  NovoRapid
Â®. The 
overall safety profile for faster aspart and NovoRapidÂ®was similar and as expected for insulin 
aspart.
The safety profile of faster aspart is expected to be similar to that of NovoRapidÂ®. The insulin aspart 
molecule has a well-known safety profile based on more than 15 years of clinical experience. 
Compared to NovoRapidÂ®faster aspart contains excipi[INVESTIGATOR_853203] a faster init ial 
absorption of insulin aspart following subcutaneous injection. The added excipi[INVESTIGATOR_853238] U.S. Food and Drug Administrationâ€™s (FDA) list for approved drug products for injections, and no toxicological concerns have been predicted from subcutaneous use in humans at the proposed concentrations. For further details, please refer to the current version of the Fiasp
Â®SmPC21. If not 
approved in the country of interest detailed information for faster aspart is available in the current edition of the Investigatorâ€™s Brochure (IB)
22and any updates hereof.
At the time of this protocol issuance, faster aspart is approved in EU, US and Canada among others.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 17 of 112
3.1.4 Insulin  degludec
Insulin degludec (marketed as TresibaÂ®) is a basal insulin with an ultra-long duration of action for 
once-daily subcutaneous administration at any time of the day, preferably at the same time every 
day. After subcutaneous injection, soluble and stab le multi-hexamers are formed creating a depot of 
insulin in the subcutaneous tissue. Insulin degludec monomers gradually separate from the multi-
hexamers thus resulting in a slow and continuous delivery of insulin degludec into the circulation, 
leading to the observed ultra-long pharmacokinetic and pharmacodynamic profiles and thereby a flat and stable glucose-lowering effect. The duration of action of insulin degludec is beyond 42 hours within the therapeutic dose range.
For further details please refer to the current version of the Tresiba
Â®SmPC23. If not approved in the 
country of interest detailed information for insulin degludec is available in the current edition and 
any updates of the IB24.
At the time of this protocol issuance, insulin degludec is approved in more than [ADDRESS_1187444] and compare safety of faster aspart compared to 
NovoRapidÂ®both in combination with insulin degludec wi th or without metformin in subjects with 
T2DM treated with a basal-bolus reg imen. This trial will provi de new i nformation in subjects with 
T2DM already treated with a basal-bolus reg imen as this was not studied in the phase 3a
programme.
In the European Medicines Agency (EMA) and FDA note for guidance on clinical investigation of 
medicinal products for the treatment of diabetes, HbA 1cis considered the most widely accepted 
measure of overall, long-term glucose control. Consequently, HbA 1cwill be included as the primary 
endpoint.25, 26
The trial is intended to confirm that administration of faster aspart gives overall glycaemic control 
non-inferior to NovoRapidÂ®and to confirm that faster aspart, with its faster onset of action, is 
capable of demonstrating superior control of post prandial glucose regulation and excursions as well 
as a greater reduction in HbA 1cin subjects with T2DM.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187445] in terms of glycaemic control of treatment with faster aspart compared to 
NovoRapidÂ®both in combination with insulin degludec wi th or without metformin in adults with 
T2DM treated with a basal-bolus regimen, using a non-inferiority approach.
Secondary objectives
To confirm superiority of faster aspart compared to NovoRapidÂ®both in combination with insulin 
degludec with or without metformin in adults w ith T2DM treated with a basal-bolus regimen in 
terms of:
!Postprandial glucose regulation
!Overall glycaemic control 
!Postprandial glucose excursions 
To compare the safety of faster aspart to NovoRapidÂ®both in combination with insulin degludec 
with or without metformin in adults with  T2DM treated with a basal-bolus regimen.
4.2 Endpoints
Baseline is defined as randomisation (Visit 14) 
4.2.1 Primary endpoint
Change from baseline in HbA 1c16 weeks after randomisation
4.2.2 Secondary endpoints
[IP_ADDRESS] Confirmatory secondary endpoints
!Change from baseline in 1-hour PPG incremen t 16 weeks after randomisation (meal test)
!Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisationCONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 19 of 112
[IP_ADDRESS] Supportive secondary endpoints
Supportive secondary efficacy endpoints
!Change from baseline in fasting plasma glucose (FPG) 16 weeks after randomisation
!If a subject achieves HbA 1ctargets 16 weeks after randomisation:
oHbA1c < 7.0% 
oHbA1c < 7.0% without severe hypoglycaemia
!Change from baseline in 30- minutes, 1- hour,  2- hour, 3- hour and 4- hour PPG and 30-
minutes, 2- hour, 3- hour and 4- hour PPG incremen t 16 weeks after randomisation (meal 
test)
!Change from baseline in endpoints derived from the 7-9-7-point self-measured plasma 
glucose (SMPG)  profile 16 weeks after randomisation:
oMean of the 7-9-7-point profile
oPostprandial glucose and PPG increment (mean, breakfast, lunch, main evening meal)
oFluctuation in 7-9-7-point profile
oChange in the nocturnal SMPG measurements
!If a subject achieves PPG target (overall mean of daily PPG measurements in 7-9-7-point 
SMPG profile) 16 weeks after randomisation:
oOverall PPG (1 hour) â‰¤7.8 mmo l/L [140 mg/dL]
oOverall PPG (1 hour) â‰¤7.8 mmo l/L [140 mg/dL] without severe hypoglycaemia
!Insulin dose (Units/day and Units/kg/day; tota l basal, total bolus and individual meal insulin 
dose) 16 weeks after randomisation
!Change from baseline in lipi[INVESTIGATOR_805]-lipoproteins profile 16 weeks after randomisation (total 
cholesterol, high density lipoproteins (HDL) cholesterol, low density lipoproteins (LDL) 
cholesterol)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 20 of 112
Supportive secondary safety endpoints
!Number of treatment emergent adverse events (AEs) during 16 weeks after randomisation
!Number of treatment emergent injection site reactions during 16 weeks after randomisation
!Number of treatment emergent hypoglycaemic epi[INVESTIGATOR_853239] 16 weeks after randomisation
oOverall
oDaytime hypoglycaemic epi[INVESTIGATOR_853206] (00:01-05:59 â€“ inclusive)
oHypoglycaemic epi[INVESTIGATOR_853207] 1, 2, 4 hours and from 2 hours 
(exclusive) to 4 hours (inclusive) after start of meal
!Change from baseline in clinical evaluations 16 weeks after randomisation:
oPhysical examination
oVital signs (diastolic blood pressure, systolic blood pressure and pulse)
oElectrocardiogram 
oFundoscopy/fundus photography
!Change from baseline in central laboratory assessments 16 weeks after randomisation:
oHaematology (erythrocytes, haematocrit, haemoglobin, leucocytes, thrombocytes)
oBiochemistry (alanine aminotransferase (A LT), aspartate aminotransferase (AST), 
albumin, alkaline phosphatase, creatinine, potassium, sodium, total bilirubin)
!Change from baseline in body weight and body mass i ndex 16 weeks after randomisationCONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 21 of 112
5 Trial design
5.1 Type of trial
This is a phase 3b, 16-week, multicentre, multinational, 1:[ADDRESS_1187446] and safety of faster aspart to NovoRapid
Â®both in combination with insulin degludec with or without 
metformin in subjects with T2DM tr eated with a basal-bolus regimen. 
Figure 5â€“1 Trial Design.
The trial design is summarised in Figure 5â€“1 . The total duration of the trial is approximately 34 
weeks divided into the following periods:
!An approximately 2-week screening period
!A 12-week run-in period primarily for optimisation of the basal insulin and subject training
!A 16-week treatment period
!A 30-day follow-up period: FU1; 7 days after end of treatment and FU2; 30 days after end 
of treatment 
The trial includes a screening period followed by [CONTACT_413846]/phone contacts during the trial. At 
Visit 2, all eligible subjects will be enrolled in a 12-week run-in period. After the run-in period, 
subjects eligible for randomisation (HbA 1câ‰¤ 9.0% measured at Visit 13) will be randomised (1:1) to 
receive double blinded treatment with either faster aspart or NovoRapidÂ®both in combination with 
once daily insulin degludec with or without metformin.     -14    -12 weeks                            0                                                            16 weeks +7d+30d   Screening RandomisationFaster aspart + insulin degludec Â± metformin
NovoRapidÂ®+ insulin degludec Â± metformin 
End of 
treatment
Basal titration Bolus titrationBolus insulin analogue + insulin 
degludec Â± metforminFU1   FU2
12-week run-in period 16-week treatment 
periodHbA1câ‰¤9.0 % CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187447] at baseline (Visit 14 before randomisation) and at 
end of treatment (Visit 30). The meal test will be described in more details in section 8.3.[ADDRESS_1187448] a 30-day safety follow-up period.
5.2 Rationale for trial design
The 12-week run-in period has been included to ensure the subjects are being trained in the trial 
procedures and that the basal insulin titration is  optimised. A 16-week treatment period is needed to 
obtain valid and adequate efficacy and safety data. 
The rational for the simple carbohydrate counting (carbohydrate awareness) is to ensure that 
subjects are able to better control the carbohydrate amount of their meals aiming at a similar 
carbohydrate intake between days as a supplement to the algorithm based titration.
The rationale for the meal test is to evaluate PPG regulation after a standardised meal when 
injecting faster aspart compared to NovoRapidÂ®.
The treat-to-target approach, and thereby [CONTACT_853253], has been chosen in 
order to ensure optimal titration of faster aspart and NovoRapidÂ®.
The 7-day follow-up visit and 30-day follow up contact [CONTACT_853254]-up period.
5.2.1 Rational for choice of non-inferiority margin 
In a recently finalised faster aspart trial (NN1218-4049, data on file) with a bolus insulin naÃ¯ve 
T2DM adult population comparing a basal insulin treatm ent in addition to metformin to a full basal -
bolus insulin treatment in addition to metformin the estimated treatment effect in change from baseline HbA
1cwas - 0.94% [-1.17; -0.72]. In this trial the addition of 3 times daily faster aspart led 
to a reduction in HbA 1cof 1.16% after 18 weeks of treatment. In a similar phase 4 trial27
investigating the stepwise addition of NovoRapidÂ®to a full basal-bolus regimen in bolus naÃ¯ve 
T2DM adults the observed reduction in HbA 1cafter 21 weeks of treatment was 1.15% (data ANA-
3786, data on file) with 3 times daily NovoRapidÂ® added to basal insulin. This gives some 
indication that the effect of NovoRapidÂ®versus placebo would be close to the 0.94% observed in 
trial NN1218-4049. Thus using a non-inferiority margin of 0.4%, one of the suggested margins in the FDA guidance
26, an improvement of approximately 0.54% would have been preserved using the 
0.4% non-inferiority margin.
5.[ADDRESS_1187449] CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187450] be stopped at Visit 2. For subjects treated with metformin prior to the trial, they should continue with their pre-trial dose of metformin. The dose and dosing frequency of metformin should not be changed at any time during the trial, unless due to safety concerns. Initiation of any other diabetes treatment is not allowed during the screening, run -in or treatment period and must be 
reported (see section 8.2.6 ).This includes metformin for subjects not treated with metformin prior 
to the trial. During the run-in period, the investigator will focus on optimising the basal insulin treatment using a treat-to-target approach following the titration guideline ( Appendix A ). The bolus 
insulin will not be titrated during the run-in period unless the investigator finds it necessary to adjust the bolus insulin for safety reasons. All subjects will receive dietary training regarding simple carbohydrate counting (carbohydrate awareness) in the run-in period.
All subjects should consume 3 main meals (breakfast, lunch and dinner) daily throughout the trial.In the treatm ent period, eligiblesubjects must discontinue their pre-trial bolus insulin analogue and 
will receive double blinded treatment with either faster aspart or NovoRapid
Â®both in combination 
with once daily insulin degludec with or wit hout metformin. The invest igator should focus on 
optimising the bolus insulin treatment following the bolus dosing algorithm as described in the 
titration guideline ( Appendix A ). Surveillance of insulin titration will be performed by [CONTACT_49753].
The maximum duration of  treatment will be 28 weeks. No maximum dose is specified. Doses are 
adjusted according to SMPG values ( Appendix A ).
Use of flash glucose monitoring or a real time continuous glucose monitoring system is not allowed 
throughout the trial.
5.[ADDRESS_1187451] and long half-life of insulin 
degludec.
5.5 Rationale for treatment
Based on the currently available pharmacokinetic data on faster aspart, it is anticipated that 
treatment with faster aspart as a mealtime insulin will enable insulin therapy to more closely 
approach a physiologic insulin secretory pattern. Consequently, the PPG excursions may be more 
effectively controlled. For further details, please refer to the current version of the faster aspart SmPC
21or IB.22CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 24 of 112
NovoRapidÂ®will be used as a comparator to faster aspart in order to compare the effect and safety 
of faster aspart to the currently marketed insulin aspart formulation. As this is a double-blind trial, 
NovoRapidÂ®and faster aspart will be titrated following the same recommendations.
Insulin degludec has been chosen as the basal insulin because it is a once-daily basal insulin and as 
effect and safety has been confirmed in adult subjects. The flat and stable glucose-lowering effect of 
insulin degludec makes it optimal when assessing the properties of bolus insulin (faster aspart 
compared to NovoRapidÂ®).
Combination of insulin treatment with metformin is associated with better glycaemic control, fewer 
hypoglycaemic events, and less weight gain than treatment with insulin alone, therefore metformin 
should be continued when type 2 patients are on insulin therapy.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 25 of 112
6 Trial population
6.1 Number of subjects 
Number of subjects planned to be screened: 1803
Number of subjects planned to be included in the run-in period: 1262Number of subjects planned to be randomised: 1072
A screening failure rate of approximately 30% and a run-in failure rate of approximately 15% are 
anticipated for this trial.
6.[ADDRESS_1187452] be answered â€œyesâ€. 
1. Informed consent obtained before any trial-r elated activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability for the trial. 
2. Male or female, age â‰¥ 18 years at the time of signing informed consent.
3. Diagnosed with type 2 diabetes mellitus â‰¥ 10 years prior to screening (Visit 1).
4. Treated with a basal-bolus insulin regimen â‰¥ 1 year prior to the day of screening (Visit 1). A 
basal-bolus insulin regimen is defined as basal insulin once or twice daily and bolus insulin analogue taken with meals at least 3 times daily. Treatment with premixed insulin or soluble 
insulin combination is not considered a basal-bolus regimen.
5. Treated with or without oral antidiabetic  drugs including extended release formulations. 
6. HbA
1c7.0-10.0% (both inclusive) as assessed by [CONTACT_21922] (Visit 1).
7. Able and willing to adhere to the protocol including performance of SMPG profiles and 
meal test.
8. Able and willing to consume 3 main meals (breakfast, lunch and dinner) daily throughout 
the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187453] be answered â€œnoâ€. 
1. Known or suspected hypersensitivity to trial product(s) or related products.2. Previous participation in this trial. Participation is defined as signed informed consent. 3. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measure 
as required by [CONTACT_17993]). 
For Bulgaria, Czech Republic, [LOCATION_013], Greece, Italy, Poland, Romania and Spain: The 
following contraceptive measures are considered adequate: 
ocombined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation (ora l, transdermal or intravaginal)
oprogestogen-only hormonal contraception associated with inhibition of ovulation
(oral, injectable or implantable)
ointrauterine device
ointrauterine hormone-releasing system
osexual abstinence
ovasectomised partner
odouble barrier method (a combination of male condom with either cap, diaphragm or 
sponge with spermicide)
4. Participation in any clinical trial of an approved or non-approved investigational medicinal 
product within 30 days before screening (Visit 1). Clinical trials do not include non-
interventional studies.
5. Any disorder, except for conditions associated with type 2 diabetes mellitus, which in the 
investigatorâ€™s opi[INVESTIGATOR_339639]â€™s safety or compliance with the protocol.
6. Any of the following: myocardial infarction, stroke, hospi[INVESTIGATOR_826623] 180 days prior to the day of screening (Visit 1). 
7. Subjects presently classified as being in  [LOCATION_001] Heart Association (NYHA) Class IV. 
8. Planned coronary, carotid or peripheral artery revascularisation known on the day of 
screening (Visit 1).
9. Inadequately treated blood pressure defined as Grade 3 hypertension or higher (Systolic 
â‰¥180 mmHg or diastolic â‰¥110 mmHg) at screening (Visit 1).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 27 of 112
10. Treatment with injectable GLP-1 receptor agonists in a period of 90 days prior to screening 
(Visit 1). 
11. Anticipated initiation or change in concomitant medications (for more than 14 consecutive 
days) known to affect weight or glucose metab olism (e.g. treatment with orlistat, thyroid 
hormones,  or corticosteroids).
12. Proliferative retinopathy or maculopathy requiring acute treatment. Verified by [CONTACT_853255] [ADDRESS_1187454] 5 years prior to the day of 
screening (Visit 1). Basal and squamous cell skin cancer and any carcinoma in-situ is 
allowed. 
14. For subjects treated with metformin: Any contraindications or restrictions to use of 
metformin (according to local labelling) at investigatorâ€™s discretion.
6.[ADDRESS_1187455] be withdrawn from the trial during the run-in period if the following applies after 
screening (Visit 1), and before or at randomisation (Visit 14): 
1. Included in the trial in violation of the inclusion and/or exclusion criteria.
2. Pregnancy
3. Intention of becoming pregnant4. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product.
5. Any of the following: myocardial infarction, stroke, hospi[INVESTIGATOR_853240] a or 
transient ischaemic attack.
6. Planned coronary, carotid or peripheral artery revascu larisation.7. Any disorder which in the investigatorâ€™s opi[INVESTIGATOR_36174]â€™s safety.
8. Inability or lack of willingness to adhere to the protocol, based on the investigatorâ€™s 
judgement.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187456] be answered â€œyesâ€.
1. HbA 1câ‰¤ 9.0% measured by [CONTACT_23258] 13 (week -1).
6.[ADDRESS_1187457] with the site in relation to the trial will be considered as withdrawn from the trial (see Section 6.7).
The subject may be prematurely discontinued from trial products at the discretion of the investigator 
due to a safety concern.
The subject must be prematurely discontinued from trial products if the following applies after 
randomisation:
1. Included in the trial in violation of the inclusion and/or exclusion criteria and/or randomised 
in violation of the randomisation criterion.
2. Pregnancy 3. Intention of becoming pregnant4. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product
5. Lack of efficacy defined as fulfilment of all4 below criteria:
!No reduction in HbA1c measured by [CONTACT_853288] (Visit 1) to visit 
18, 22 or 26 AND
!A daily average of 4-point SMPG readings (before breakfast, before lunch, before dinner 
and at bed time) on 3 consecutive days hi gher than 240 mg/dL (13.3 mmol/L) within the 
last two weeks period AND
!A confirmatory FPG exceeding 240 mg/dL (13.3 mmol/L) or a confirmatory random PG 
exceeding 300 mg/dL (16.7 mmol/L) measured by [CONTACT_853289]
!No treatable intercurrent cause (e.g. non-compliance) for the hyperglycaemia at the 
investigatorâ€™s judgment
6. Unacceptable adverse event (including toxicity) that cannot be solved by [CONTACT_853290]-acceptable risk at the investigator's judgment.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187458] is considered withdrawn from trial if the following applies before Visit 30:
!Subject is lost to follow up (see Section 8.1.10 ))
!Subject withdraws consent 
!Death
Subjects withdrawing from trial before randomis ation are considered scr eening or run-in failures.
If the subject considers withdrawing consent the investigator must underline to the subject the 
importance of continuing in the trial despi[INVESTIGATOR_826624]. If the subject agrees to discontinue trial products but to stay in the trial, procedures described in section 8.1.[ADDRESS_1187459] 365 days, but are not optimally controlled as demonstrated by [CONTACT_361996] 1c
â‰¥ 7.0%, and may benefit from intensified insulin titration using a treat-to-target approach. The 
subjects need to have had T2DM for at least [ADDRESS_1187460] been adequately educated and are familiar with using the intensive regimen required in this trial. This will also help to avoid including newly 
diagnosed patients that could enter  in the metabolic remission period.
Subjects with an HbA
1c> 10% are not included in this trial. This is because the trial protocol 
requires strict adherence and good subject compliance and a likely cause of elevated HbA 1c> 10% 
in a diabetic subject is poor compliance with treatment regimens or an atypi[INVESTIGATOR_853209]. The upper HbA 1climit is also expected to select a population that can achieve adequate 
basal insulin coverage in the 12-week run-in basal insulin titration period. Subjec ts in good 
glycaemic control defined as HbA 1c<7.0 % may not benefit from this trial and hence the lower cut-CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 30 of 112
off value has been chosen. Subjects with an HbA 1c> 9% are not eligible to be randomised into the 
treatment period of the trial. This is because th e trial protocol requires strict adherence and good 
subject compliance, a likely cause of HbA 1c> 9% after 12-week basal insulin titration period is poor 
compliance with treatment regimens or an atypi[INVESTIGATOR_853210].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 31 of 112
7 Milestones
Planned duration of recruitment period: [ADDRESS_1187461] visit (LPLV) .
Recruitment:
The screening and randomisation rate will be followed closely via the interactive voice/web 
response system (IWRS) in order to estimate when to stop screening. All investigators will be 
notified immediately when the recruitment period ends, after which no further subjects may be 
screened and the IWRS will be closed for further screening. All subjects screened during the recruitment period and found eligible for randomisati on can be randomised within the timelines 
specified in the flow chart (see Section 2).
Trial registration:
Information of the trial will be disclosed at clinicaltrials.gov and novonordisk-trials.com . According 
to the Novo Nordisk Code of Conduct for Clinical Trial Disclosure28, it will also be disclosed 
according to other applicable requirements such as those of the International Committee of Medical 
Journal Editors (ICMJE)29, the FDA Amendment Act (FDAAA)30, European Commission 
Requirements31, 32and other relevant recommendations or regulations. If a subject requests to be 
included in the trial via the Novo Nordisk e-mail contact [CONTACT_36283], Novo Nordisk may 
disclose the investigatorâ€™s contact [CONTACT_18026]. As a result of increasing requirements for 
transparency, some countries require public disclosure of investigator names and their affiliations.
Primary Completion Date is the last assessment of the primary endpoint, and is for this protocol last 
subject first visit + [ADDRESS_1187462] is withdrawn/dropout 
early the Primary Completion Date is the date when  the last subject would have completed Visit 30. 
The Primary Completion Date determines the deadline for results disclosure at clinicaltrials.gov
according to FDAAA.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 32 of 112
8 Methods and assessments
8.1 Visit procedures
The following sections describe the assessments and procedures. These are also included in the flow 
chart (see Section 2).
8.1.1 Screening (Visit 1)
Informed consent must be obtained before any trial related activity, see Section 18.2.
All subjects must be provided with a copy of their own signed and dated informed consent form.
Subjects will continue on their current diabetes treatment until start of run-in period (Visit 2) and 
they will not be supplied with any trial products until then.
The investigator must keep a subject screening log, a subject identification code list and a subject 
enrolment log. Only subjects who have signed the informed consent form should be included on the logs. The subject screening log and subject enrolment log may be combined in one log.
At screening, subjects will be provided with a card stating that they are participating in a trial and 
giving contact [CONTACT_49761](es) and telephone number(s) of re levant trial site staff. Subjects should be 
instructed to return the card to the investigator at the last trial visit or to destroy the card after the last visit.
Each subject will be assigned a unique 6-digit subject number which will remain the same 
throughout the trial. A screening session must be performed in the IWRS.
Screening failures
For screening failures the screening failure form in the electronic case report form (eCRF) must be 
completed with the reas on for not continuing in the trial. Serious AEs (SAEs) from screening 
failures must be transcribed by [CONTACT_215546]. Follow-up on SAEs must be carried 
out according to Section 12.
A screening failure session must be made in the IWRS. When data has been monitored and queries 
have been resolved the case book must be signed.
Re-screening is NOT allowed if the subject has failed one of the inclusion, exclusion or 
randomisation criteria, this includes re-sampling if the subject has failed one of the inclusion,exclusion or randomisation criteria related to laboratory parameters.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187463] not be ticked â€œY esâ€ or â€œNoâ€ in the eCRF before source data is 
available. In case source data is not available â€œResult pendingâ€ must be chosen. This is particularly 
relevant for lab samples and in some cases the ECG (electrocardiogram) and eye examination result. The results of all the screening assessments must be available (including central laboratory results) and must have been reviewed by [CONTACT_853256]-in 
period.
At start of the run-in period (Visit 2), the subject will receive the basal insulin trial product (Insulin 
degludec). The subjects must be trained in how to handle the insulin pen injectors (see section 8.6.2 ). Training may be repeated during the trial if necessary. First date of trial product (basal 
insulin) must be recorded in the eCRF.
A run-in dispensing session must be performed in the IWRS. A drug accountability session 
confirming dispensing of allocated trial product s hould also be performed when dispensing trial 
product.
The BG meter and diary s hould be provided to the s ubjects at Visit 2. Subjects must be trained in 
use of the BG meter and completion of the diary. 
Run-in failures
If the subject is not eligible to be randomised (i.e. has met one of th e run-in period exclusion 
criteria, has not met the randomisation criterion or withdraw from trial before randomisation) then 
the subject will be considered a run-in failure. Cons equently, a run-in failure session must be made 
in the IWRS system and a run-in failure form must be completed in the eCRF together with the reason for not continuing in the trial. The last date of trial product must be captured in the eCRF. 
No follow-up visit should take place and no additional assessments are needed. The diary should be 
returned to the site.SAEs and non-serious AEs from run-in failures must be recorded by [CONTACT_56276]. Follow-up of AEs must be carried out according to section 12.3.
When data has been monitored and queries have been resolved the case book must be signed in the 
eCRF.
8.1.[ADDRESS_1187464] will at 
Visit 14 be randomised into one of the two treatment arms using an IWRS randomisation session. A CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187465] (bolus insulin) must be recorded in the eCRF.The subject must attend randomisation visit fasting. For definition of fasting, please see section 
8.1.[ADDRESS_1187466] subjects
how to self-titrate (section 8.3.4 and Appendix A ).
8.1.[ADDRESS_1187467] attend the visits specified in the flowchart (section 2) in a fasting condition. 
Fasting is defined as at least eight hours without drink or food intake prior to the visit except for 
water.
Insulin dosing (including basal insulin) and medication which should be taken with or after a meal 
should be withheld until blood sampling has b een performed. If a subject attends the visit non -
fasting, then the subjectâ€™s blood samples, meal test and body weight measurement must be re-scheduled within the visit window and at Visit [ADDRESS_1187468] the actual date of the rescheduled 
assessment (i.e. the actual visit date will diffe r from the assessment date under the same visit).
8.1.[ADDRESS_1187469] be recorded on the concomitant medication (diabetes) form in eCRF, as described in section 8.2.6 .CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 35 of 112
8.1.8 Follow-up period
The follow-up visit 1 (FU1) is a site visit and must take place 7-[ADDRESS_1187470] 2 (FU2) is a phone contact a nd must take place 30-35 days after the end of 
treatment visit.
Follow-up visit 1
The following data will be collected:
!AEs 
!Concomitant medication
!Current diabetes medication
!Hypoglycaemic epi[INVESTIGATOR_1841]
!Additional informati on on injection site r eactions
Follow-up contact 2
The following data will be collected:
!AEs
!Concomitant medication
!Current diabetes medication
!Hypoglycaemic epi[INVESTIGATOR_1841]
8.1.[ADDRESS_1187471] prematurely discontinues trial products after randomisation (Visit 14), the investigator 
must undertake procedures similar to those for Visit 30 as soon as possible, also called Visit 30A 
(see flowchart section 2). 
Premature discontinuation of trial products must be registered in IWRS . This must be performed at 
least [ADDRESS_1187472].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187473] at the discretion of the investigator. 
The medication should be recorded on the conco mitant medication (diabetes) form in the eCRF, as 
described in section 8.2.[ADDRESS_1187474] should also complete the follow-up visits (FU1 and FU2) [ADDRESS_1187475]. Visit 31 (FU1) can be converted into a phone contact [CONTACT_853291] s ubjects that discontinue trial products prematurely.
In addition, subjects prematurely discontinued from  trial products s hould continue with the per
protocol planned visits at 4 (Visit 18), 8 (Visit 22), 12 (Visit 26), 16 (Visit 30) weeks after randomisation depending on when the subject discontinues trial products. The meal test at Visit 30
should be done with the subjectsâ€™ currently prescribe d insulin treatment with the same bolus insulin 
dose as at baseline. 
The following assessments are not applicable for subjects that prematurely discontinue trial 
products: [ADDRESS_1187476]:
!If Visit 30A is within 2 weeks of one of the per protocol planned visits, only Visit 30A 
should be performed
!If any per protocol planned visit and the windows of a follow-up visit are overlappi[INVESTIGATOR_853211], only the per protocol planned visit should be performed
It should be documented in the medical records if  subject refuses to attend a visit from Visit 30A 
and onwards.A subject that permanently discontinues trial product before the End of Treatment visit 
(V30), will be considered to be a treatment non-completer. 
Diary records after premature discontinuation of trial products
Date, actual clock time and value of the SMPG measurements performed as part of the 7-9-7-point 
profiles on the three consecutive days prior Visit 30A, Visit [ADDRESS_1187477] be performed with bolus trial insulin according to randomisation. If it is not feasible due to safety reasons including CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187478] aim to perform the follow up visits (FU1 and FU2) [ADDRESS_1187479] is not obliged to give his/her reason(s) for withdrawing consent, the investigator 
must make a reasonable effort to ascertain the reason(s), while fully respecting the subjectâ€™s rights. Where the reasons are obtained, the primary reason for withdrawing consent must be specified in 
the eCRF.
A subject that is withdrawn from trial before the End of Treatment Visit (V30), will be considered 
to be a treatment non-completer and a trial non-completer. 
[IP_ADDRESS] Lost to follow-up
The following actions must be taken in relation to a subject who fails to attend the site for a 
required visit:
!The site must attempt to contact [CONTACT_49878]
!The site must re-train the subject in the importance of maintaining the scheduled visits 
In cases in which the subject is deemed lost to fo llow-up the investigator must make every effort to 
regain contact [CONTACT_1155] (e.g. telephone calls to friends or family members, e-mails or 
certified letter to the subject as applicable). These contact [CONTACT_853260]â€™s medical records. Should the subject continue to be unreachable, only then will he/she be considered to have withdrawn from the trial with  the primary reason being â€œlost to follow -upâ€.
8.1.[ADDRESS_1187480]â€™s medical record.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187481]â€™s medical record. Care must be taken not to bias the subject. Any 
discrepancies or missing data points available elsewhere related to a 7-9-[ADDRESS_1187482] related information/assessments 8.2.1 Demogr aphy
Demography will be recorded at screening and consists of:
!Date of birth (according to local regulation)
!Sex
!Ethnicity (according to local regulation)
!Race (according to local regulation)
8.2.2 Diabetes his tory and diabetes complications 
Diabetes history and diabetes complications w ill be recorded at screening and consists of:
!Date of diagnosis of T2DM
!Information regarding d iabetes complications including date of onset
â€“ Diabetic retinopathy
â€“ Diabetic neuropathyâ€“ Diabetic nephropathyâ€“ Macroangiopathy (including peripheral vascular disease)
8.2.3 Hypoglycaemia unawareness 
Information on hypoglycaemia unawareness will be recorded at screening according to Clarkeâ€™s 
questionnaire, question 8.
[ADDRESS_1187483]: â€œTo what exten t can you tell by [CONTACT_222668]?â€ The s ubject can answer never, rarely, sometimes, often 
or always.
Subjects answering â€˜never, rarely or sometimesâ€™ are considered as having impaired awareness of 
hypoglycaemia.
8.2.4 Concomita nt illness and medical history
â€“A  concomitant illness is any illness that is present at the start of the trial (i.e. at the first 
visit (Visit 1)) or found as a result of a screening procedure or other trial procedures performed before exposure to trial product. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 39 of 112
T2DM and diabetes complications should be reported separately in the Diabetes History/Diabetes 
Complications Form in the eCRF.
Medical history is a medical event that the subject has experienced in the past. Only relevant 
medical history, as judged relevant by [CONTACT_093], should be reported. 
The information collected for concomitant illness and medical history s hould include diagnosis, 
date of onset and date of resolution or continuation, as applicable.
Any change to a concomitant illness should be recorded during the trial. A clinically significant 
worsening of a concomitant illness must be reported as an AE.
It must be possible to verify the subjectâ€™s medi cal history in source documents such as subjectâ€™s 
medical record. If a subject is not from the investigators own practice; the investigator must make 
reasonable effort to obtain a copy of subjectâ€™s medical record from relevant party e.g. primary physician. The investigator must document any attempt to obtain external medical information by [CONTACT_18031](s) when information was requested and who has been contact[INVESTIGATOR_530].
8.2.[ADDRESS_1187484](s), which is taken during 
the trial, including the screening, run-in, treatment and follow-up periods.
Details of any concomitant medication must be recorded at Visit 1. Changes in concomitant 
medication must be recorded at each visit as they occur. 
The information collected for each concomitant medi cation includes trade name [CONTACT_18058], 
indication, start date and stop date or continuation. 
If a change is due to an AE, then this must be reported according to Section 12. If the change 
influences the subjectâ€™s eligibility to continue in the trial, the monitor must be informed.
8.2.6 Concomitant medication (diabetes)
Any diabetes medication other than the trial product(s) which is taken during the trial, including the 
screening, run-in, treatment and follow-up periods must be recorded in a separate concomitant 
medication (diabetes) form in the eCRF including the trade name [CONTACT_18058], total daily dose, 
frequency, start date and stop date or continuation. For subjects treated with metformin it is the start 
date and dose of last stable met formin dose which should be reported.
At the run-in visit (Visit 2) basal insulin and all OADs except for metformin must be discontinued 
and a stop date recorded. For subjects treated with metformin, investigator should at each weekly CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187485] (visit or phone contact), confirm with the subject that dose and frequency of metformin has 
been unchanged. This should be documented in the medical records. 
At the randomisation visit (Visit 14) pre-trial bolus insulin must be discontinued and a stop date 
recorded.
It is important to ensure subjects adhere to treatment. Therefore, during the treatment period (from 
randomisation to End of Treatment) the investigator must also at each weekly contact (visit or 
phone contact), evaluate if the subject has taken any ancillary treatment since last contact. Ancillary treatment is defined as any diabetes medication - other than randomised treatment (trial 
products in the basal-bolus reg imen with or without metformin) initiated in case of unsatisfactory 
glycaemic control. It should be registered as su ch on the concomitant medication (diabetes) form in 
the eCRF. For subjects not treated with metformin prior to the randomisation, initiation of long term use of metformin is considered as  ancillary treatment. A medication error (Section [IP_ADDRESS] ) is as 
such not considered  as ancillar y treatment.
8.2.[ADDRESS_1187486] be instructed to use adequate 
contraceptive methods throughout the trial and until 1 week after end of treatment.
Female of non-childbearing potential is defined as:
!Female who has undergone a hysterectomy, bilateral oophorectomy or bilateral tubal 
ligation 
!Postmenopausal defined as no menses for 12 months without an alternative medical cause
!Other medical reasons preventing childbearing potential 
8.2.[ADDRESS_1187487] one 
cigarette or equivalent daily. Smoking status:
!Never smoked
!Previous smoker
!Current smokerCONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187488] at two visits (see flowchart section 2) and 
will have their [ADDRESS_1187489] is 
expected to be up to 6 hours including preparations. During that time 6 blood samples will be 
drawn, as specified in the Table 8â€“[ADDRESS_1187490] should be instructed to: 
!Follow normal routine regarding eating and exercis e habits on the day prior to the meal test
!Refrain from intake of alcohol and use of medications that affect motility (i.e. prokinetics, 
anticholinergics, tricyclic antidepressants) on the day prior to the meal test, unless the 
subject was on this medication at trial entry and does not change the product or product dose
!Remember to bring their current/trial bolus and basal insulin, diary and BG meter to the 
meal test visits
!Attend the meal test visits in a fasting conditi on. For definition of fa sting, please refer to 
section 8.1.[ADDRESS_1187491]
!Achieve an SMPG value within a range of  4.0-8.8 mmol/L [71- 160 mg/dL] before 
beginning the meal test. The SMPG value should be verified at the site before starting the 
meal test.
The meal test should be re-scheduled within the visit window and at Visit [ADDRESS_1187492] in case:
!any hypoglycaemic epi[INVESTIGATOR_853212] 
!the subject is not fasting or 
!the SMPG value is outside the range.
At Visit 14 (randomisation visit) the investigator must evaluate if the subject is eligible to continue 
in the trial before the meal test is performed. Only subjects eligible for randomisation should have 
the Visit [ADDRESS_1187493] carbohydrate calculation
The standardised liquid meal will be provided by [CONTACT_3454]. The volume of the liquid meal 
should be measured out by [CONTACT_853292] 78 grams of digestible 
carbohydrates (total carbohydrate content minus fibre). CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187494], the bolus insulin dos e should be calculated by [CONTACT_853293] a calculated insulin:carbohydrate 
ratio. The insulin:carbohydrate ratio in this trial is calculated by [CONTACT_60875] 500 by [CONTACT_853262] (taken from the day before) of both basal and bolus insulin. The calculated dose should be rounded to the nearest whole unit. 
Same bolus insulin dose will be used for the meal test at end of treatment. The insulin should be 
administered subcutaneously in the abdomen in accordance with Table 8â€“[ADDRESS_1187495]â€™s body weight must be  measured before start and a blood sample must be drawn two 
minutes before intake of the standardised meal. 
For the meal test at Visit [ADDRESS_1187496] both at Visit 30A and ag ain at Visit 30; t he meal test at Visit [ADDRESS_1187497] consumed the required volume of the standardised liquid meal in the eCRF.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 43 of 112
Table 8â€“[ADDRESS_1187498] schedule
Time point 
(minutes)Blood 
sample SMPG 
values Standardised meal Bolus insulin injection
Before start 
of meal testX (within target 
range 4.0-8.8 
mmol/L [71- 160 
mg/dL])
-2X
0
X (as appropriate 
to ensure 
subjectâ€™s safety)XX
Insulin injection at the start of the meal
30X
60X
120X
180X
240X
End of meal 
testX (for subjectâ€™s 
safety)
Conduct of meal test
The subject should stay in the clinic to have the blood samples drawn after 30 minutes, 1, 2, 3 and 4 
hours from the start of the standardised meal, as detailed in Table 8â€“[ADDRESS_1187499], except for water consumption which is allowed two hours after intake of the standardised meal.
If SMPG values â‰¤3.9 mmol/L [70 mg/dL] are measured, then the hypoglycaemia should be treated 
with glucose rescue treatment according to local practice and the meal test should continue 
according to the investigatorâ€™s discretion. The hypoglycaemic epi[INVESTIGATOR_853213]. Please see section 8.4.[ADDRESS_1187500]. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187501]: 
!Fasting status
!SMPG value measured before the meal test and within allowed ranges and the time of the 
measurement
!Actual clock start and end time of standardised meal
!Volume of meal consumed
!Confirmation that the subject consumed the required volume of the standardised meal
!Batch number of the standardised meal consumed
!Actual clock time and dose of bolus insulin 
!Actual clock t ime of bl ood samples
!Hypoglycaemic epi[INVESTIGATOR_1841], if relevant
oSMPG value, time of intervention and amount of glucose rescue treatment and 
hypoglycaemic epi[INVESTIGATOR_853214]. The meal test results will not be provided to the investigator until after LPLV in order to 
keep the blinding of the subject and investigator.
8.3.[ADDRESS_1187502] used the glycaemic data collection system (the combination of the 
MyGlucoHealth Wireless BG-meter and an electronic diary (eDiary)) have been instructed to 
discontinue this system and use an alternative BG-meter until a new trial BG-meter and paper diary is provided by [CONTACT_3454].
The following must be recorded by  [CONTACT_56276]:
!Start date of new trial BG-meter
8.3.[ADDRESS_1187503] be corrected. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187504] strips calibrated to plasma values. Therefore, all measurements performed 
with capi[INVESTIGATOR_36191], which will be 
shown on the display. 
Only the BG meter provided by [CONTACT_156056].
4-point self-measured plasma glucose profile 
The 4-point SMPG profile will be recorded for insulin titration purposes. Subjects will be instructed 
to perform 4-point profiles every day from Visit 2 to Visit 30 for titration purposes. The measurements should be performed at the following time points:
!Before breakfast
!Before lunch
!Before main evening meal (dinner)
!At bedtime
For SMPG measurements actual clock time, time po int (e.g. before breakfast), date and value 
should be recorded in the diary.
SMPG values measured before breakfast, lunch, main evening meal, and at bedtime should be 
performed before any injection of bolus insulin and just before the start of the meal (breakfast, 
lunch or main evening meal). SMPG values measured before breakfast should be performed in a 
fasting condition. The 4-point profile is part of the 7- or 9-point profiles which are measured prior to selected site visits.
7-9-[ADDRESS_1187505] before selected visits as outlined in the flowchart in section 2. See Table 8â€“2 (7-point profiles 
indicated as X and the 9-point profile indicated as âˆš). CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 46 of 112
Table 8â€“[ADDRESS_1187506] X âˆ€âˆ€ âˆ€ #X)a 
60 minutes after the start of 
breakfastX âˆ€ X
Before lunch X âˆ€ X
60 minutes after the start of 
lunchX âˆ€ X
Before main evening meal X âˆ€ X
60 minutes after the start of 
main evening mealX âˆ€ X
At bedtim e X âˆ€ X
At 4 am âˆ€ 
aThe last SMPG in the 9-point profile and the first SMPG of the 7-point profile on day-1 are overlappi[INVESTIGATOR_007].
For SMPG measurements actual clock time, time point (e.g. before breakfast), date and value
should be recorded in the diary. SMPG values measured before breakfast, lunch and main evening meal and at bedtime should be performed before any insulin injection and just before the start of the meal (breakfast, lunch or main evening meal). SMPG values measured before breakfast should be 
performed in a fasting condition.
The measurements will be used to evaluate the glucose profile.
8.3.[ADDRESS_1187507] should be instructed to report the following concerning dosing of trial products in the 
diary:
!Date, actual clock time and dose of basal and bolus insulin on a daily basis from Visit 2 to 
Visit 30.
!Date, actual clock time, and dose for other (extra) bolus insulin administration as well as 
time and type of previous main meal and reason for the extra bolus from Visit [ADDRESS_1187508] be corrected. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 47 of 112
Dosing and dose adjustment (new dose)
The recommended insulin doses will be calculated in the eCRF based on recommendations from the 
Insulin Titration Guideline (see Appendix A ). At each visit/phone contact [CONTACT_853294]â€™s insulin doses by [CONTACT_853295]. 
Investigator must hand out the subject mealtime insulin dose adjustment guide at Visit [ADDRESS_1187509] subjects to perform self-titration of bolus ( mealtime) trial insulin between the 
scheduled visits/phone contacts from Visit [ADDRESS_1187510] the following in the eCRF:
!Prescribed doses of trial products
!Reason for deviating in dose adjustments from the titration guideline, if applicable
The subject should report the following in the diary: 
!Dose adjustment of bolus trial insulin 
8.[ADDRESS_1187511] be 
reported as an AE.
8.4.1 Adverse events
Adverse events (AEs) must be reported at each visit in accordance with the procedures outlined in 
Section 12.
[IP_ADDRESS] Medication error
If a medication error is observed during the trial, the following information is required and a 
specific event form must be completed in the eCRF in addition to the AE form:
!Trial product(s) involved
!Classification of medication error
!Whether the subject experienced any hypoglycaemic epi[INVESTIGATOR_36192]/or AEs as a result of the 
medication error
!Suspected primary reason for the medication error
For definition of medication errors, see Section 12.1.4 .CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 48 of 112
[IP_ADDRESS] Adverse events requiring additional data collection
For some AEs additional data collection is required and specific event forms must be completed in 
the eCRF in addition to the AE form. 
In case any of these events fulfil the criteria for a SAE, please report accordingly, see Section 12.
Injection site reaction
If an event of injection site reaction is observed the following additional information must be 
obtained if available on the injection site reaction form:
!Type of reaction â€“ local or generalised
!Symptoms associated with the event
!Treatment given for the event
!Association with the trial product(s)
!Relevant risk factors associated with the event
The investigator has to evaluate whether further actions are needed (e.g. extra visits, supervised 
injection, premat ure discontinuation of trial produc t s, dermatologist consultation).
If any injection site reactions occur after Visit [ADDRESS_1187512] ill be rec orded as AEs, but the 
additional data collection on the specific even t form in the eCRF is not required.
8.4.2 Hypoglycaemic epi[INVESTIGATOR_688133] a hypoglycaemic epi[INVESTIGATOR_36190]. 
All plasma glucose (PG) values:
!â‰¤ 3.9 mmol/L (70 mg/dL) or 
!> 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms 
should be reported in the diary by [CONTACT_248463] 2 to Visit 32 (FU2) and in the eCRF by [CONTACT_853296]. 
Upon onset of a hypoglycaemic epi[INVESTIGATOR_41105] 15 
minutes until the SMPG value is >3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved in accordance to current guidelines.
34
A SMPG value â‰¤3.9 mmol/L (70 mg/dL) or hypoglycaemic symptoms must trigger a 
hypoglycaemic epi[INVESTIGATOR_36197]. Repeated SMPG measurements and/or 
symptoms, occurring within a period of 60 minutes after onset on a hypoglycaemic epi[INVESTIGATOR_1865], will by [CONTACT_156095][INVESTIGATOR_41106] a succeeding SMPG value is >3.9 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 49 of 112
mmol/L (70 mg/dL) and/or symptoms have been resolved and should be reported on one 
hypoglycaemic epi[INVESTIGATOR_215510]. SMPG measurements â‰¤3.9 mmol/L (70 mg/dL)  or hypoglycaemic 
symptoms after the [ADDRESS_1187513] to fill out a new hypoglycaemic epi[INVESTIGATOR_708719] a succeeding measurement is >3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved.
In case of several low SMPG values within the [ADDRESS_1187514] SMPG value and/or symptom.
The record should include the following information:
!Start date and time of the hypoglycaemic epi[INVESTIGATOR_1865] 
!The PG level before treating the epi[INVESTIGATOR_1865] (if available) and any follow up measurements. 
The lowest value measured during the hypoglycaemic epi[INVESTIGATOR_135516], the remaining values will be kept as source data in the diary.
!Whether the epi[INVESTIGATOR_36202] (Yes/No)
A hypoglycaemic epi[INVESTIGATOR_708720]. 
!Whether the subject was able to treat him/herself
!If the severity of a hypoglycaemic epi[INVESTIGATOR_513395], only one hypoglycaemic epi[INVESTIGATOR_826661].Date, time and dose 
of last bolus insulin administration prior to the epi[INVESTIGATOR_1865] 
!Date, time and dose of last basal administration prior to the epi[INVESTIGATOR_1865] 
!Date and time of last main meal (not including snacks) prior to the epi[INVESTIGATOR_1865]
!Whether the epi[INVESTIGATOR_826662]
!Change in any concomitant illness
!Any sign of fever and/or other acute disease 
!Whether the subject was asleep when the epi[INVESTIGATOR_36206]
â€“ If yes, whether the symptoms of the epi[INVESTIGATOR_513399]: "Was the subject able to treat him/herself?" must be answered "No" for 
an epi[INVESTIGATOR_36208], glucagon, or 
take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence 
that the event was induced by a low PG concentration.
[ADDRESS_1187515] is unconscious.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 50 of 112
If the question "Was the subject able to treat him/herself?" is answered "No", the following 
information should be recorded by [CONTACT_423]:
!Who assisted in the treatment of the hypoglycaemic epi[INVESTIGATOR_1865] (i.e. medical person or non-
medical person)?
!Where the treatment was administered (in clinic/emergency room/hospi[INVESTIGATOR_36209]. If the 
subject was treated in clinic/emergency room/hospi[INVESTIGATOR_307], whether they were transported in an 
ambulance or not)
!Type of treatment provided by [CONTACT_19015] (i.e. oral carbohydrates, glucagon, IV glucose 
or other)
!Were symptoms alleviated after administration of treatment?
!Factors contributing to the epi[INVESTIGATOR_1865] (i.e. physical activity, missed meal, diet change, 
medication error (i.e. overdose, mix-up b etween products, incorrect use of device), 
miscalculation of dose of antidia betic medicatio n, other factors not listed or unknown)
!Did the subject experience seizure?
!Was the subject unconscious/comatose? 
!Did the subject experience any of the following symptoms35(layman term used in the diary
is specified in brackets if different from the protocol term)? 
â€“ Autonomic: sweating, trembling, hunger or palpi[INVESTIGATOR_814] (rapid or irregular heart beat)
â€“ Neuroglycopenic: confusion, drowsiness, speech  difficulty, visual disturbances, odd 
behaviour, impaired balance or incoordination  (reduced ability to coordinate movement)
â€“ General malaise: headache or malaise (feeling discomfort/unease)
!Other symptoms 
The investigator must review the diary for low SMPG values not reported as hypoglycaemic 
epi[INVESTIGATOR_1841]. The subject must be questioned whether any of the low values were severe, i.e. whether 
the subject was able to self-treat or not. If the subject was not able to self-treat, it has to be reported 
as a severe hypoglycaemic epi[INVESTIGATOR_1865].Low SMPG v alues for non-severe hypoglycaemic epi[INVESTIGATOR_853241] a hypoglycaemic epi[INVESTIGATOR_853242] [ADDRESS_1187516] be re-trained in how to report hypoglycaemic epi[INVESTIGATOR_156038].
If the hypoglycaemic epi[INVESTIGATOR_135520] a safety 
information form (SIF) must also be filled in the eCRF, see Section 12. One AE-form and SIF can 
cover several hypoglycaemic epi[INVESTIGATOR_853221].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 51 of 112
8.4.3 Eye examination
Fundus photography/pharmacologically dilated fundoscopy must be performed by [CONTACT_093], 
a local ophthalmologist, or an optometrist acc ording to local practice. The result of the fundus 
photography/pharmacologically dilated fundoscopy must be interpreted locally by [CONTACT_093]. 
To document this, the investigator must sign and date the result page or write the interpretation in 
the subjectâ€™s medical records. 
The evaluation must follow the categories:
!Normal
!Abnormal
â€“ Was the result clinically significant? (Yes/No)
Abnormal and clinically significant findings must  be recorded as described in Section 8.4.
If a fundus photography/pharmacologically dilated fundosco py has been performed within [ADDRESS_1187517]â€™s medical records that this procedure was not performed in relation to the trial.
The eye examination must be performed prior to administration of bolus trial insulin at Visit 14 (the 
results do not need to be available for randomisat ion). An eye examination performed within 14 
days prior to randomisation is acceptable.
Eye examination obtained within 21 days prior to Visi t 30 is acceptable if the result is available at 
the visit.
For subjects prematurely discontinued trial produ cts: eye examination performed 21 days in 
advance of Visit 30A are acceptable if the results are available at the scheduled visits. However eye 
examination performed at Visit 14 cannot be accepted for the Visit 30A.
8.4.4 Electro cardiogram â€“ 12 lead
An electrocardiogram (ECG)-[ADDRESS_1187518]â€™s medical records.
The evaluation must follow the categories:
!Normal
!Abnormal
â€“ Was the result clinically significant? (Yes/No)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187519]  be recorded as described in Section 8.4
If an ECG-12 lead has already been performed within  21 days before screening (Visit 1), and if the 
results are available at the screening visit, the procedure does not need to be repeated. If performed before the subject consents to participate in the trial it must also be stated in the subjectâ€™s medical records that this procedure was not performed in relation to the trial.
ECGs performed 21 days in advance of Visit 14 and Visit 30 are acceptable if the results are 
available at the scheduled visits.
For subjects prematurely discontinued trial products : ECGs performed 21 days in advance of Visit 
30A are acceptable if the results are available at the scheduled visits. However ECGs performed at 
Visit 14 cannot be accepted for the Visit 30A.
8.4.5 Body measurements
Height (without shoes) will be measured at site in centimetres (cm) or inches (in) and recorded to 
one decimal place in the eCRF.
Body weight should be measured in kilograms (kg) or pounds (lb) without overcoat and shoes, and 
wearing only light clothing. Body weight must  be measured prior to the start of the meal test at 
Visit [ADDRESS_1187520]. The body weight should be assessed on the 
same weighing scale equipment throughout the trial, if possible. 
BMI will auto matically be calcu lated by [CONTACT_51084].
8.4.6 Physical examination
Physical examination will include examination of:
!the respi[INVESTIGATOR_2133]
!the cardiovascular system
!the central and peripheral nervous system
!the gastrointestinal system, including the mouth
!the musculoskeletal system
!the skin
!the head, ears, eyes, nose, throat and neckCONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187521] be transcribed to the eCRF as:
!Normal
!Abnormal
â€“ Was the result clinically significant? (Yes/No)
Abnormal and clinically significant findings must  be recorded as described in Section 8.[ADDRESS_1187522] is using antihypertensive medication to 
control the blood pressure, then the medication s hould be taken as usual prior to assessing vital 
signs. 
At screening (Visit 1) blood pressure needs to be measured three times and all values should be 
recorded in the eCRF. The mean value will be calcu lated by [CONTACT_51084], and must be used to assess 
the relevant exclusion criterion; please see section 6.3.
Abnormal and clinically significant findings must  be recorded as described in Section 8.4
8.5 Laboratory assessments
Except for urine pregnancy testing, which will be pe rformed locally, all laborat ory analyses will be 
performed by a central laboratory contracted by [CONTACT_3454]. The central laboratory will provide 
all laboratory supplies for the sampling and transportation of all blood and urine samples taken 
during the trial.
A detailed description of the procedures for obtaining the samples, handling, storage, and shipment 
of the samples are specified in a trial-specific la boratory manual provided to the sites by [CONTACT_11378]. Informatio n regarding laboratory materia ls such as tubes and labels are also described. 
Laboratory samples can be drawn on another day than on the day of the actual visit, as long as it is 
within the visit window, as stated in the flowchart in section 2. 
If laboratory samples need to be retaken due to missing result(s) (e.g. haemolysed, sample leaked 
during transit, sample not being conclusive, lost in transit, etc.), the subject should be called in for 
resampling. Please see the laboratory manual for further guidance.
Samples will be coded in order to keep subjectâ€™s identity anonymous. The laboratory provides resu lts to the trial sites in the units preferred by [CONTACT_135545].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187523] be documented either  on the documents and/or in the subject's medical 
record.
Only laboratory samples specified in the protocol must be sent to the central laboratory for analysis; 
if additional laboratory sampling is needed, e.g. to follow up on AEs, this must be done at a local 
laboratory.
Laboratory samples will be destroyed on an ongoi ng basis and no later than at finalisation of the 
clinical trial report.
8.5.[ADDRESS_1187524] attend these visits fasting. 
For definition of fasting, see Section 8.1.5 .
A FPG result â‰¤3.9 mmol/L (70 mg/dL) should not be reported as a hypoglycaemic epi[INVESTIGATOR_36189] a 
clinical laboratory AE (CLAE) at the discretion of the investigator (see Section 12.1.1 ). 
The level of 1,5-anhydroglucitol (GlycoMark) is measured in order to evaluate post prandial 
glucose excursions. 
Blood samples will be drawn to determine the HbA 1clevel in order to evaluate metabolic control. 
Fasting C-peptide is measured at randomisation in order to reflect endogenous insulin secretion.
Lipi[INVESTIGATOR_853222]:
!Total cholesterol
!High density lipoprotein (HDL) cholesterol
!Low density lipoprotein (LDL) cholesterolCONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 55 of 112
8.5.2 Laboratory a ssessments for safety
Biochemistry
Blood samples for biochemistry will be analysed to determine:
!ALT
!AST
!albumin
!alkaline phosphatase
!creatinine
!potassium
!sodium
!total bilirubin
!total protein
!eGFR(estimated glomerular f iltration rate) at screening
eGFR will be calculated by [CONTACT_167808]-EPI 
[INVESTIGATOR_853243] 14 according to local label.33
Haematology
Blood samples for haematology w ill be analysed to determine:
!erythrocytes
!haematocrit
!haemoglobin
!leucocytes
!thrombocytes 
Pregnancy testing
For females of childbearing potential (see section 8.2.7 ), a blood human Chorion Gonadotropin 
(hCG) pregnancy test w ill be pe rformed at the visits indicated in the flowchart in section 2. In 
addition, urine pregnancy tests will be performed locally during the trial if pregnancy is suspected
or if required by [CONTACT_1769]. A positive urine test should be followed by a confirmatory serum-hCG 
(central laboratory).
The central laboratory will provide the pregnancy kits for urine testing performed locally at the site.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 56 of 112
8.6 Other assessments
8.6.1 Dietary training in simple carbohydrate counting
During the run-in period all subjects should ha ve dietary training regarding simple carbohydrate 
counting (e.g. sessions with a diabetes educator, dietician or qualified site staff) to improve subjectâ€™s carbohydrate awareness and understanding of their eating habits effect on their diabetes. It 
is the investigatorâ€™s responsibility to ensure that the subject is adequately trained and has a 
satisfactory knowledge  in:
!Recognition of carbohydrates in commonly eaten foods 
!Ability to count the carbohydrate content in typi[INVESTIGATOR_853224]
!Ability to inte rpret a nutrition label for carbohydrate content 
!Glycaemic targets 
!Preventing and treating hypoglycaemia using carbohydrate foods
!Ability to sum the carbohydrate content of a meal 
[ADDRESS_1187525] prior to the visits indicated in the 
flowchart (Section 2) in order to evaluate the subjectâ€™s ability to count the carbohydrate content of 
the meal. The meal records will not  be collected by [CONTACT_456].
8.6.[ADDRESS_1187526] be repeated according to flowchart (Section 2) in order to ensure correct use of the 
pen injector. The following should be emphasised:
!Always use a new needle for each injection as this will prevent contamination and blocked 
needles
!Remember to prime the pen to ensure product flow 
!The needle should be kept in the skin while counting slowly to [ADDRESS_1187527] been delivered.
!Always check that the correct insulin pen is us ed (bolus or basal) e.g. by [CONTACT_853266]. Use the pen differentiation guide as a reference.
!In-use time and storage conditions of pen-injectors (Section 9.3).
8.6.3 Diary
At the run-in visit (Visit 2) the subjects will be  provided with a diary. The investigator must 
carefully instruct the subject in how to use the diary. At each following site visit the subject will be 
provided with a new diary. The diary must be collected  at the next site visit and retained at the site 
as source data in accordance with Section 14. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187528]â€™s medical record.
All data entered in the diary is considered source data, as described in sections 8.3.3 ,8.3.4 and 
8.4.2 .
The subjects will be instructed in recording the following in the diary:
!Daily 4-point profiles
!Date, dose, clock time and time point of bolus insulin
!Date, dose and time of basal insulin
!7-9-7- profiles (before visits 14, 22, 30 and 30A)
!Date of first basal dose of trial product (V2)
!Date of first bolus dose of trial product (V14)
!Date of last dose of trial product (V30)
!Hypoglycaemic epi[INVESTIGATOR_853244] 8.4.[ADDRESS_1187529] the following in the diary:
!prescribed doses of trial insulin
!time and date of next visit and/or phone contact
!subject ID and site contact [CONTACT_853297], including any overall change in 
health and concomitant medication, are reported. The review must be documented on the front page 
of the diary and data must be  transcribed into the eCRF.
Selected titration data (e.g. certain SMPGs and dose data) will only be used during the trial for 
central titration surveillance, to ensure compliance with the titration guideline ( Appendix A ), and 
will not be reported in the CTR. All data will be stored by [CONTACT_3454] (Section 24).
Diary records after premature discontinuation of trial product:
The Subject will be handed out premature discontinuation diaries at visit 30A to record the 
following:
!Hypoglycaemic epi[INVESTIGATOR_1841]
!7-9-7- profiles (visit 22 and 30)
8.[ADDRESS_1187530] compliance will be assessed by 
[CONTACT_853269], please refer to the flow chart (Section 2). The CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187531] (IMP) will be assessed against the dispensed 
amount and, in case of discrepancies, the subject must be asked to clarify.
If a subject is found to be non-compliant, the investigator will remind the subject of the importance 
of following the instructions given including taking the trial products as prescribed.
The investigator will at each weekly contact (vi sit or phone contact) assess the subjectâ€™s compliance 
by [CONTACT_222680], adherence to treatment and the visit schedule and completion 
of the subjectâ€™s diary including the SMPG profiles, dose and hypoglycaemia reporting.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 59 of 112
9 Trial supplies
Trial supplies comprise trial products and aux iliary supplies. Additional details regarding trial 
supplies can be found in the Trial Materials Manual (TMM).
Trial products must not be dispensed to  any person not included in the trial.
Trial product must not be used, if it does not appear clear and colourless.
9.1 Trial products
The following trial products will be provided by [CONTACT_3454] A/S, Denmark:
Table 9â€“[ADDRESS_1187532] Strength Dosage formRoute of 
administrationContainer/
delivery device
Faster aspart, 
(IMP), test product
100 U/ml Solution for 
injectionSubcutaneously3 ml prefilled 
pen Insulin aspart (NovoRapid
Â®)
(IMP), reference therapy
Insulin degludec
(IMP), test product100 U/mlSolution for 
injectionSubcutaneously3 ml prefilled 
pen
The following non-investigational medicinal products (NIMP) will not be provided by [CONTACT_49753]. However, they will be reimbursed if required according to local regulations.
!Rapid acting insulin analogues (NovoRapidÂ®or marketed formulations of insulin lispro or 
insulin glulisine) in the run-in period
!Metformin, tablets for oral use
The comparator and active drug are visually ident ical.
9.2 Labelling
The trial products will be labelled  in accordance with Annex 1338, local regulations and trial 
requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187533] dispensing visit (Visit 2). Additionally, th e pen differentiation guide must be provided to 
subjects at randomisation (Visit 14). Direction for us e and pen differentiation guide can be provided 
as needed at the following dispensing visits.
9.3 Storage 
Table 9â€“2 Storage conditions
Trial productStorage conditions
(not-in-use)In-use conditions In-use timea
Faster aspartStore in refrigerator
(2Â°C â€“ 8Â°C)
Do not freeze
Protect from lightStore below 30Â°C
Do not refrigerate
Do not freeze
Protect from lightUse within 4 
weeks Insulin aspart
(NovoRapidÂ®)
Insulin degludec Store in refrigerator
(2Â°C â€“ 8Â°C)Do not freezeProtect from lightDo not store above 30Â°C
Protect from lightCan be stored in refrigerator (2Â°C â€“ 8Â°C)
Do not freezeUse within [ADDRESS_1187534] has been stored outside specified conditions (e.g. outside temperature range). Additional 
details regarding handling of temperature deviations can be found in the TMM.
Trial product that has been stored improperly must not be dispensed to any subject before it has 
been evaluated and approved for further use by [CONTACT_3454]. The investigator must take appropriate action to ensure correct storage.
9.[ADDRESS_1187535] (used/partly used and/or unused), expi[INVESTIGATOR_687590]-allocated trial product.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 61 of 112
Non-allocated trial products (expi[INVESTIGATOR_5697], damaged and available) must be accounted as unused at the 
latest at closure of the trial site.
Subjects are instructed to return all used, partly used and unused trial product at each dispensing 
visit after Visit 2. Please refer to the flowchart (section 2) for timing of the dispensing visits.
Destruction of trial products can be performed on an on-going basis and will be done according to 
local procedures after accountability is finalised and reconciled by [CONTACT_853270]. Destruction of products must be documented in the IWRS.
9.5 Auxiliary supplies
The following will be provided by [CONTACT_3454]:
!Direction for use for the prefilled pens
!Novo Nordisk needles
!Standardised liquid meal (for the meal test)
!BG meter and strips , lancets and control solution for BG meter
Only needles provided by [CONTACT_215572].
Please refer to the TMM for further auxiliary details.
10 Interactive voice/web response system
A trial-specific IWRS will be set up which can be accessed at any time via the internet or telephone. 
Access to the IWRS must be restricted to and controlled by [CONTACT_36301]. 
IWRS is used for:
!Medication arrival
!Screening
!Screening failure
!Run-in dispensing
!Run-in failure
!Randomisation
!Dispensing
!Dispensing Verification (when barcode scanner is used)
!Treatment discontinuation 
!Completion
!Code break
!Drug accountability
!Data change
IWRS user manuals will be provided to each trial site.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 62 of 112
11 Randomisation procedure and breaking of blinded codes
At randomisation (Visit 14) the subject will be randomised to either faster aspart or NovoRapidÂ®, 
both in combination with once daily insulin degludec with or without metformin.
The randomisation will be carried out in a 1: 1 manner to the 2 different treatment possibilities 
described below using the IWRS:
!Faster aspart and insulin degludec with or without metformin
!NovoRapidÂ®and insulin degludec with or without metformin
The investigator, subject and sponsor will be blinded to the bolus treatment.
11.1Breaking of blinded codes
The IWRS will notify Novo Nordisk (monitor and the Global Safety department) immediately after 
the code is broken.
The code for a particular subject may be broken in a medical emergency if knowing the actual 
treatment would influence the treatment of the subject. Whenever a code is broken the person 
breaking the code must print the Code Break Confirmation Notification generated by [CONTACT_8784], record the reason, and sign and date the document.
When the code is broken, the treatment allocation will be accessible to the investigator and the 
Novo Nordisk Global Safety department. If IWRS is not accessible at the time of code break the 
IWRS helpdesk should be contact[INVESTIGATOR_530]. Contact [CONTACT_136758] I.
If the code has been broken by [CONTACT_1697], the subject must discontinue treatment with trial 
product and a treatment discontinuation session must be completed in IWRS.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 63 of 112
12 Adverse events, technical complaints and pregnancies
12.1 Definitions
12.1.1 Adverse event 
An adverse event (AE) is any untoward medical occurrence in a subject administered a medicinal 
product, and which does not necessarily have  a causal relati onship with this treatment. 
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. 
An AE includes:
!A clinically significant worsening of a concomitant illness.
!A clinical laboratory AE (CLAE): a clinical laboratory abnormality which is clinically 
significant, i.e. an abnormality that suggest s a disease and/or organ toxicity and is of a 
severity that requires active management. Active management includes active treatment or 
further investigations, for example change of medicine dose or more frequent follow -up due to the abnormality.
The following should not be reported as AEs:
!Pre-existing conditions, including those fo und as a result of screening or other trial 
procedures performed before exposure to trial product (pre-existing c onditions s hould be 
reported as medical history or concomitant illness).
!Pre-planned procedures unless the condition for which the procedure was planned has 
worsened from the first trial related activity after the subject has signed the informed 
consent.
!Non-serious hypoglycaemia is an AE, but is reported on a hypoglycaemic epi[INVESTIGATOR_135524], see Section 8.4.2 .
The following three definitions are used when assessing an AE:
!Severity 
â€“Mild â€“ no or transient symptoms, no interference with the subjectâ€™s daily activities.
â€“Moderate â€“ marked symptoms, moderate interference with the subjectâ€™s daily activities.
â€“Severe â€“ considerable interference with the subjectâ€™s daily activities; unacceptable.
!Causality 
Relationship between an AE and the relevant trial product(s): 
â€“Probable - Good reason and sufficient documentation to assume a causal relationship.
â€“Possible - A causal relationship is conceivable and cannot be dismissed.
â€“Unlikely - The event is most likely related to aetiology other than the trial product.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 64 of 112
â€¢Final outcome
â€“Recovered/resolved - The subject has fully recovered, or by [CONTACT_36303]-related activity after the subject signed the informed consent.
â€“Recovering/resolving - The condition is improving and the subject is expected to recover 
from the event. This term is only applicable if the subject has completed the trial or has died 
from another AE.
â€“Recovered/resolved with sequelae - The subject has recovered from the condition, but 
with lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an 
SAE criterion, the AE must  be reported as an SAE.
â€“Not recovered/not resolved - The condition of the subject has not improved and the 
symptoms are unchanged, or the outcome is not known.
â€“Fatal - This term is only applicable if the subj ect died from a condition related to the 
reported AE. Outcomes of other reported AEs in a subject before he/she died should be 
assessed as â€œrecovered/resolvedâ€, â€œrecovering/resolvingâ€, â€œrecovered/resolved with sequelaeâ€ or â€œnot recovered/not resolvedâ€. An AE with fatal outcome must be reported as an SAE.
â€“Unknown - This term is only applicable if the subject is lost to follow-up.
12.1.2 Serious adverse event
A serious adverse event (SAE) is an experience that at any dose results in  any of the following:
!Death.
!A life-threatening
aexperience.
!In-patient hospi[INVESTIGATOR_535154].
!A persistent or significant disability or incapacityc.
!A congenital anomaly or birth defect.
!Important medical events that may not result in death, be life threateningaor require 
hospi[INVESTIGATOR_36221] - based on appropriate medical judgement 
- they may jeopardise the subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in the definition of SAEd. 
a.The term â€œlife threateningâ€ in the definition of SAE refers to an event in which the subject was at 
risk of death at the time of the event. It does not refer to an event which hypothetically might have 
caused death if it was more severe.
b.The term â€œhospi[INVESTIGATOR_11956]â€ is used when a subject: 
â€“ Is admitted to a hospi[INVESTIGATOR_36222]-patient, irrespective of the duration of physical stay, or â€“ Stays at the hospi[INVESTIGATOR_36223] [ADDRESS_1187536] should be 
regarded as a hospi[INVESTIGATOR_11956]. Hospi[INVESTIGATOR_17957], trial related and social purposes do CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187537]â€™s ability to conduct normal life functions (e.g. follow ing the 
event or clinical investigation the subject has significant, persistent or permanent change, impairment, damage or disruption in his/her body function or structure, physical activity and/or 
quality of life).
d.For example intensive treatment in an emergency room or at home of allergic bronchospasm, 
blood dyscrasia or convulsions that do not result in hospi[INVESTIGATOR_11956], or development of drug dependency or drug abuse.
The following AEs must always be reported as an SAE using the important medical event criterion 
if no other seriousness criteria are applicable:
!suspi[INVESTIGATOR_853245] 
!risk of liver injury defined as ALT or AST >3 x UNL and total bilirubin >2 x UNL, where 
no alternative aetiology exists (Hy's law).
12.1.3 Non-serious adverse event
A non-serious AE is any AE which doe s not fulfil the definition of an SAE.
12.1.4 Medicati on errors
A medication error concerning trial products is defined as:
!Administration of wrong drug. 
Note: Use of wrong dispensing unit number (DUN) i s not considered a medication error unless 
it results in administration of wrong drug.
!Wrong route of administration, such as intramuscular instead of subcutaneous.
!Administration of an overdose with the intention to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product.
!Accidental administration of a lower or highe r dose than intended. The administered dose 
must deviate from the intended dose to an extent where clinical consequences for the trial 
subject were likely to happen as judged by [CONTACT_093], although they did not 
necessarily occur.
Medication errors must be reported on an AE form and a specific event form, see Section [IP_ADDRESS] .
12.1.[ADDRESS_1187538].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 66 of 112
In this trial the following AEs require th e completion of specific event forms in the eCRF
!Injection site reaction
For details, see Section [IP_ADDRESS] .
12.1.[ADDRESS_1187539] 
(medicine or device) defects. The technical complaint may be associated with an AE, but does not concern the AE itself.
Examples of technical complaints:
!The physical or chemical appearance of trial products (e.g. discoloration, particles or 
contamination)
!All packaging material including labelling
!Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push 
button or interface between the pen and the needle)  
12.[ADDRESS_1187540]-treatment follow-up period (FU2). For subjects discontinuing trial products prematurely 
this also includes events after the post-treatment follow-up period until the last contact (Visit 30). The events must be recorded in the applicable eCRF forms in a timely manner, see timelines below and Figure 12â€“[ADDRESS_1187541] be asked about AEs and technical 
complaints, for example by [CONTACT_7939]: â€œHave you e xperienced any problems since the last contact?â€
All AEs, either observed by [CONTACT_1720] s ubject, must be reported by [CONTACT_36306].
All AEs must be recorded by [CONTACT_49738]. The investigator should report the 
diagnosis, if available. If no diagnosis is available, the investigator should record each sign and symptom as individual AEs using separate AE forms.
For SAEs, a safety information form must be completed in addition to the AE form. If several 
symptoms or diagnoses occur as part of the same clinical pi[INVESTIGATOR_1103], one safety information form can 
be used to describe all the SAEs. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187542].
Timelines for initial reporting of AEs:
The investigator must complete the following forms in the eCRF within the specified timelines:
!SAEs: The AE form within 24 hours and the safety information form within 5 calendar
days of the investigatorâ€™s first knowledge of the SAE. Both forms must be signed within 7 
calendar days from the date the information was entered in the eCRF. 
For SAEs requiring reporting on a specific event form : In addition to the above the 
specific event form within 14 calendar days from the investigatorâ€™s first knowledge of the 
AE.
If the eCRF is unavailable, the concerned AE information must be reported on a paper AE form and 
sent to Novo Nordisk by [CONTACT_6791], e-mail or courier within the same timelines as stated above. When the 
eCRF becomes available again, the investigator must enter the information on the form into the eCRF.
Contact [CONTACT_8972] (fax, telephone, e-mail and address) are provided in the investigator trial master file. 
AE identifiedDoes the AE require 
a specific event 
form?
AE  for m < 24 hours
SIF < 5 calendar da ys
Specific event form 
For SAEs: 
< 14 calendar days
Is the Adverse Event 
serious or non-
serious?
AE formNon-seriousSerious
NoYes
Queries and follow-up 
requests to be resolved 
< 14 calendar days
Timelines are for the completion of forms from the time of investigatorâ€™s awareness.
AEs requiring specific event forms are descibed in Section 12.1.4 and 12.1.5 .
No additional action
AE: Adverse Event   SIF: Safety Information form
Figure 12â€“1 Reporting of AEs CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 68 of 112
Novo Nordisk assessment of AE expectedness: 
Novo Nordisk assessment of expectedness is performed according to the following reference 
documents:
!Faster aspart IB22current version and any updates thereto.
!Insulin degludec Company Core Data Sheet current version and any updates thereto.
!NovoRapidÂ®, Company Core Data Sheet current version and any updates thereto.
Reporting of trial product-related S[LOCATION_003]Rs by [CONTACT_3454]:
Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious 
adverse reactions (S[LOCATION_003]Rs) in accordance with local requirements and ICH GCP.1In addition, the 
investigator will be informed of any trial-related SAEs that may warrant a change in any trial 
procedure.
In accordance with regulatory requirements, Novo N ordisk will inform the regulatory authorities, 
including EMA, of trial product-related S[LOCATION_003]Rs. In addition, Novo Nordisk will inform the IRBs/IECs of trial product-related S[LOCATION_003]Rs in accordance with local requirement and ICH GCP
1, 
unless locally this is an obligation of the investigator.
Novo Nordisk and non-Novo Nordisk products used as concomitant medication or non-
investigational medicinal product:
If an AE is considered to have a causal relat ionship with a non-Novo Nordisk and Novo Nordisk 
marketed product used as NIMP (NovoRapidÂ®in run-in period) and metformin or concomitant 
medication in the trial, it is important that the suspected relationship is reported to Novo Nordisk, e.g. in the alternative aetiology section on the sa fety information form. Novo Nordisk may need to 
report this AE to relevant regulatory authorities.
12.[ADDRESS_1187543] be reported to Novo Nordisk according to the following:
!SAEs: All SAEs must be followed until the outcome of the event is â€œrecovered/resolvedâ€, 
â€œrecovered/resolved with sequelaeâ€ or â€œfatalâ€, and until all queries have been resolved. 
Cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to 
another AE) may be closed with the outcome â€œrecovering/resolvingâ€ or â€œnot recovered/not 
resolvedâ€. Cases can be closed with the outcome of â€œrecovering/resolvingâ€ when the subject has completed the follow-up period and is expected by [CONTACT_36308].
The SAE follow-up information should only include new (e.g. corrections or additional) 
information and must be reported within 24 hours of the investigatorâ€™s first knowledge of the CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 69 of 112
information. This is also the case for previously non-serious AEs which subsequently become 
SAEs. 
!Non-serious AEs: Non-serious AEs must be followed until the outcome of the event is 
â€œrecovering/resolvingâ€, â€œrecovered/resolvedâ€ or â€œrecovered/resolved with sequelaeâ€ or until 
the end of the follow-up period stated in the protocol, whichever comes first, and until all 
queries related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE) may be closed with the 
outcome â€œrecovering/resolvingâ€ or â€œnot recovere d/not resolvedâ€. Cases can be closed with 
the outcome of â€œrecovering/resolvingâ€ when the subject has completed the follow -up period and is expected by [CONTACT_36308].
The investigator must ensure that the recording of the worst case severity and seriousness of an 
event is kept throughout the trial. A worsening of an unresolved AE must be reported as follow up 
with re-assessment of severity and/or seriousness of the event.
Queries or follow-up requests from Novo Nordisk must be responded to within [ADDRESS_1187544].
SAEs after end of trial: If the investigator becomes aware of an SAE with a suspected causal 
relationship to the IMP occurring to a subject after  the subject has ended the trial, the investigator 
should report this SAE within the same timelines as for SAEs during the trial. 
12.4 Technical complaints and technical complaint samples12.4.1 Reporting of tec hnical complaints
For Novo Nordisk Products
All technical complaints on an y of the following products:
!Faster aspart, 100 U/mL solution for subcu taneous injection, 3 mL PDS290 pen injector 
(blinded)
!NovoRapid
Â®, 100 U/mL solution for subcutaneous injection, 3 mL PDS290 pen injector 
(blinded)
!Insulin degludec, 100U/mL solution for subcutaneous in jection, 3 mL PDS290 pen injector 
(open)
!Novo Nordisk Needles
which occur from the time of first usage of the product until the time of the last usage of the 
product, must be collected and reported to Customer Complaint Center, Novo Nordisk.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187545] details (fax, e-mail and address) are provided in Attachment I to the protocol.
The investigator must assess whether the technical complaint is related to any AEs and/or SAEs. 
Technical complaints must be reported on a separate technical complaint form:
!One technical complaint form must be completed for each affected DUN
!If DUN is not available, a technical complaint form for each batch, code or lot number must
be completed
The investigator must complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint:
!Technical complaint assessed as related to an SAE within 24 hours
!All other technical complaints within [ADDRESS_1187546] coordinate the shipment to 
Customer Complaint Center, Novo Nordisk (the address is provided in Attachment I ) and ensure 
that the sample is sent as soon as possible. A copy of the technical complaint form must be included 
in the shipment of the sample. If several samples are returned in one shipment, the individual sample and the corresponding technical complaint form must be clearly separated.
The investigator must ensure that the technical complaint sample contains the batch, code or lot 
number and, if available, the DUN. All parts of the DUN should be returned.
If the technical complaint sample is unobtainable, the investigator must specify on the technical 
complaint form why it is unobtainable. 
Storage of the technical complaint sample must be done in accordance with the conditions 
prescribed for the product.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187547](s).
The investigator must follow the pregnancy until th e pregnancy outcome and the newborn infant is 
one month of age.
The investigator must report information about the pregnancy, pregnancy outcome, and health of 
the newborn infant(s), as well as AEs in connection with the pregnancy, and AEs in the foetus and newborn infant.
The following must be collected and reported by [CONTACT_136760] 
(e.g. in PDF format), or by [CONTACT_36310]:
1. Reporting of pregnancy information
Information about the pregnancy and pregnancy outco me/health of the newborn infant(s) has to 
be reported on Maternal Form 1A and 1B, respectively.
When the pregnancy outcome is abnormal (i .e. congenital anomalies, foetal death including 
spontaneous abortion and/or any anomalies of the foetus observed at gross examination or during autopsy), and/or when a congenital anomaly is  diagnosed within the first month, further 
information has to be reported for the female subject on Maternal Form 2. In addition, 
information from the male partner has to be reported on the Paternal Form, after an informed consent has been obtained from the male partner.
Initial reporting and follow-up information must be reported within 14 calendar days of the 
investigatorâ€™s first knowledge of initial or follow-up information.
2. Reporting of AE information
The investigator has to report AEs in connection with the pregnancy as well as in the foetus and 
newborn infant(s). The SAEs that must be reported include abnormal outcome, such as foetal 
death (including spontaneous abortion), and congenital anomalies (including those observed at 
gross examination or during autopsy of the foetus), as well as other pregnancy complications fulfilling the criteria of an SAE.
Forms and timelines for reporting AEs:
Non-serious AEs: 
!AE formawithin 14 calendar days of the investigatorâ€™s first knowledge of the initial or 
follow-up information to the non-serious AE.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 72 of 112
SAEs: 
!AE formawithin 24 hours of the investigatorâ€™s first knowledge of the SAE.
!Safety information form within 5 calendar days of the investigatorâ€™s first knowledge of the 
SAE.
!SAE follow-up information to the AE form and/or sa fety information form within 24 
hours of the investigatorâ€™s first knowledge of the follow-up information.
a It must be clearly stated in the AE diagnosis field on the AE form if the event occurred in 
the subject, foetus or newborn infant. If the AE occurred in the foetus or newborn infant, the AE can only be reported on paper AE and safety information form.
Any queries or follow-up requests from Novo Nord isk to non-serious AEs, SAEs and pregnancy 
forms must be responded to by [CONTACT_19452] [ADDRESS_1187548].
12.6 Precautions and/or overdose
During treatment with insulin, there is a risk of hypoglycaemia (see section 8.4.2 ). Symptoms of 
hypoglycaemia usually occur suddenly and may include cold sweat, nervousness or tremor, anxious 
feelings, unusual tiredness, confusion, difficulty in concentration, excessive hu nger, temporary vision changes, headache, nausea, and palpi[INVESTIGATOR_332]. Prolonged or severe hypoglycaemia can lead to a loss of self-control, spasms, and/or unconsciousness and, in extreme cases, death.
Asymptomatic hypoglycaemia and symptoms of hypoglycaemia s hould be treated with 
carbohydrates. Mild to moderate symptoms can be treated by [CONTACT_826697] (for example, juice). Severe hypoglycaemia resulting in the loss of consciousness should be treated with parenteral glucose, glucagon or dextrose.
For further details, please refer to the current version of faster aspart IB
22, Insulin degludec IB24and 
for NovoRapidÂ®, please refer to the current versions of the SmPC19or U.S. NovologÂ®Label 
Information.20
12.7 Committees related to safety12.7.1 Novo Nordisk safety committee
Novo Nordisk will constitute an internal faster aspart safety committee to perform ongoing safety 
surveillance. The faster aspart safety committee may recommend unblinding of any data for further 
analysis, and in this case an independent ad hoc group will be established in order to maintain the
blinding of the trial personnel.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187549] or an 
assessment has not been done and will not be available, or if the question is irrelevant (e.g. is not 
applicable), indicate this according to the data entry instructions.
The following will be provided as paper case report forms (CRFs):
!Pregnancy forms
The following will be provided as paper CRFs to be used when access to the eCRF is revoked or if 
the eCRF is unavailable:
!AE forms 
!Safety information forms
!Technical complaint forms (also to be used to report complaints that are not subject related 
(e.g. discovered at trial site before allocation)
On the paper CRF forms print legibly, using a ballpoint pen. Ensure that all questions are answered, 
and that no empty data blocks exist. Ensure that no information is recorded o utside the data blocks. 
If a test/assessment has not been done and will not be available, indicate this by [CONTACT_565] â€œNDâ€ (not done) in the appropriate answer field in the CRF. If the question is irrelevant (e.g. is not applicable) indicate this by [CONTACT_565] â€œNAâ€ (not applicable) in the appropriate answer field. Further guidance can be obtained from the instructions in the CRF.
The investigator must ensure that all information is consistent with the source documentation. By 
[CONTACT_853298], the investigator confirms that the information in 
the eCRF and related forms is complete and correct.
13.[ADDRESS_1187550] igatorâ€™s delegated staff. 
An audit trail will be maintained in the eCRF application containing as a minimum: the old and the new data, identification of  the person entering the data, date and time of the entry and reason for the 
correction.
If corrections are made by [CONTACT_093]â€™s delegate d staff after the date the investigator has signed 
the case book, the case book must be signed and dated again by [CONTACT_093].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187551] ensure that data is recorded in the eCRF as soon as possible, preferably 
within 5 days after the visit. Once data has been entered, it will be available to Novo Nordisk for data verification and validation purposes. The SMPG values and corresponding insulin doses for titration purposes should be entered within 24 hours on week days after th e site visi t/telephone 
contact [CONTACT_853299].
Site specific eCRF data (in an electronic readable format) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site.
[ADDRESS_1187552] visit at the trial site and no later than 4 
weeks after. The monitoring visit intervals will depend on the outcome of the centralisedmonitoring of the eCRFs (remote assessment of data by  [CONTACT_3454]), the trial site's recruitment 
rate and the compliance of the trial site to the protocol and GCP, but will not exceed [ADDRESS_1187553] access to all source documents (original documents, data and 
records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) and report(s) that are important to the evaluation of the trial. If the electronic medical record does 
not have a visible audit trail, the investigator must provide the monitor with signed and dated 
printouts. In addition the relevant trial site st aff should be available for discussions at monitoring 
visits and between monitoring visits (e.g. by [CONTACT_756]).
All data must be verifiable in source documentation other than the eCRF.
Data collected prior to the discontinuation of the glycaemic data collection system (the combined 
use of the MyGlucoHealth BG-meter and an electronic diary):Data entered by [CONTACT_853300] w ill be recorded directly in the device. All data 
entered in the eDiary device will be automatically transferred to a database, where it is kept as a 
certified copy of the source data. Data entered in the device will upon confirmation of a successful 
back-up be deleted from the dev ice. Hence the certified copy in the database is regarded as source 
data. For data entered by [CONTACT_853301], the database is regarded as source 
data. For all data recorded the source document must be defined in a source document agreement at 
each trial site. There must only be one s ource defined at any time for any data element.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 75 of 112
Source data generated by [CONTACT_535292] c orrected by [CONTACT_535293]; an y correction must be explained, signed and dated 
by [CONTACT_36324].
The monitor will ensure that the eCRFs are completed and that paper CRFs are collected.
The following data will be source data verified for screening failures: 
!Date for obtaining informed consent. 
!Screen failure date and reason
!Date of visit
!Demography (date of birth, sex and race (according to local regulation))
!Eligibility criteria
!SAE
Monitors will review the subjectâ€™s medical records  and other source data to ensure consistency 
and/or identify omissions compared to the eCRF . If discrepancies are found, the investigator must 
be questioned about these.
[ADDRESS_1187554] research organisation (CRO).
Appropriate measures, including encryption of data files containing person identifiable data, will be 
used to ensure confidentiality of subject data, when they are transmitted over open networks.
Data from central laboratories will be transferred electronically. In cases where data is transferred 
via non-secure electronic networks, data will be encrypted during transfer.
The subject and any biological m aterial obtained from the sub ject will be identified by [CONTACT_36325]. Appropriate measures such as encryption or leaving out certain identifiers will 
be enforced to protect the identity of subjects in all presentations and publications as required by 
[CONTACT_5737], regional and national requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187555] Operating Procedures and IT architecture documentation. The use and control of these systems are documented.
Investigators working on the trial may use their own electronic systems to capture source data.
Data collected prior to the discontinuation of the glycaemic data collection system (the combined 
use of the MyGlucoHealth BG-meter and an electronic diary):The eDiary software and hardware implementation are compliant with the requirements of FDA 21 CFR Part 11 and ICH E6 (EU directive for personal data protection). After trial finalisation, each 
site will be supplied with long-life DVDs. These DVDs will contain site-specific subject records 
including the subjectâ€™s eDiary data and audit trail as well as any data additions and corrections made on each form. The eDiary vendor will furthermore retain and securely store copi[INVESTIGATOR_56246] 50 years or as required by [CONTACT_56325]. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187556] ical analysis plan will be 
finalised before database lock.
General considerations
In general, for endpoints evaluated as a change from baseline and/or where a baseline adjustment is 
made, baseline is defined as information co llected at randomisation (Visit 14). In case a 
measurement is not available at randomisation, the most recent measurement prior to randomisation will be used as baseline. 
Two observation periods are defined, â€œin-trialâ€ and â€œon-treatmentâ€, and it will be specified which 
period each analysis will use.
!In-trial: The observation period from date of randomisation and until last trial -related 
subject-site contact. The in-trial observation period includes data collected after treatment 
discontinuation.
!On-treatment: The observation period from date of first dose of randomised 
NovoRapid
Â®/faster aspart and to [ADDRESS_1187557] occurrence of:
oThe day of last dose of randomised NovoRapidÂ®/faster aspart
oThe day before initiation of ancillary treatment
All efficacy endpoints will be summarised and analysed using the full analysis set (FAS), unless 
otherwise stated. Safety endpoints will be summarised using the safety analysis set and analysed 
using the FAS. The FAS is defined in section 17.2.
Presentation of resu lts from a statist ical analysis w ill include the estimated mean treatment effects 
(LSMeans) for change from baseline, if applicable. Estimated mean treatment differences (or ratios) will be presented together with two-sided 95% confidence interval (CI) for all endpoints analysed 
statistically. 
Data collected before randomisation (Visit 14) will only be summarised descriptively.The primary objective of the trial is to confirm the effect of treatment with faster aspart compared to 
NovoRapid
Â®, both in combination with insulin degludec with or without metformin in adults with 
T2DM in terms of glycaemic control, using a non-inferiority approach. 
More specifically the upper limit of the 95% confidence interval for the difference between faster
aspart and NovoRapidÂ®should be compared to a non-inferiority margin of 0.4%. If it is below or 
equal to 0.4% non-inferiority will be consid ered established and effect demonstrated. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 78 of 112
The trial also aims to confirm superiority of treatment with faster aspart  for a number of secondary 
confirmatory endpoints. The family-wise type I error rate will be controlled in the strong sense 
using a hierarchical (fixed sequence) testing procedure. This is based on a priority ordering of the null-hypotheses, and testing them in this order using the two-sided 95% confidence interval approach until an insignificant result appears. The effect is that rejection of a null hypothesis only 
will be considered for analyses where all previous null-hypotheses have been rejected in favour of 
faster aspart. 
The steps in the hierarchical testing procedure are as follows:Step 1 (Primary analysis) :  HbA
1cnon-inferiority of faster aspart versus NovoRapidÂ®
Step 2 : 1-hour PPG increment (meal test) superiority of faster aspart versus NovoRapidÂ®
Step 3 : HbA 1csuperiority of faster aspart versus NovoRapidÂ®
Step 4 : 1,5-anhydroglucitol superiority of faster aspart versus NovoRapidÂ®
Estimands
Primary estimand
The primary estimand is defined as the treatment difference between subjects randomised to faster
aspart and NovoRapidÂ® both in combination with insulin degludec with or without metformin, in 
adults with T2DM not optimally controlled with a basal-bolus regimen assessed by [CONTACT_853274] 1c16 weeks after randomisation for all randomised subjects regardless of treatment 
discontinuation or use of ancillary treatment.  
The primary estimand assesses the expected benefit a future population with T2DM can achieve if 
prescribed to faster aspart as compared to NovoRapidÂ®. By [CONTACT_853275], this estimand aims at a difference as close as possible to the one that can be 
expected in real-world clinical practice, provided that the treatment adherence and use of ancillary treatment reflects clinical practice. Thereby [CONTACT_3433] e primary estimand provides a treatment difference 
for clinicians concerning the glycaemic effect of faster aspart compared to NovoRapid
Â® in the day 
to day life in subjects with T2DM in an adult population.
Secondary estimand
A secondary estimand is defined as the treatment difference in change from baseline in HbA 1c16 
weeks after randomisation between treatment with faster aspart and treatment with NovoRapidÂ®
both in combination with insulin degludec with or without metformin in adult subjects with T2DMCONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 79 of 112
not optimally controlled with a basal-bolus regimen if all subjects had adhered to randomised 
treatment and did not r eceive ancillary tr eatment.  
The condition â€˜adhered to randomised treatment and did not receive ancillary treatmentâ€™ should be 
interpreted as the exclusion of information collected after initiation of antidiabetic treatment that 
can mask or exaggerate the effect of the initially randomised treatment. Only data collected prior to 
discontinuation of trial product or initiation of ancillary tr eatment is used to draw inference. This 
avoids confounding effects of ancillary treatment.
The two estimands will be repeated for the confirmatory endpoints
!Change from baseline in 1-hour PPG increment (meal test) 16 weeks after randomisation
!Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation
17.1 Sample size calculation
The sample size is determined to ensure a sufficient power for step 1 and step 2 in the hierarchical 
testing procedure for the primary estimand presented in section 17. The power for step 3 and 4 in 
the hierarchical testing procedure will also be presented. The sample size is determined using a non-
inferiority limit of 0.4% in step 1, which was chosen as described in section 5.2.[ADDRESS_1187558] 
been high. Therefore it will be expected that treatment discontinuation might be as low as 10% 
where trial discontinuation constitutes half of these and with similar withdrawal reasons in the treatment arms.
Power for the non-inferiority step (Step 1) is base d on a t-statistic under the assumption of a one-
sided test of size 2.5% for the FAS. A mean treatment difference of -0.1% for the comparison 
between faster aspart and NovoRapid
Â®in favour of faster aspart is expected. As trials in this 
population where da ta from treatment withdrawn subjects is retrieved is limited, a conservative 
estimate of the standard deviation (SD) in change from baseline in HbA 1c of 0.8% was chosen. The 
power for superiority in step 3 will be calculated using the same assumptions as for step 1 but 
without the non-inferiority margin. 
For determination of power in step 2 in the hierarchical testing, where change from baseline in 1-
hour PPG increment 16 weeks after randomisation is compared between faster aspart and 
NovoRapidÂ®a t-statistic with a two-sided test of size 5% is used, where the treatment difference is 
expected to be at least 0.6 mmol/L [11 mg/dL]. The SD=3.5 mmol/L [63 mg/dL] in change from 
baseline in 1-hour PPG increments [ADDRESS_1187559] will be considered reasonable based on trials NN1218-3852 and 
NN1218-3853.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 80 of 112
The power in step 4, where superiority of faster aspart over NovoRapidÂ®in change from baseline in 
1,5-anhydroglucitol [ADDRESS_1187560] of size 
5% is used. The mean treatment differe nce is expected to be at least 0.2 Î¼g/mL and an SD of 
3.5Î¼g/mL will be used based on trials NN1218-3852 and NN1218-3853.
The power calculations are done using proc power in SAS 9.4. Please refer to Table 17â€“1 for 
assumptions for the sample size calculation.
Table 17â€“[ADDRESS_1187561] One-sided 2.5 % FAS 0.4 % (absolute) 0.8 % -0.1 % 1:[ADDRESS_1187562] Two-sided 5.0% FAS NA 3.5 mmol/L 0.6 mmol/L 1:[ADDRESS_1187563] Two-sided 5.0% FAS NA 0.8 % -0.1 % 1:[ADDRESS_1187564] Two-sided 5.0% FAS NA 3.5 Î¼g/mL 0.2 Î¼g/mL 1:1
In Table 17â€“2 the sensitivity of the sample size to the power shown for three different sizes of FAS. 
Three different choices of the mean difference are used to calculate the power in step 2.
Table 17â€“[ADDRESS_1187565] 
per 
armStep 
1Step 2 Step 
3Step 4
FAS FAS Mean 
diff
(%)SD
(%)Power 
(%)Mean 
diff
(mmol/L)SD
(mmol/L)Power 
(%)Mean 
diff
(%)SD
(%)Power 
(%)Mean
diff
(Î¼g/mL)SD
(Î¼g/mL)Power 
(%)
-0.1 0.8 >99.9 0.5 3.5 58.1 -0.1 0.8 47.4 0.2 3.5 13.9
920 460 -0.1 0.8 >99.9 0.6 3.5 73.8 -0.1 0.8 47.4 0.2 3.5 13.9
-0.1 0.8 >99.9 0.7 3.5 85.8 -0.1 0.8 47.4 0.2 3.5 13.9
-0.1 0.8 >99.9 0.5 3.5 64.7 -0.1 0.8 53.4 0.2 3.5 15.5
1072 536 -0.1 0.8 >99.9 0.6 3.5 80.1 -0.1 0.8 53.4 0.2 3.5 15.5
-0.1 0.8 >99.9 0.7 3.5 90.5 -0.1 0.8 53.4 0.2 3.5 15.5
-0.1 0.8 >99.9 0.5 3.5 70.4 -0.1 0.8 58.9 0.2 3.5 17.0
1224 612 -0.1 0.8 >99.9 0.6 3.5 85.0 -0.1 0.8 58.9 0.2 3.5 17.0
-0.1 0.8 >99.9 0.7 3.5 93.8 -0.1 0.8 58.9 0.2 3.5 17.0CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 81 of 112
In conclusion, 1072 subjects in the FAS (536 subjects per group) will ensure a marginal power of 
>99.9% to show non-inferiority in step 1, given that the actual treatment difference is -0.1%, and a 
marginal power of 80.1% to show superiority in step 2, given that the actual treatment difference is 0.6 mmol/L.
Assuming a screening failure rate of 30% and run-in failure rate of 15%, 1803 subjects should be 
screened for inclusion in the trial.
17.2 Definition of analysis sets
The following analysis sets are defined in accordance with the ICH-E9 guidance
39.
!Full Analysis Set (FAS) includes all randomised subjects. In exceptional cases, randomised 
subjects may be excluded from the FAS. In such cases, the reason for exclusion will be 
justified and documented. Subjects in the FAS will contribute to the evaluation â€œas 
randomisedâ€
!Per Protocol (PP) Analysis Set includes all subjects in the FAS, excluding subjects who:
oHave violated any inclusion criteria
oHave fulfilled any exclusion criteria
Subjects in the PP analysis set will contribute to the evaluation â€œas treatedâ€ 
!Safety Analysis Set includes all subjects receiving at least one dose of randomised 
treatment. Subjects in the safety analysis set will contribute to the evaluation â€œas treatedâ€. 
Randomised subjects who are lost to follow-up, and where no exposure information of the trial 
product or its comparator is available after randomisation, will be handled as unexposed.
Before data are released for statistical review, a blinded review of all data will take place to identify 
serious non-adherence to the protocol that may poten tially affect the results. Furthermore, extreme 
values and outliers will be identified by [CONTACT_853277], 
according to ICH-E9.39This will be performed by [CONTACT_2329] a fake randomisation.
The subjects or observations to be excluded, and the reasons for their exclusion must be documented and signed by [CONTACT_36331]. The subjects and observations 
excluded from analysis sets, and the reason for this, will be described in the clinical trial report.
17.3 Primary endpoint
The primary endpoint is change from baseline in HbA
1c16 weeks after randomisation. 
Primary analysis:
1) The primary estimand will be addressed by [CONTACT_853278]-trial obse rvation period. Note that if subjects withdraw CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187566]-randomisation measurements 
contribute to the analysis, as the missing values will be imputed. The analysis will be implemented as follows: 
!In the first step, intermittent missing values are imputed using a Markov Chain 
Monte Carlo method, in order to obtain a monotone missing data pattern. This 
imputation is done for each group separately and 100 copi[INVESTIGATOR_853227]. 
!In the second step, for each of the 100 copi[INVESTIGATOR_136691], an analysis of variance 
model with region and metformin use at baseline (Yes/No) as factors and baseline 
HbA
1cas covariate is fitted to the change in HbA 1cfrom baseline to week 4 for each 
treatment group separately. The estimated pa rameters, and their variances, from 
these models are used to impute missing values at week 4 for subjects in each 
treatment group, based on region, metformin use at baseline (Yes/No) and baseline 
HbA 1c.
!In the third step, for each of the [ADDRESS_1187567] as for week 4. The imputations are based on an analysis
of variance model with region and metformin use at baseline (Yes/No) as factors and 
baseline HbA 1cand change from baseline in HbA 1cat week 4 as covariates.
!This stepwise procedure is then repeated sequentially for week 12 and 16.
!For each of the complete data sets, the change from baseline to week 16 is analysed 
using an analysis of variance model with treatment, region and metformin use at 
baseline (Yes/No) as factors, and baseline HbA 1cas a covariate. 
!The estimates and standard deviations for the [ADDRESS_1187568] deviation using Rubinâ€™s formula:
m  =1
100 m    
   CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 83 of 112
SD  = 1
100 SD     
   + 1[PHONE_4579]  1
100âˆ’1  (m âˆ’m  )    
   
where m iand SD iare the estimated means and standard deviations for the 100 copi[INVESTIGATOR_853228], and m MIand SD MIare the pooled estimates.
!From m MI  and  SD MI, the 95% confidence interval for the treatment differences is 
calculated. 
Non-inferiority of faster aspart will be considered confirmed if the upper boundary of the two-sided 
95% confidence interval is below or equal to 0.4% or equivalent if the p-value for the one-sided test 
of
H0: D > 0.4%    against   H A: D â‰¤ 0.4%
is less than or equal to 2.5%, where D is the mean tr eatment difference (faster aspart minus 
NovoRapidÂ®).
Note that as the anticipated number of subjects discontinuing treatment, but not trial is low, multiple 
imputations based on such subjects is not expected to be suitable.
Provided that the hierarchical testing allows, the evaluation of superiority will be based on the same 
statist ical model, as the primary analysis 1). The associated sensitivity analysis that follows will 
investigate the robustness of non-inferiority a nd superiority (analysis 3b a nd 3c) as well.
Sensitivity analysis for the primary analysis addressing the primary estimand
All sensitivity analyses for the primary analysis addressing the primary estimand will use the in -trial 
observation period.
2) First the primary analysis in 1) will be repeated, but excluding all factors except from 
treatment in the model. This analysis will explore the influence of the different factors.
3) The primary analysis approach chosen for this trial relies on the assumption that missing data 
is missing at random (MAR). This assumption implies that the HbA 1cfor subjects leaving the 
trial, after their withdrawal, develops in a similar way as the HbA 1cfor similar subjects that 
remain in the trial (not necessarily on treatment) and had similar development of HbA 1c
before withdrawal. The MAR assumption may be questionable for subjects withdrawing at own will. Therefore the statist ical mode ls using mult iple impu tation will be repeated with the 
following alteration:CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 84 of 112
a) Imputations will be done from the treatment arm that the subject was randomised to and 
a value of 0.4% (non-inferiority margin) is added to the change from baseline in HbA 1c
at week [ADDRESS_1187569] er aspart who withdrew from the trial.40
b) Imputations will be done from the comparator arm (NovoRapidÂ®). This will serve as a 
supplementary sensitivity analysis for the superiority analysis. It does not rely on the 
MAR assumption, but assumes that all subjects who withdraw from the trial in the faster
aspart arm shift to NovoRapidÂ®. The imputation will be done conditional on observed 
information for subjects that withdraw from the faster aspart arm such that the treatment effect diminishes gradually after trial discontinuation (copy reference/conditional 
imputation). The analysis will use data from the in-trial observation period.
c) Imputation will be done from the comparator arm (NovoRapid
Â®). This will serve as a 
supplementary sensitivity analysis for the superiority analysis. It does not rely on the MAR assumption, but it is assumed that all subjects who withdraw from the trial in the 
faster aspart arm respond at week [ADDRESS_1187570] been treated with NovoRapid
Â®for 
the entire trial. That is, all collected post-randomisation data for subjects who withdraw from the trial in the faster aspart arm will be set to missing. The analysis will use data from the in-trial observation period.
Analyses addressing the secondary estimand
All analyses addressing the secondary estimand will use the on-treatment observation period.
4) The secondary estimand will be analysed using the same statistical model using multiple 
imputations as the primary analysis in 1) excep t using the on-treatmen t observation period. 
5) A tippi[INVESTIGATOR_853229] a statist ical model using multiple impu tation model similar 
to 1), using the on-treatment observation period, will be made. In this analysis observations 
for subjects that discontinue randomised treatment are imputed based on the treatment arm they were randomised to and subjects discontinuing treatment in the faster aspart group are 
given a penalty. This is done to investigate th e robustness of the conclusion in the p rimary 
analysis with respect to the MAR assumption and mimics a scenario where the HbA
1cof the 
subjects discontinuing treatment in the faster aspart groups evolve less favourably than predicted. As a first step imputations will be done without penalty assuming MAR in the treatment group. Second, the imputed values for week 16 in the faster aspart group will be 
added a penalty. This is done repeatedly, gradually increasing the penalty until the 
conclusion from the non-inferiority analysis no longer holds. This will serve as a sensitivity 
analysis for the non-inferiority analysis and the specific value of the penalty that changes the conclusion will be used to evaluate the robus tness of the conclusion of the non-inferiority 
analysis.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 85 of 112
6) A tippi[INVESTIGATOR_853229] a statist ical model using multiple impu tation, similar to 5) 
but with the modification that subjects discontinuing treatment due to non-eligibility 
(Subjects discontinuing randomised treatment prematurely due to criteria 1, 2, 3, and 4, which are defined in section 6.6) in the faster aspart group will not have a penalty added. 
These analyses are motivated by [CONTACT_853302]-eligibility can reasonably be assumed to be missing 
completely at random. 
7) The same statis tical model using multiple impu tations as the analysis in 4), but using the PP 
analysis set and analysed using the on-treatm ent observation peri od. This an alysis will 
investigate the situation that subjects might have  deviated from the inclusion and exclusion 
criteria and will serve as sensitivity analysis for the non-inferiority analysis.
17.[ADDRESS_1187571] of treatment with faster aspart for a number of secondary confirmatory endpoints using a hierarchical (fixed sequence) testing procedure as described in section 17
(General consideration). This is based on a priority ordering of the null-hypotheses, and testing 
them in this order using the two-sided 95% confidence interval approach until an insignificant result 
appears. The effect is that rejection of the null hypothesis only, will be confirmed for endpoints where all previous null-hypotheses have been rejected in favour of faster aspart.
The confirmatory secondary endpoints are:
!Change from baseline in 1-hour PPG incremen t 16 weeks after randomisation (meal test)
!Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation
The steps in the hierarchical testing procedure are as follows:
Step 1 (Primary analysis) :  HbA
1cnon-inferiority of faster aspart versus NovoRapidÂ®
Step 2 : 1-hour PPG increment (meal test) superiority of faster aspart versus NovoRapidÂ®
Step 3 : HbA 1csuperiority of faster aspart versus NovoRapidÂ®
Step 4 : 1,5-anhydroglucitol superiority of faster aspart versus NovoRapidÂ®
The primary estimand for the primary endpoint will be repeated for the confirmatory secondary 
endpoints, change from baseline in 1-hour PPG increment (meal test) and change from baseline in 
1,5-anhydroglucitol 16 weeks after randomisation. The analyses related to these estimands are CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 86 of 112
defined below and will be used for the decisio ns to continue or not, throughout the hierarchical 
testing procedure. These analyses will be based on the FAS and use the in-trial observation period.
As sensitivity analysis the secondary analysis 4) will also be repeated for the confirmatory 
secondary endpoints. The analyses will be based on the FAS and using the on-treatment observation period.
Change from baseline in 1-hour PPG increment 16 weeks after randomisation (meal test) 
(step 2)
As the second step of the hierarchical testing procedure changes from baseline in 1-hour PPG 
increment (meal test) 16 weeks after randomisation will be tested for superiority of faster aspart 
compared to NovoRapid
Â®.
The 1-hour PPG increment will be analysed based on the laboratory measured values in the meal 
test.
The 1-hour PPG increment endpoint will be analysed using the FAS and the in-trial observation 
period based on a multiple imputation technique where the change from baseline in 1-hour PPG 
increment at week 16 for subjects withdrawn from trial are imputed based on data from trial completers in the NovoRapid
Â®arm. Multiple copi[INVESTIGATOR_014] (100 copi[INVESTIGATOR_014]) of the full dataset will be 
generated by [CONTACT_853280]: 
!An analysis of variance model with region and metformin use at baseline (Yes/No) as 
factors and baseline 1-hour PPG increment as covariate is fitted to the change from baseline 
in 1-hour PPG increment at week 16 for the NovoRapidÂ®group only. The estimated 
parameters, and the variance, from this model are used to impute missing values using stochastic simulation at week 16 for subjects in both treatment groups in order to generate 100 complete datasets.
!For each of the complete data sets, the change from  baseline to week 16 is analysed using an 
analysis of variance model with treatment, region  and metformin use at baseline (Yes/No) as 
factors, and baseline 1-hour PPG increment as covariate.
!The estimates and standard deviations for the [ADDRESS_1187572] deviation using Rubins form ula. From this, the pooled estimates and 
95% confidence interval for the treatment difference is calculated.
The superiority will be assessed by [CONTACT_30357] 95% CI to 0. If the upper 95% 
CI is below 0 then superiority will be confirmed.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 87 of 112
Change from baseline in HbA 1c16 weeks after randomisation (step 3)
Step [ADDRESS_1187573] of treatment with faster aspart compared to NovoRapidÂ®. 
Superiority will be based on the same 95% CI that was used for addressing the primary analysis. Superiority will be confirmed if the upper boundary of the two-sided 95% confidence interval of the 
mean treatment difference (faster aspart minus NovoRapid
Â®) is below 0%.
Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation (step 4)
Step [ADDRESS_1187574] of treatment with faster aspart compared 
to NovoRapidÂ®. The endpoint will be analysed based on all planned post baseline measurements 
until or at 16 weeks after randomisation using a model similar to the primary analysis 1), but with baseline 1,5-anhydroglucitol as covariate. Superiority will be confirmed if the upper boundary of the two-sided 95% confidence interval of the mean treatment difference ( faster aspart minus 
NovoRapid
Â®) is below 0.
17.4.2 Supportive secondary endpoints
[IP_ADDRESS] Efficacy endpoints
All endpoints except insulin dose in this section will be assessed using the FAS and the in-trial 
observation period and repeated using the on-t reatment observation period. Insulin dose w ill be 
presented using the safety analysis set and will therefore only use the on-treatment observation 
period.
Change from baseline in FPG [ADDRESS_1187575] baseline measurements until or at 16 weeks after randomisation using a model similar to 1) except with baseline FPG as covariate.
If a subject achieves HbA
1ctarget 16 weeks after randomisation
HbA 1c< 7.0%
A dichotomous (responder/non-responder) endpoint will be defined based on whether a Subject has 
met the HbA 1ctarget (HbA 1c<7.0%) 16 weeks after randomisation.  
This responder endpoint will be analysed ba sed on a logistic regression model using treatment ,
region and metformin use at baseline (Yes/No) as factors, and baseline HbA 1cas covariate. In 
analysis of the in-trial observation period subjects without an HbA 1cmeasurement at week 16 will CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 88 of 112
be treated as non-responders. In the analysis usi ng the on-treatment observation period both subjects
who discontinue randomised treatment or withdra w from trial is included as non -responders.
HbA 1c< 7.0% without severe hypoglycaemia
A dichotomous (responder/non-responder) endpoint will be defined based on whether a Subject has 
met the HbA 1ctarget (HbA 1c<7.0%) 16 weeks after randomisation without treatment emergent 
severe hypoglycaemic epi[INVESTIGATOR_1841].
This responder endpoint will be analysed based on a logistic regression model using treatment ,
region and metformin use at baseline (Yes/No) as factors and baseline HbA 1cas covariate. In the 
analysis of the in-trial observation period subjects without an HbA 1cmeasurement at week 16 will 
be treated as non-responders. In the analysis using the on-treatment observation period both subjects
who discontinue randomised treatment or withdraw from trial will be included as non-responders.
Change from baseline in 30- minutes, 1- hour, 2- hour, 3- hour and 4- hour PPG and 30-
minutes, 2- hour, 3- hour and 4- hour PPG increment 16 weeks after randomisation (meal 
test)
Laboratory measured PG from the meal test will be analysed for 30 minutes, 1-hour, 2-hours, 3-
hours and 4-hours PPG separately. The corresponding PPG increments will be derived separately using each PPG measurement minus the pre-prandial PG measurement.
Change from baseline in PPG and PPG increment 16 weeks after randomisation will be analysed 
separately using a model similar to the model us ed in hierarchical testing procedure step 2 for 1-
hour PPG increment 16 weeks after randomisation ( meal test) except with the corresponding 
baseline value as covariate.
Change from baseline in endpoints derived from the 7-9-7-point SMPG profile 16 weeks after 
randomisation
In general, analyses will be based on the entire 7-9-7-point SMPG profile except for the analyses of 
nocturnal endpoints where information in the 9-point SMPG profile will be utilised. 
PPG and PPG increments based on the 7-9-7-point SMPG profiles will be derived separately for PG 
measurements made 1 hour after the meal. In the following section this distinction will be considered implicit and without further explanation.
Pre-prandial PG and PPG will be recorded by [CONTACT_853281] 7-9-7-point SMPG profile 
prior to three defined visits. Individual mean mealtime PPG (post-breakfast, post-lunch, post-main 
evening meal) will be derived from the three profiles. Overall mean PPG will be derived from the 
individual derived mealtime PPG values.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 89 of 112
PPG increment for each meal (breakfast, lunch, main evening meal) will be derived from the 7-9-7-
point SMPG profile as the difference between PPG values and the PG value before meal in each 
separate profile. The mean of the derived increments will then be calculated separately for each meal. Mean 1 hour PPG increments over all meals will be derived as the mean of all corresponding mean meal increments. 
!Change from baseline in mean of the 7-9-7-point SMPG profile
The mean of the 7-9-7-point SMPG profile is defined as the area under the curve profile 
divided by [CONTACT_36336], and is calculated using the linear trapezoidal technique.
Change from baseline in the mean of the 7-9-7-point SMPG profile [ADDRESS_1187576] baseline measurements until or at 16 weeks after randomisation using a model similar to 1) except with the corresponding 
baseline value as covariate.
!Change from baseline in PPG and PPG increment (mean, breakfast, lunch and main evening 
meal)
Change from baseline in PPG and PPG increment endpoints [ADDRESS_1187577] baseline measurements until or at 16 weeks after randomisation using a 
model similar to 1) except with the corresponding baseline value as covariate.
!Change from baseline in fluctuation in 7-9-7-point SMPG profile
The fluctuation in the 7-9-7-point SMPG profile is defined as:
1
 
 |  ( )âˆ’      | 
   
where T, PG(t) and       denotes the length of the profile, the PGvalue at time tand the mean 
of the profile, respectively. It will be calculated using the linear trapezoidal technique.
Fluctuation in the 7-9-7-point SMPG profile will be logarithmically transformed and 
analysed based on all planned post baseline measurements until or at 16 weeks after 
randomisation using a model similar to 1) except with the corresponding log-transformed baseline value as covariate. Estimated treatment means and the estimated treatment differences with corresponding 95% CI will be back-transformed to the original scale, 
resulting in estimated geometric means, a treatment ration and a 95% CI for the treatment 
ratio.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 90 of 112
!Change from baseline in nocturnal SMPG measurements
Change from baseline in nocturnal SMPG measurements will be assessed by [CONTACT_853303], at [ADDRESS_1187578] value 
the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value 
minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value).
Change from baseline in nocturnal SMPG measurements [ADDRESS_1187579] baseline measurements until or at 16 weeks after 
randomisation using a model similar to 1) except with the corresponding baseline values as 
covariate.
If a subject achieves PPG target (based on overall mean of daily PPG measurements in 7-9-7-
point SMPG profile) 16 weeks after randomisation:
Overall PPG (1 hour) âˆƒâˆƒ7.8 mmol/L [140 mg/dL]
A dichotomous (responder / non-responder) endpoint will be defined based on whether a Subject 
has reached an overall mean 1 hour PPG âˆƒ7.8 mmol/L [140 mg/dL] 16 weeks after randomisation, 
where PPG is derived from the 7-9-7-point SMPG profile. 
This responder endpoint will be analysed base d on a logistic regression model using treatment , 
region and metformin use at baseline (Yes/No) as factors, and baseline overall 1-hour mean PPG as covariate. In analysis of the in-trial observation period subjects without an overall mean 1 hour PPG 
at week 16 will be treated as non-responder. In the on- treatment observation period analysis both 
subjects who discontinue randomised treatment or withdraw from trial will be included as non-responders.
Overall PPG (1-hour ) 
âˆƒ7.8 mmol/L [140 mg/dL] without severe hypoglycaemia
A dichotomous (responder / non-responder) endpoint will be defined based on whether a Subject 
has reached an overall 1-hour PPG âˆƒ7.8 mmo l/L [140 mg/dL] 16 weeks after randomisation without 
any treatment emergent severe hypoglycaemic epi[INVESTIGATOR_1841]. 
This responder endpoint will be analysed base d on a logistic regression model using treatment ,
region and metformin use at baseline (Yes/No) as factors, and baseline mean 1-hour PPG as covariate. In analysis of the in-trial observati on period subjects without an overall mean 1 hour PPG 
at week 16 will be treated as non-responders. In the on- treatment observation period analysis both 
subjects who discontinue randomised treatment or withdraw from trial will be included as non-
responders. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 91 of 112
Insulin dose (Units/day and Units/kg/day; total basal, total bolus, total daily insulin dose and 
individual meal insulin dose) 16 weeks after randomisation
The insulin doses will be summarised descriptively by [CONTACT_853282], both 
by [CONTACT_853304] a nd units/kg (total daily and separately for each 
mealt ime dose). Insulin doses will be summarised using the on-treatment observation period and 
using the safety analysis set.
Change from baseline in lipi[INVESTIGATOR_805]-lipoproteins profile 16 weeks after randomisation
Change from baseline in lipid endpoints (total cholesterol, HDL cholesterol, LDL cholesterol) will 
be logarithmically transformed and analysed separately based on all planned post baseline 
measurements until or at 16 weeks after randomisation using a model similar to 1) except with the 
corresponding log-transformed baseline as covariate. Estimated treatment means and the estimated treatment difference with corresponding 95% CI will be back-transformed to the original scale, 
resulting in estimated geometric means, a treatment ratio and a 95% CI for the treatment ratio.
[IP_ADDRESS] Safety endpoints
In terms of AEs, as a minimum, SAEs will be tabulated separately using the in-trial observation 
period.
All events in the in-trial observation period will be listed with information about whether it 
appeared in the on-treatment observation period or not.
Number of treatment emergent adverse events
Adverse events (AEs) will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). AEs will be presented based on system organ class and preferred terms.
A Treatment Emergent Adverse Event (TEAE) is defined as an event that has an onset date on or 
after the first day of exposure to randomised treatment, and no later than seven days after the last day of exposure to randomised treatment.
TEAEs are summarised descriptively, whereas AEs not defined as treatment emergent are presented 
in listings, including AEs reported in the 30-day  follow-up period. The summaries of TEAEs are 
made displaying the number of subjects with at least one event, the percentage of subjects with at least one event, the number of events and the event rate per 100 patient years of exposure. These summaries are done by [CONTACT_12917], severity, relation to insulin treatment, relation to technical 
complaint, premature treatment discontinuation due to AEs, AEs leading to withdrawal from trial
and outcome.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 92 of 112
Furthermore, summary tables based on system organ class and preferred terms are made for:
!All TEAEs
!Serious TEAEs
!Possibly and probably related TEAEs
!Severe TEAEs
!TEAEs with preferred term that are experienced by [CONTACT_2669] 5% of the subjects in any 
treatment arm or by [CONTACT_2669] 5% of all subjects
For AEs where additional information is recorded, this will be listed.AEs occurring during the run-in period are considered non-treatment emergent and will be 
summarised separately.
Number of treatment emergent injection site reactions
Treatment emergent injection si te reactions occ urring during the tria l will be summarised and listed.
Classification of Hypoglycaemia
Treatment emergent: hypoglycaemic epi[INVESTIGATOR_853230], and no later than 
one day after the last day of exposure to randomised treatment.
Nocturnal hypoglycaemic epi[INVESTIGATOR_1841]: epi[INVESTIGATOR_111378] 00:01 and 05.59 both inclusive.   
Hypoglycaemic epi[INVESTIGATOR_513417] (see Figure 17â€“1 ) and the ADA classification of hypoglycaemia (see Figure 17â€“2 ).
Novo Nordisk classification of hypoglycaemia
In normal physiology, symptoms of hypoglycaemia occur below a PG level of 3.1 mmol/L (56 
mg/dL).41Therefore, Novo Nordisk has included hypogl ycaemia with PG levels below this  cut-off 
point in the definition of BG confirmed hypoglycaemia.
Novo Nordisk uses the following classification (see Figure 17â€“1 ) in addition to the ADA 
classification: CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 93 of 112
!Severe hypoglycaemia according to the ADA classification.34
!Severe or BG confirmed hypoglycaemia: An epi[INVESTIGATOR_635610]34or BG confirmed by a PG value <3.1 mmol/L (56 mg/dL) with orwithout 
symptoms consistent with hypoglycaemia. 
Hypoglycaemic
epi[INVESTIGATOR_156028] â‰¤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurementPG < 3.1 mmol/L
(56 mg/dL)
with symptoms
PG < 3.1 mmol/L
(56 mg/dL)
without
symptomsSymptomatic BG 
confirmed 
hypoglycaemia
Asymptomatic BG 
confirmed 
hypoglycaemiaYesNo
Severe or 
BG confirmed 
symptomatic 
hypoglycaemia
BG confirmed 
hypoglycaemia
Severe or BG 
confirmed 
hypoglycaemia
Note: Glucose measurements are performed with capi[INVESTIGATOR_156029]: blood glucose  PG: plasma glucose  SMPG: Self-measured plasma glucose  Subject 
able to 
treat him/
herselfSevere 
hypoglycaemia
(ADA 2013)
Figure 17â€“1 Novo Nordisk classification of hypoglycaemiaCONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 94 of 112
ADA classification34of hypoglycaemia 
!Severe hypoglycaemia: An epi[INVESTIGATOR_826669], glucagon, or take other corrective actions. Plasma glucose 
concentrations may not be available during an event, but neurological recovery following 
the return of PG to normal is considered sufficient evidence that the event was induced by a low PG concentration.
!Asymptomatic hypoglycaemia: An epi[INVESTIGATOR_36245], but with a measured PG concentration â‰¤ 3.9 mmol/L (70 mg/dL).
!Documented symptomatic hypogly caemia: An epi[INVESTIGATOR_826670] a measured PG concentration â‰¤ 3.9 mmol/L (70 
mg/dL).
!Pseudo-hypoglycaemia: An epi[INVESTIGATOR_36247] a measured PG concentration > 3.9 mmol/L (70 
mg/dL) but approaching that level.
!Probable symptomatic hypoglycaemia: An epi[INVESTIGATOR_135529] a PG determination but that was presumably caused 
by a PG concentration â‰¤ 3.9 mmol/L (70 mg/dL).
Hypoglycaemic 
epi[INVESTIGATOR_36249] â‰¤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurementAsymptomatic 
hypoglycaemia
Documented 
symptomatic 
hypoglycaemia
Pseudo-
hypoglycaemia
Probable 
symptomatic 
hypoglycaemiaNo
Yes
No measurement 
with symptomsPG > 3.9 mmol/L 
(70 mg/dL)
with symptomsPG â‰¤3.9 mmol/L 
(70 mg/dL)
with symptomsPG â‰¤3.9 mmol/L 
(70 mg/dL)
without symptoms
NoYes
Note: Glucose measurements are performed with capi[INVESTIGATOR_135530]: plasma glucose  SMPG: Self-measured plasma glucose  Subject 
able to 
treat him/
herselfSevere 
hypoglycaemia
(ADA 2013)
Figure 17â€“2 ADA classification of hypoglycaemiaCONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187580] one event (N), the percentage of subjects with at least one event (%), the number of events 
(E) and the event rate per 100 years of exposure (R). Separate summaries are made by [CONTACT_853284][INVESTIGATOR_1841], nocturnal and daytime epi[INVESTIGATOR_853246]. All epi[INVESTIGATOR_853232], including summaries in relation to time 
since start of meal, as occurring during1, 2, and 4 hours after start of meal, and from 2 hours 
(exclusive) to 4 hours (inclusive) after start of meal, respectively.
The number of treatment emergent severe or BG confirmed hypoglycaemic epi[INVESTIGATOR_1841] (all, daytime, 
nocturnal, 1 hour, 2 hours, 4 hours and from 2 hours (exclusive) to 4 hours (inclusive) after start of 
the meal) will be analysed based on the FAS using a negative binomial regression model with a log -
link function and the logarithm of the time peri od in which a hypoglycaemic ep isode is considered 
treatment emergent as offset. The model will include treatment, region and metformin use at baseline (Yes/No) as factors. To the extent where data allow, separate analysis will be performed 
for severe hypoglycaemic epi[INVESTIGATOR_1841].
Change from baseline in clinical evaluations 16 weeks after randomisation:
Physical examination
The physical examination parameters (head, ears, eyes, nose, throat, neck, respi[INVESTIGATOR_2133], 
cardiovascular system, gastrointestinal system in cl. mouth, musculoskeletal system, central and 
peripheral nervous system, skin), and their change  from baseline, will be summarised descriptively
using the on-treatment period. All findings will be listed.
Vital signs
Vital signs include diastolic blood pressure, sy stolic blood pressure and pulse. The measurements 
will be summarised descriptively using the on-t reatment period and both actual values as mean 
change and change from baseline.
Electrocardiogram
ECG findings will be summarised descriptively using the on-treatment period and including 
summaries of the change from baseline. Change from baseline will be summarised as normal/abnormal not clin ically significant/abnormal clinically significant categorisation in shift 
tables.
Fundoscopy/fundus photography
Fundoscopy/fundus photogra phy findings w ill be summarised descriptively using the on-treatment 
period and including summaries of the change from baseline. Change from baseline will be CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 96 of 112
summarised as normal/abnormal not clinically significant/abnormal clinically significant 
categorisation in shift tables.
Change from baseline in clinical laboratory assessments 16 weeks after randomisation
Change from baseline 16 weeks after randomisation in central laboratory assessments:
!Haematology (erythrocytes, haematocrit, haemoglobin, leucocytes, thrombocytes)
!Biochemistry (ALT, AST, albumin, alkaline phosphatase, creatinine, potassium, sodium, 
total bilirubin)
Individual laboratory values will be compared to their relevant reference range (when existing) and 
flagged as being below or above the range. The measurements and their change from baseline will 
be summarised descriptively using the on-tr eatment period. Change from baseline will be 
summarised both the actual values and the low/normal/high categorisation in shift tables.
Change from baseline in body weight and body mass index [ADDRESS_1187581] baseline 
measurements until or at 16 weeks after randomisation using a statistical model similar to 1) except with the corresponding baseline measurement as covariate.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187582] T2DM at a stage where basal-bolu s treatment is needed (i .e. subjects must have 
been diagnosed with T2DM for [ADDRESS_1187583] 365 days prior to screening). 
Subjects taking metformin at the enrolment in the trial should continue the metformin treatment 
unchanged. Metformin plus basal/bolus insulin is a recommended treatment for subjects with 
T2DM9and the combination of metformin and basal-bolus insulin therapy with faster aspart or 
NovoRapidÂ®as the bolus insulin was included in the phase 3A faster aspart trials in T2DM. 
The most common side effect of all available insulin preparations is hypoglycaemia. The 
investigator will explain to the subject how they should check their BG with the BG meter provided 
by [CONTACT_853285].
Trial products will be provided by [CONTACT_853286]. When treatment 
with trial products ends, the subject and investigator will decide on the best available treatment on the market. Novo Nordisk will not offer any free medications after the completion of the trial.
Summary of clinical pharmacology
The pharmacokinetic and pharmacodynamic profiles of faster aspart consistently demonstrated a 
left shift compared to that of NovoRapid
Â® in subjects with T1DM and the profiles for faster aspart 
and NovoRapidÂ®were similar in overall shape. Faster aspart produced a faster onset of exposure 
and increased initial absorption rate compared to NovoRapidÂ®resulting in a faster onset of action 
and increased early glucose-lowering effect. Overall, the differences in the pharmacokinetic and pharmacodynamic properties for faster aspart compared to NovoRapid
Â®were consistent across 
trials.22No safety concerns were raised during any of the trials. 
Similar clinical pharmacology trials have not been performed in subjects with T2DM, however the phase 3A programme for faster aspart included trials in bolus naÃ¯ve T2DM subjects. Non-inferiority 
to NovoRapid
Â®with regard to HbA 1cchange from baseline was d emonstrated. In subjects with 
T2DM faster aspart s tatist ically si gnificantly improved control of the 1-hour PPG increment when 
compared to NovoRapidÂ®.22No safety issues for faster aspart have been identified based on data 
from the clinical development programme, and the safety profile is similar to NovoRapidÂ®.22CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187584] and compare safety of faster aspart compared to 
NovoRapidÂ®both in combination with insulin degludec wi th or without metformin in subjects with 
T2DM treated with a basal-bolus regimen.
For the individual subjects, the personal health-related benefits are related to the medical 
examination and the benefit from an intensified treatment regimen anticipated to be better than or 
equal to the treatment they receive at the time they  enter the trial. However, subjects will have to 
spend some extra time monitoring and recording data and on additional visits to the clinic and phone contacts.
The very high frequency of contacts between the subject and the investigator and the thorough 
evaluation of SMPG values will provide the opportunity for optimising the titration of basal and bolus insulin based on SMPG values and thereby [CONTACT_826708]
1c
results. All subjects will have reinforced dietary training including simple carbohydrate counting.
For the individual subjects, the anticipated risks include hypoglycaemia, hyperglycaemia, systemic 
allergic reactions, injection site reactions, lipodystrophy, and antibody development. The risks will be mitigated by [CONTACT_826709].
A consequence of the pharmacodynamics of rapid-acting insulin analogues is that if hypoglycaemia 
occurs, it may occur earlier after an injection than with soluble human insulin. A phase 3A trial with 
faster aspart in T2DM showed a slight shift in distribution of the occurrence of hypoglycaemic epi[INVESTIGATOR_853233] a meal when comparing to NovoRapid
Â®. A stati stical significant higher rate 
of hypoglycaemic epi[INVESTIGATOR_853234] [ADDRESS_1187585]â€™s safety. 
Lipodystrophy (including lipohypertrophy, lipoatrophy ) at the injection site can occur. Continuous 
rotation of the injection site within the particular  injection area may help to reduce the risk of 
developi[INVESTIGATOR_826655].
The blood samples during meal tests might be inconvenient to the subjects, but are not of any safety 
concern.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187586] to mixing up the pens used for basal 
and bolus injection. Subjects will be trained in distinguishing between the pens. It is expected that the risk of mixing up basal and bolus insulin in this trial is similar to other clinical trials.
No maximum dose of insulin is specified as doses are titrated individually. All subjects will perform 
4-point profiles on a daily basis throughout the trial for safety purposes and for the purpose of insulin titration.
Conclusion
Subjects in this trial will benefit from an intensif ied insulin treatment in a basal-bolus regimen in a 
treat-to-target setting under close supervision.
The safety profile of insulin aspart is well established from the market use of NovoRapid
Â®. The data 
available for faster aspart in non-clinical and clinical studies taken together with review of the 
additional excipi[INVESTIGATOR_853247] n have not revealed any safety issues that would 
prohibit the administration of faster aspart formulations in accordance with this trial.
It is therefore concluded that th e clinical benefits from the trial as well as the contribution to the 
development of a new faster aspart outweigh the potential risks of participating in this trial.
18.[ADDRESS_1187587] comply with applicable 
regulatory requirement(s) and adhere to ICH GCP1and the requirements in the Declaration of 
Helsinki.[ADDRESS_1187588] 
before any trial-related activity.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187589]â€™s willingness to continue 
participating in the trial, the investigator must inform the subject in a timely manner, and a revised 
written subject information must be provided and a new informed consent must be obtained.
18.[ADDRESS_1187590]â€™s data will be handled 
as follows:
!Data already collected and any data collected at the end-of-trial visit including follow-up 
visits will be retained by [CONTACT_3454], entered into the database and used for the clinical 
trial report. 
!Safety events will be reported to Novo Nordisk and regulatory authorities according to 
local/national requirements.
If data is used, it will always be in accordance with local regulations and IRBs/IECs.
18.[ADDRESS_1187591] may 
receive a â€œwelcome to the trial letterâ€ and a â€œthank you for your participation letterâ€ after 
completion of the trial. Further the subject may receive letters during the trial.
All written information to subjects must be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_244168] a pproval or notification according to local regulations.
18.5 Premature termination of the trial and/or trial site
Novo Nordisk, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial 
or a trial site at any time, but agreement on procedures to be followed must be obtained.
If the trial is suspended or prematurely termin ated, the investigator must inform the subjects 
promptly a nd ensure appropriate therapy and follow- up. The investigator and/or Novo Nordisk must 
also promptly inform the regulatory authorities and IRBs/IECs and provide a detailed written explanation. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187592] be 
provided to the IRBs/IECs in case it has an impact on th e planned follow-up of subjects who have 
participated in the trial. If it has an impact, the actions needed to inform and protect the subjects should be described.
[ADDRESS_1187593] be documented and explained in a protocol deviation by [CONTACT_18030], date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be acknowledged and confirmed via edit checks in the eCRF or via listings from the trial database.
Documentation on protocol deviations must be kept  in the investigator trial master file and sponsor 
trial master file.
19.[ADDRESS_1187594] be instructed to complete their diary ongoing according to the protocol. Missing 
data will not be recorded retrospectively due to the decreased validity of such data
36, 37; however a 7 
daysâ€™ timeline is applied for reporting of missing hypoglycaemic epi[INVESTIGATOR_1865], The subject will be 
retrained in correct completion of the diary if missing data is identified.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 102 of 112
The investigator will make every effort to ensure that all assessments are performed and data is 
collected. If missing data does occur the reason will be collected via the protocol deviation process, 
see section 19.1. Novo Nordisk will monitor protocol de viations on an on-going basis throughout 
the trial followed by [CONTACT_687661] (e.g. re -training of site staff).
[ADDRESS_1187595] to a udits conducted by [CONTACT_36341]/IECs. Audits and inspections may take place during or after the trial. The investigator an d the site staff as well as Novo Nordisk staff 
have an obligation to cooperate and assist in audits and inspections. This includes giving auditors 
and inspectors direct access to all source documents and other documents at the trial site relevant to 
the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) and report(s) that are relevant to the evaluation of the trial.
[ADDRESS_1187596] be available to Novo Nordisk:
!Regulatory approval and/or acknowle dgement of notification as required 
!Approval/favourable opi[INVESTIGATOR_36254]/IECs clearly identifying the documents reviewed as 
follows: protocol, any protocol amendments, subject information/informed con sent form, 
any other written information to be provided to the subject and subject recruitment m aterials
!List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
!Curricula v itae of investigator and sub-investigator(s) (current, dated and signed - must 
include documented GCP training or a certificate)
!Signed receipt of IB
!Signed and dated Agreement on Protocol
!Signed and dated Agreement on Protocol Amendment, if applicable
!Contract, signed by [CONTACT_1755]/or appropriate parties on behalf of the investigatorâ€™s 
site and Novo Nordisk
!Source document agreement
!Central laboratory certification and normal ranges
!Insurance statement, if applicable
!Financial disclosure form from investigator and sub-investigator(s)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 103 of 112
!For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest
!For US trial sites: FDA form [ADDRESS_1187597] be comp leted and signed by [CONTACT_237205] 1572:
For US sites:
!Intended for US sites
!Conducted under the Investigational new drug (IND)
!All US investigators, as described above, will sign FDA Form 1572
For sites outside the US:
!Intended for participating sites outside of the US
!Not conducted under the Investigational new drug (IND)
!All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will analyse and report data from all sites together if more than one site is involved in 
the trial.
By [CONTACT_36343], each investigator agrees to comply fully with ICH GCP1,
applicable regulatory requirements and the Declaration of Helsinki.2
By [CONTACT_36343], each investigator also agrees to allow Novo Nordisk to make 
investigatorâ€™s name [CONTACT_36374] [CONTACT_36344].
[ADDRESS_1187598] of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the trial site. If any tasks are delegated, the investigator 
must maintain a log of appropriately qualified persons to whom he/she has delegated specified trial-related duties. The investigator must ensure th at there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigatorâ€™s responsibility to supervise the 
conduct of the trial and to protect the rights, safety, and well-being of the subjects.
A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible 
for all trial-related  medical decisions.
The investigator will follow instructions from Novo Nordisk when processing data.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 104 of 112
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data 
produced) in the investigator trial master file. The documents including the subject identification 
code list must be kept in a secure locked facility, so no unauthorized persons can get access to the data.
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any unauthorised access to data or any other processing of data against applicable law. The investigator must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.
During any period of unavailability, the investigator must delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk.
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187599], if deemed necessary by [CONTACT_3454]. Provided that certain 
conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial to researchers who require access for research projects studying the same disease and/or trial product studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted clinical trial report for this trial.
One investigator will be appointed by [CONTACT_853305] 
(signatory investigator) on behalf of all participating investigators. The signatory investigator will be appointed based upon the criteria defined by [CONTACT_339722].
[ADDRESS_1187600] for 
Clinical Trial Disclosure.28
Novo Nordisk reserves the right to defer the release of data until specified milestones are reached, 
for example when the clinical trial report is available. This includes the right not to release the results of interim analyses, because the release of such information may influence the results of the 
entire trial.
At the end of the trial, one or more scientific publications may be prepared collaboratively by [CONTACT_1275](s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to [ADDRESS_1187601] intellectual property.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 106 of 112
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. All authors will be given the relevant 
statistical tables, figures, and reports needed to evaluate the planned publication. In the event of any disagreement on the content of any publication, both the investigatorsâ€™ and Novo Nordisk opi[INVESTIGATOR_222662].
Where required by [CONTACT_18038], the investigator from each trial site will be named in an 
acknowledgement or in the s upplementary m aterial, as specified by [CONTACT_18038]. 
Novo Nordisk maintains the right to be informed of plans by [CONTACT_36347], presentation, communication or other information concerning the 
investigation described in this protocol. Any such communication must be submitted in writing to 
Novo Nordisk before submission for comments. Comments will be given within four weeks from receipt of the pl anned communication .
Authorship
Authorship of publications should be in accordance with the Uniform Requirements of the 
International Committee of Medical Journal Editors
42(sometimes referred to as the Vancouver 
Criteria).
Site-specific publication(s) by [CONTACT_1697](s)
For a multi-centre clinical trial, analyses based on single-site data usually have significant statist ical 
limitations and frequently do not provide meaningful information for healthcare professionals or subjects, and therefore may not be supported by [CONTACT_3454]. It is a Novo Nordisk policy that 
such individual reports do not precede the primar y manuscript and should always reference the 
primary manuscript of the trial.
Novo Nordisk reserves the right to prior review of such publications. Further to allow for the 
primary manuscript to be published as the first, Novo Nordisk asks for deferment of publication of individual site results until the primary manuscript is accepted for publication. As Novo Nordisk 
wants to live up to the industry publication po licy, submission of a primary publication will take 
place no later than [ADDRESS_1187602] their own research subjects' data, and will be provided with the 
randomisation code after results are available.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187603]â€™s medical records must be kept for the maximum period permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper-
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if 
not otherwise notified. The investigator should not destroy any documents without prior permission 
from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk can refer the investigator to an independent archive provider that has a system in place to allow only 
the investigator to access the files.
The investigator must be able to access his/her trial documents without involving Novo Nordisk in 
any way. Site-specific CRFs and other subject data (in an electronic readable format or as paper copi[INVESTIGATOR_17951]) will be provided to the investigator before access is revoked to the systems and/or 
electronic devices supplied by [CONTACT_3454]. These data must be retained by [CONTACT_21655]. If the 
provided d ata (e.g. the CD-ROM) is not readable during th e entire storage period, the investigator 
can request a new copy. A copy of all  data will be stored by [CONTACT_3454].
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for at least [ADDRESS_1187604].
The files from the trial si te/institution must be  retained for 15 years after end of trial as defined in 
Section 7, or longer if required by [CONTACT_36348]. In any case trial files cannot 
be destroyed until the tr ial site/institution is no tified by [CONTACT_3454]. The deletion process must 
ensure confidentiality of data and must be done in accordance with local regulatory requirements.  CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 108 of 112
25 Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval or favourable opi[INVESTIGATOR_36256]/IEC prior to commencement of 
the trial.
During the trial, the investigator or Novo Nordisk, as applicable, must promptly report the 
following to the IRB/IEC, in accordance with local requirements: updates to IB, unexpected SAEs where a causal relationship cannot be ruled out, protocol amendments according to local 
requirements, deviations to the protocol implemented to eliminate immediate hazards to the 
subjects, new information that may affect adversely the safety of the subjects or the conduct of the 
trial (including new benefit-risk analysis in case it will have an impact on the planned follow-up of the subjects), annually written summaries of the trial status, and other documents as required by [CONTACT_1036]/IEC.
The investigator must ensure submission of the clinical trial report synopsis to the IRB/IEC.
Protocol amendments must not be implemented  before approval or favourable opi[INVESTIGATOR_36257], unless necessary to eliminate immediate hazards to the subjects.
The investigator must maintain an accurate and complete record of all submissions made to the 
IRB/IEC. The records must be filed in the investigator trial master file and copi[INVESTIGATOR_36258].
Regulatory Authorities:
Regulatory authorities will receive the clinical tr ial application, protocol amendments, reports on 
SAEs, and the clinical trial report according to national requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187605] liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials  in any country, unle ss others have shown 
negligence.
Novo Nordisk assumes no liability in the event of negligence, or any other liability of the sites or 
investigators conducting the trial, or by [CONTACT_18033].
Novo Nordisk accepts liability in accordance with:Poland: Novo Nordisk carries liability for the tr ial exclusively in the scope defined by [CONTACT_136778] 6 September 
2001 (uniform version Journal of Laws of 2008 No. 45 item 271 with amendments). In order to support potential claims for liability attributable to the trial, Novo Nordisk and the investigators are covered by [CONTACT_36352].
Russia: Federal law of 12 April 2010 No. 61-FZ â€˜On Medicinal Drugsâ€™ Circulation and Ministry of 
Healthcare of Russian Federationâ€™ order of 01 April 2016 No. 200n â€œApproval of rules of good clinical practice.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 110 of 112
27 References
1. International Conference on Harmonisation. ICH Harmonised Tripatite Guideline. Guideline 
for Good Clinical Practise E6(R2), Step 4. [ADDRESS_1187606] of intensive treatment 
of diabetes on the development and progression of long-term complications in insulin-
dependent diabetes mellitus. The Diabetes Control and Comp lications Trial Research Group. 
N Engl J Med. 1993;329(14):977-86.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of comp lications in patients with type 2 diabetes ([LOCATION_006]PDS 33). [LOCATION_006] 
Prospective Diabetes Study ([LOCATION_006]PDS) Group. Lancet. 1998;352(9131):837-53, Erratum 
1999; 354: 602.
5. Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, et al. Impact of fasting 
and postprandial glycemia on overall glycemic control in type 2 diabetes - Importance of 
postprandial glycemia to achieve target HbA1c levels. Diabetes Research and Clinical 
Practice. 2007;77(2):280-5.
6. International Diabetes Federation Guideline Development G. Guideline for management of 
postmeal glucose in diabetes. Diabetes Res Clin Pract. 2014;103(2):256-68.
7. Leiter LA, Ceriello A, Davidson JA, Hanefeld M, Monnier L, Owens DR, et al. Postprandial 
glucose regulation: New data and new implications. Clin Ther. 2005;27(Suppl B):S42-S56.
8. Brange J, Owens DR, Kang S, Volund A. Monomeric Insulins and Their Experimental and 
Clinical Implications. Diabetes Care. 1990;13(9):923-54.
9. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin 
aspart. A randomized double-blind cross-over tr ial in type 1 diabetes. Diabetes Care. 
1999;22(5):801-5.
10. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycaemia in type 2 diab etes: a patient-centered approach. Position 
statement of the American Diabetes Association (ADA) and the European Association for 
the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-96.
11. Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. A comparison of two 
intensification regimens with rapid-acting insulin aspart in type 2 diabetes inadequately 
controlled by [CONTACT_8206]-daily insulin detemir and oral antidiabetes drugs: the STEP-Wise 
randomized study. Endocr Pract. 2011:727-36.
12. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B, et al. Comparison of insulin 
analogue regimens in people with type 2 di abetes mellitus in the PREFER Study: a 
randomized controlled trial. Diabetes Obes Metab. 2009;11(1):45-52.
13. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Munoz-Torres M, et al. Insulin 
degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment 
with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, 
randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498-
507.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 111 of 112
14. Home PD, Lindholm A, Riis A, European Insulin Aspart Study Group. Insulin aspart vs. 
human insulin in the management of long-term bl ood glucose control in Type 1 diabe tes 
mellitus: a randomized controlled trial. Diabet Med. 2000;17(11):762-70.
15. Raskin P, Riis A, Guthrie RA, Jovanovic L, Leiter L. Use of insulin aspart, a fast-acting 
insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. 
Diabetes Care. 2000;23(5):583-8.
16. Gallagher A, Home PD. The effect of improved post-prandial blood glucose control on post-
prandial metabolism and markers of vascular risk in people with Type [ADDRESS_1187607]. 2005;67(3):196-203.
17. Perriello G, Pampanelli S, Porcellati F, Avogaro A, Bosi E, Petrella G, et al. Insulin aspart 
improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, 
stratified, double-blind and cross-over trial. Diabet Med. 2005;22(5):606-11.
18. Bretzel RG, Arnolds S, Medding J, Linn T. A direct efficacy and safety comparison of 
insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with 
type 2 diabetes. Diabetes Care. 2004;27(5):1023-7.
19. Novo Nordisk A/S. NovoRapidÂ®(insulin aspart), EU Summary of Product Characteristics 
(SmPC). 15 Nov 2016.
20. Novo Nordisk A/S. NovoLog (insulin aspart), US Prescribing Information (PI). [ADDRESS_1187608] 
2016.
21. Novo Nordisk A/S. Fiasp (insulin aspart ), EU Summary of Produ ct Characteristics (SmP C). 
03 Feb 2017.
22. Novo Nordisk A/S. Investigator's Brochure, Faster-acting Insulin Aspart (9th Edition). 2016.
23. Novo Nordisk A/S. TresibaÂ®(insulin degludec) EU Summary of Product Characteristics 
(SmPC). August 2015.
24. Novo Nordisk A/S. Investigator's Brochure, insulin degludec (TresibaÂ®), project NN1250, 
(edition 12). 14 Dec 2016.
25. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). 
Guideline on clinical investigation of medicinal products in the treatment or prevention of 
diabetes mellitus (CPMP/EWP/1080/00 Rev. 1). Adoption by [CONTACT_13633]. 14 May 2012.
26. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance 
for Industry. Diabetes Mellitus: Developi[INVESTIGATOR_339672], Draft Guidance. 2008.
27. Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensification with 
stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy 
(FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol. 
2014;2(1):30-7.
28. Novo Nordisk A/S. http://www.novonordisk-tri als.com/website/content/how-we-disclose-
trial-information.aspx.
29. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):1250-1.
30. U.S. Food and Drug Administration. Food and Drug Administration Amendments Act of 
2007 as amended by [CONTACT_43679] "Clinical Trials Registration and Results Information 
Submission". 21 September 2017.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 112 of 112
31. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Councill of [ADDRESS_1187609] of clinical trials on medicinal 
products for human use, article 11. Official Journal of the European Communities. 1 May 
2001.
32. The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down 
Community procedures for the authorisation  and supervision of medicinal products for 
human and veterinary use and establishing a European Medicines Agency, article 57. 
Official Journal of the European Communities. 2004.
33. Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced 
awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic 
frequency and associated symptoms. Diabetes Care. 1995;18(4):517-22.
34. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia
and diabetes: a report of a workgroup of the American Diabetes Association and the 
Endocrine Society. Diabetes Care. 2013;36(5):1384-95.
35. McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. 
Diabet Med. 2001;18(9):690-705.
36. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance 
for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to 
Support Labeling Claims. December 2009.
37. Stull DE, Leidy NK, Parasuraman B, Chassa ny O. Optimal recall periods for patient-
reported outcomes: challenges and potential solutions. Curr Med Res Opin. 2009;25(4):929-
42.
38. European Commission. The Rules Governing Medicinal Products in the European Union, 
Volume 4, Annex 13, Investigational Medicinal Products. Brussels, February 2010.
39. International Conference of Harmonisation. ICH Harmonised Tripartite Guideline E9. 
Statistical Principles for Clinical Trials, Step 4 Version. 5 Feb 1998.
40. Koch GG. Comments on 'Current issues in non-inferiority trials' by [CONTACT_19617] R. Fleming, 
Statistics in Medicine, DOI: 10.1002/sim.2855. Stat Med. 2008;27(3):333-42.
41. Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of 
glucose counterregulatory systems are higher than  the threshold for symptoms. J Clin Invest. 
1987;79(3):777-81.
42. International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals; current version 
available at www.icmje.org.CONFIDENTIAL
Trial ID: NN1218-4113
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Protocol - Appendix A Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 1 of 9
Appendix A: Titration Guideline
Trial ID: NN1218-[ADDRESS_1187610]-acting Insulin Aspart Compared to 
NovoRapidÂ®both in Combination with Insulin Degludec with or 
without Metformin in Adults with Type 2 Diabetes (onsetÂ®9)
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
partiesCONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Trial ID: NN1218-4113
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Protocol - Appendix A Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187611] of in-text tables......................................................................................................... .................................2
1 Introduction.................................................................................................................. .............................3
2 Treatment regimens............................................................................................................ ......................4
2.1 Injection area.............................................................................................................. ....................4
2.2 Time of injection........................................................................................................... .................4
3 Initiation and titration ...................................................................................................... ........................5
3.1 Initiation of insulin degludec (Visit 2).................................................................................... .......5
3.2 Titration insulin degludec during run-in.................................................................................... ....5
3.3 Treatment with bolus insulin during run-in .................................................................................. .6
3.4 Initiation of faster aspart or NovoRapidÂ®at Visit 14.....................................................................6
3.5 Titration of faster aspart or NovoRapidÂ® from randomisation (Visit 14).......................................[ADDRESS_1187612] of in-text tables
Page
Table 1 Increase of insu lin degludec Dose ....................................................................................... ..........5
Table 2 Reduction of insulin degludec Dose ...................................................................................... ........6
Table 3 Faster aspart or NovoRapidÂ® dose adjustment algorithm...............................................................7CONFIDENTIAL
Trial ID: NN1218-4113
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Protocol - Appendix A Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187613] shown that this is difficult to achieve, unless plasma glucose (PG) values are intensively 
monitored and the insulin dose(s) frequently adjusted 1-6.
To ensure treatment uniformity between the sites, as well as to ensure that subjects receive an optimal treatment, titration algorithms have been developed specifying recommended dose 
adjustments at different PG levels.
It is recognised that treatments differ between different regions and countries. Likewise, specific 
titration guidelines may not be applicable in certain clinical situations. It is important that other 
information, such as symptoms of hypo/hyperglycaemia, previous response to dose adjustments, 
other glucose measurements and other indicators of the subjectâ€™s level of glycaemic control, is 
taken into consideration when decisions on dosing are made. The investigator should always use his 
clinical judgement to avoid safety hazards. The investigator is responsible for the treatment of the 
subjects and can therefore overrule the guideline.
To optimise and maintain glycaemic control, the Investigator should, throughout the trial be at least 
in weekly contact [CONTACT_853306]â€™s welfare.CONFIDENTIAL
Trial ID: NN1218-4113
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Protocol - Appendix A Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 4 of 9
2 Treatment regimens
All subjects will be treated with insulin degludec and NovoRapidÂ®/fast-acting insulin aspart (faster 
aspart) in a basal-bolus regimen.
At Visit 2 eligible subjects will be transferred from their previous basal insulin dose to insulin 
degludec once daily according to Section 3.1.
During the following 12 weeks the Investigator will focus on adjusting the basal insulin dose 
according to Section 3.2.
In addition, the subjects will continue their pre-trial bolus insulin analogue with or without 
metformin at Visit 2. No adjustments of bolus insulin should be performed by [CONTACT_853307]-in period.
At randomisation (after 12 weeks) eligible subjects will be randomised 1:1 into two parallel 
treatment groups:
1. mealtime faster aspart + insulin degludec
2. mealtime NovoRapidÂ®+ insulin degludec
During the following 16 weeks treatment period the Investigator will focus on adjusting the bolus
insulin dose according to Section 3.5.
2.1 Injection area
Insulin degludec should be injected subcutaneously into the thigh, or upper arm (deltoid area). 
Faster aspart or NovoRapidÂ® should be injected subcutaneously into the abdominal wall.
Rotation of injection sites within a given region is recommended.
2.2 Time of injection
Insulin degludec should be administered once daily at any time of the day, preferably at the same 
time every day.
Faster aspart or NovoRapidÂ® should be given 0-[ADDRESS_1187614], lunch and main evening meal. Extra bolus dosing is allowed at 
the Investigatorâ€™s recommendation.CONFIDENTIAL
Trial ID: NN1218-4113
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Protocol - Appendix A Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 5 of 9
3 Initiation and titration
3.1 Initiation of insulin degludec (Visit 2) 
Subjectsâ€™ previous basal insulin should be switched to insulin degludec once daily on unit-to-unit
basis at Visit 2 by [CONTACT_737]â€™s discretion. However, when switching from ToujeoÂ®or twice 
daily basal insulin, 20% dose reduction in basal dose should be considered. 
3.2 Titration insulin degludec during run-in
Insulin degludec dose will be adjusted weekly by [CONTACT_853308]-in period in connection 
with the scheduled visit/phone contacts.
The dose of insulin degludec should be titrated based on the mean of three pre-breakfast SMPG
values measured on the three days prior to the contact [CONTACT_853309] [ADDRESS_1187615] the postprandial glucose excursions.
If one or more SMPGs values are missing, the adjustment should be performed on the remaining 
SMPG value(s).
If one of the SMPG values is below target (< 4.0 mmol/L or 71 mg/dL) then the insulin degludec 
dose should be reduced in accordance with Table [ADDRESS_1187616] SMPG Values Increase of insulin degludec dose 
mmol/L mg/dL U
4.0 â€“ 5.0 71 â€“ 90 No adjustment
5.1 â€“ 7.0 91  â€“ 126 + 2
7.1 â€“ 8.0 127 â€“ 144 + 4
8.1 â€“ 9.0 145 â€“ 162 + 6
> 9.0 > 162 + 8CONFIDENTIAL
Trial ID: NN1218-4113
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Protocol - Appendix A Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187617] SMPG Value Reduction of insulin degludec dose 
mmol/L mg/dL U
3.1 â€“ 3.9 56 â€“ 70 - 2
<3.1 < 56 - 4
3.3 Treatment with bolus insulin during run-in
Subjects should continue their pre-trial bolus insulin analogue with or without metformin at Visit 2, 
and no adjustments of bolus insulin should be performed by [CONTACT_853310]-in period.
3.4 Initiation of faster aspart or NovoRapidÂ®at Visit 14
Subjects should be switched to faster aspart or NovoRapidÂ®(blinded) unit-to-unit from previous 
mealtime bolus doses at Visit 14 by [CONTACT_737]â€™s discretion.
3.5 Titration of faster aspart or NovoRapidÂ®from randomisation (Visit 14) 
Titration of bolus insulin (faster aspart or NovoRapidÂ®) should be performed from randomisation 
(Visit 14) and onwards while no adjustments of basal insulin dose(s) should be performed by [CONTACT_853311].
Subjects will be instructed to perform 4-point prof iles at pre-breakfast, pre-lunch, pre- main evening 
meal and bedtime every day during the conduct of the trial for titration purposes.
Faster aspart or NovoRapidÂ®should be titrated twice weekly to reach the glycaemic target of pre-
prandial and bedtime plasma glucose between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target 
fashion. 
1) At the scheduled visit/phone contact, adjustment of faster aspart or NovoRapidÂ®doses should 
be performed by [CONTACT_853312]-prandial and/or bedtime SMPG values which 
are measured during last 3-4 days before each scheduled visit/phone contact.
2) In between the scheduled visit/phone contacts the subject should be instructed by [CONTACT_853313]-titrate faster aspart or NovoRapidÂ®
doses based on SMPG values measured on the remaining 4 â€“ 3 days between scheduled visits/phone contacts.
The adjustments should be according to Table 3
!Breakfast faster aspart or NovoRapidÂ®will be titrated according to pre-lunch SMPG values 
measured on previous daysCONFIDENTIAL
Trial ID: NN1218-4113
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Protocol - Appendix A Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 7 of 9
!Lunch faster aspart or NovoRapidÂ®will be titrated according to pre-dinner SMPG values 
measured on previous days 
!Main evening meal faster aspart or NovoRapidÂ®will be titrated according to bedtime SMPG
values measured on previous days
Table 3 Faster aspart or NovoRapidÂ®dose adjustment algorithm
Pre-prandial or bedtime SMPG Values Dose adjustment
Rules for dose adjustment
mmol/L mg/dL U
< 4.0 < 71 - 1 â‰¥ 1 SMPG below target
4.0 â€“ 6.0 71 -108 0 0-1 SMPG above target
No SMPGs below target
> 6.0 > 108 + 1 â‰¥ 2 SMPGs above target
No SMPGs below target
Additional bolus dosing is allowed at the investigatorâ€™s recommendation. The dose will be entered 
in the eDiary â€˜extra bolus insulinâ€™.
3.[ADDRESS_1187618] the insulin degludec, faster aspart or NovoRapidÂ®doses are based on all relevant information 
as described in Section 3. A reason for deviating from the algorithm should be entered into the 
eDiary web portal by [CONTACT_853314].CONFIDENTIAL
Trial ID: NN1218-4113
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Protocol - Appendix A Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 8 of 9
4 Data collection
The titration data and hypoglycaemic ep isodes should be entered into the eDiary within 24 hours 
(for details referring to Protocol).
If titration data on a subject is missing then the Investigator will be asked for the reason.
[ADDRESS_1187619]â€™s next site visit/phone contact. The aim is to reduce 
the time periods in which a subject may receive suboptimal treatment.
The titration data should be reviewed by [CONTACT_41194] 24 hours (on weekdays). The 
reviewer may contact [CONTACT_826726].
When the investigator receives an inquiry, a response should be received at Novo Nordisk within 24 
hours (on weekdays). 
During the trial HbA 1cwill be monitored by [CONTACT_826727]. Novo Nordisk may be in contact [CONTACT_190063] (visit or phone contact) to discuss 
progress in glycaemic control and titration of individual subjects based on SMPGs and HbA 1c. This 
will be done in an unbiased and whenever possible in a blinded manner.CONFIDENTIAL
Trial ID: NN1218-4113
CONFIDENTIALDate: 28 March 2017 1RYR1RUGLVN
Protocol - Appendix A Version: 2.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 9 of 9
6 References 
1. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 
52-week, treat-to-target trial comparing insulin detemir with insulin glargine when 
administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 
diabetes. Diabetologia 2008; 51(3):408-416.
2. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, 
randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as 
add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. 
Diabetes Care 2006; 29(6):1269-1274.
3. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. 
Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral 
antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006; 28(10):1569-1581.
4. Riddle et al. The Treat-to-Target Trial. Randomized addition of glargine or human NPH 
insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26(11): 3080-3086.
5. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, MuÃ±oz-Torres M, Rosenstock J, 
Endahl LA, Francisco AM, Hollander P: Insulin degludec, an ultra-long acting basal insulin, 
versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 
diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target 
non-inferiority trial. Lancet. 2012 Apr 21;379(9825):1498-507.
6. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, 
Philotheou A, Francisco AM, Pei H, Bode B: Insulin degludec, an ultra-long acting basal 
insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 
1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target 
non-inferiority trial. Lancet 2012 Apr 21;379(9825):1489-97.CONFIDENTIAL
Trial ID: NN1218-4113
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Protocol - Appendix A Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 1 of 9
Appendix A: Titration Guideline
Trial ID: NN1218-[ADDRESS_1187620]-acting Insulin Aspart Compared to 
NovoRapidÂ®both in Combination with Insulin Degludec with or 
without Metformin in Adults with Type 2 Diabetes (onsetÂ®9)
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
partiesCONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Trial ID: NN1218-4113
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Protocol - Appendix A Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187621] of in-text tables ......................................................................................................... ...........................2
1 Introduction .................................................................................................................. .......................3
2 Treatment regimens............................................................................................................ .................4
2.1 Injection area .............................................................................................................. ..............4
2.2 Time of in jection .......................................................................................................................4
3 Initiation and titration ...................................................................................................... ...................5
3.1 Initiation of insulin degludec (Visit 2) .......................................................................................5
3.2 Titration insulin degludec during run-in .....................................................................................5
3.3 Treatment with bolus insulin during run-in ................................................................................6
3.4 Initiation of faster aspart or NovoRapidÂ®at Visit 14 ..................................................................6
3.5 Titration of faster aspart or NovoRapidÂ® from randomisation (Visit 14) .....................................[ADDRESS_1187622] of in-text tables
Page
Table 1 Increase of insulin degludec Dose....................................................................................... .......5
Table 2 Reduction of insulin degludec Dose...................................................................................... .....6
Table 3 Faster aspart or NovoRapidÂ® dose adjustment algorithm ............................................................7CONFIDENTIAL
Trial ID: NN1218-4113
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Protocol - Appendix A Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187623] shown that this is difficult to achieve, unless plasma glucose (PG) values are intensively monitored and the insulin dose(s) frequently adjusted 
1-6.
To ensure treatment uniformity between the sites, as well as to ensure that subjects receive an 
optimal treatment, titration algorithms have been developed specifying recommended dose adjustments at different PG levels.
It is recognised that treatments differ between different regions and countries. Likewise, specific 
titration guidelines may not be applicable in certain clinical situations. It is important that other 
information, such as symptoms of hypo/hyperglycaemia, previous response to dose adjustments, other glucose measurements and other indicators of the subjectâ€™s level of glycaemic control, is taken into consideration when decisions on dosing are made. The investigator should always use his 
clinical judgement to avoid safety hazards. The investigator is responsible for the treatment of the 
subjects and can therefore overrule the guideline.
To optimise and maintain glycaemic control, the Investigator should, throughout the trial be at least 
in weekly contact [CONTACT_853306]â€™s welfare.CONFIDENTIAL
Trial ID: NN1218-4113
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Protocol - Appendix A Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 4 of 9
2 Treatment regimens
All subjects will be treated with insulin degludec and NovoRapidÂ®/fast-acting insulin aspart (faster 
aspart) in a basal-bolus regimen.
At Visit 2 eligible subjects will be transferred from their previous basal insulin dose to insulin 
degludec once daily according to  Section 3.1.
During the following 12 weeks the Investigator will focus on adjusting the basal insulin dose 
according to Section 3.2.
In addition, the subjects will continue their pre -trial bolus insulin analogue with or without 
metformin at Visit 2. No adjustments of bolus insulin should be performed by [CONTACT_853307]-in period.
At randomisation (after 12 weeks) eligible subjects will be randomised 1:1 into two parallel 
treatment groups:
1. mealtime faster aspart + insulin degludec
2. mealtime NovoRapidÂ®+ insulin degludec
During the following 16 weeks treatment period the Investigator will focus on adjusting the bolus
insulin dose according to Section 3.5.
2.1 Injection area
Insulin degludec should be injected subcutaneously  into the thigh, or upper arm (deltoid area). 
Faster aspart or NovoRapidÂ® should be injected s ubcutaneously into the abdominal w all.
Rotation of injection sites within a given region is recommended.
2.2 Time of injection
Insulin degludec should be administered once daily at any time of the day, preferably at the same 
time every day.
Faster aspart or NovoRapidÂ® should be gi ven 0-[ADDRESS_1187624], lunch and main  evening meal. Extra bolus dosing is allowed at 
the Investigatorâ€™s recommendation.CONFIDENTIAL
Trial ID: NN1218-4113
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Protocol - Appendix A Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 5 of 9
3 Initiation and titration
3.1 Initiation of insulin degludec (Visit 2) 
Subjectsâ€™ previous basal insulin should be switched to insulin de gludec once daily on unit-to-unit
basis at Visit 2 by [CONTACT_737]â€™s discretion. However, when switching from ToujeoÂ®or twice 
daily basal insulin, 20% dose reduction in basal dose should be considered. 
3.2 Titration insulin degludec during run-in
Insulin degludec dose will be adjusted weekly by [CONTACT_853308]-in period in connection 
with the scheduled visit/phone contacts.
The dose of insulin degludec should be titrated based on the mean of three pre-breakfast SMPG
values measured on the last two days prior to and on the day of con tact in accordance with Table [ADDRESS_1187625] the postprandial glucose excursions.
If one or more SMPGs values are missing, the adjustment should be performed on the remaining 
SMPG value(s).
If one of the SMPG values is below target (< 4.0 mmol/L or 71 mg/dL) then the insulin degludec 
dose should be reduced in accordance with Table [ADDRESS_1187626] SMPG Values Increase of insulin degludec dose 
mmol/L mg/dL U
4.0 â€“ 5.0 71 â€“ 90 No adjustment
5.1 â€“ 7.0 91  â€“ 126 + 2
7.1 â€“ 8.0 127 â€“ 144 + 4
8.1 â€“ 9.0 145 â€“ 162 + 6
> 9.0 > 162 + 8CONFIDENTIAL
Trial ID: NN1218-4113
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Protocol - Appendix A Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: [ADDRESS_1187627] SMPG Value Reduction of insulin degludec dose 
mmol/L mg/dL U
3.1 â€“ 3.9 56 â€“ 70 - 2
<3.1 < 56 - 4
3.3 Treatment with bolus insulin during run-in
Subjects should continue their pre-trial bolus insulin analogue with or without metformin at Visit 2, 
and no adjustments of bolus insulin should be performed by [CONTACT_853315]-in period.
3.4 Initiation of faster aspart or NovoRapidÂ®at Visit 14
Subjects should be switched to faster aspart or N ovoRapidÂ®(blinded) unit-to-unit from previous 
mealt ime bolus doses at Visit 14 by [CONTACT_737]â€™s discretion.
3.5 Titration of faster aspart or NovoRapidÂ®from randomisation (Visit 14) 
Titration of bolus insulin (faster aspart or NovoRapidÂ®) should be performed from randomisation 
(Visit 14) and onwards while no adjustments of basal insulin dose(s) should be performed by [CONTACT_853311].
Subjects will be instructed to perform 4-point prof iles at pre-breakfast, pre-lunch, pre- main evening 
meal and bedtime every day during the conduct of the trial for titration purposes.
Faster aspart or NovoRapidÂ®should be titrated twice weekly to reach the glycaemic target of pre-
prandial and bedtime plasma glucose between 4.0- 6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target 
fashion. 1) At the scheduled visit/phone contact, adjustment of faster  aspart or NovoRapid
Â®doses should 
be performed by [CONTACT_853312]-prandial and/or bedtime SMPG values which 
are measured during last 3-4 days before each scheduled visit/phone contact.
2) In between the scheduled visit/phone contacts the subject should be instructed by [CONTACT_853316]-titr ate faster aspart or No voRapidÂ®
doses based on SMPG values measured on the remaining 3-4 days between scheduled 
visits/phone contacts.
The adjustments should be according to Table 3
!Breakfast faster aspart or NovoRapidÂ®will be titrated according to pre-lunch SMPG values 
measured on the previous three daysCONFIDENTIAL
Trial ID: NN1218-4113
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Protocol - Appendix A Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 7 of 9
!Lunch faster aspart or NovoRapidÂ®will be titrated according to pre-dinner SMPG values 
measured on the previous three days 
!Main evening meal faster aspart or NovoRapidÂ®will be titrated according to bedtime SMPG
values measured on the previous three days
Table 3 Faster aspart or NovoRapidÂ®dose adjustment algorithm
Pre-prandial or bedtime SMPG Values Dose adjustment
Rules for dose adjustment
mmol/L mg/dL U
< 4.0 < 71 - 1 â‰¥ 1 SMPG below target
4.0 â€“ 6.0 71 -108 0 0-1 SMPG above target
No SMPGs below target
> 6.0 > 108 + 1 â‰¥ 2 SMPGs above target
No SMPGs below target
Additional bolus dosing is allowed at the investigatorâ€™s recommendation. The dose will be entered 
in the eCRF â€˜extra bolus insulinâ€™.
3.[ADDRESS_1187628] the insulin degludec, faster aspart or NovoRapidÂ®doses are based on all relevant information 
as described in Section 3. A reason for deviating from the algorithm should be entered into the 
eCRF .CONFIDENTIAL
Trial ID: NN1218-4113
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Protocol - Appendix A Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 8 of 9
4 Data collection
The following data should be entered into the eCRF within 24 hours (on weekdays) after a site 
visit/phone contact:
!Per protocol pre-prandial and bedtime SMPG values measured since the last visit/phone contact 
[CONTACT_853317] 3.2and 3.5
!Basal and bolus insulin doses taken.
!New insulin doses prescribed after titration
!Reasons for deviation from the titration algorithms, if applicable
5 Review procedure
Surveillance of titration data will be performed centrally by [CONTACT_197684]. It 
is important that data regarding dose titration is entered into the eCRF within 24 hours (on 
weekdays). If delays occur, action cannot be taken in due time before the subjectâ€™s next site 
visit/phone contact. The aim is to reduce the time periods in which a subject may receive suboptimal treatment.
The data listed in section 4will be reviewed by N ovo Nordisk within 24 hours (on weekdays).
The reviewer may contact [CONTACT_853318].
When the investigator receives an inquiry, a response should be received at Novo Nordisk within 24 
hours (on weekdays). 
During the trial HbA 1cwill be monitored by [CONTACT_826727]. Novo Nordisk may be in contact [CONTACT_190063] (visit or phone contact) to discuss 
progress in glycaemic control and titration of individual subjects based on SMPGs and HbA 1c. This 
will be done in an unbiased and whenever possible in a blinded manner.CONFIDENTIAL
Trial ID: NN1218-4113
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Protocol - Appendix A Version: 4.0
UTN: U1111-1180-0636 Status: Final
EudraCT no.: 2016-000878-38 Page: 9 of 9
6 References 
1. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 
52-week, treat-to-target trial comparing insulin detemir with insulin glargine when 
administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 
diabetes. Diabetologia. 2008;51(3):408-16.
2. Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P, et al. A 26-week, 
randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as 
add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. 
Diabetes Care. 2006;29(6):1269-74.
3. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. 
Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral 
antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28(10):1569-81.
4. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine Study Investigators. The treat-to-target 
trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 
diabetic patients. Diabetes Care. 2003;26(11):3080-6.
5. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Munoz-Torres M, et al. Insulin 
degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment 
with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, 
randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498-
507.
6. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, et al. Insulin degludec, an ultra-
longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime 
insulin aspart in type 1 diabetes (BEGIN Ba sal-Bolus Type 1): a phase 3, randomised, open-
label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1489-97.CONFIDENTIAL
Global and country key Novo Nordisk staff
Attachments I and II (if applicable) to the protocol are located in the Trial Master File.
Content: Global key staff and Country key staff&21),'(17,$/'DWH 1RYR1RUGLVN
9HUVLRQ
6WDWXV)DVWDFWLQJLQVXOLQDVSDUW
7ULDO,'11&OLQLFDO7ULDO5HSRUW
$SSHQGL[-XQH

)LQDOCONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 09 June 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 1.0
UTN:U1111- 1180-0636 Status: Final
EudraCT No.:2016-000878-38 Page: 1 of 3
Protocol Amendment
no 1
to Protocol, final version 2.0
dated 28 March 2017
Trial ID: NN1218-[ADDRESS_1187629]-acting Insulin Aspart Compared to NovoRapidÂ®both in 
Combination with Insulin Degludec with or without Metformin in Adults with Type 2 
Diabetes (onsetÂ®9)
Trial phase: 3b
Applicable to all countries
Amendment originator:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment
CONFIDENTIALDate: 09 June 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 1.0
UTN:U1111- 1180-0636 Status: Final
EudraCT No.:2016-000878-38 Page: 2 of 3
Table of Contents   
Page
Table of Contents.............................................................................................................. ..........................2
1 Introduction including rationale for the protocol amendment ...........................................................3
2 Changes ....................................................................................................................... .........................3CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 09 June 2017 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 1.0
UTN:U1111- 1180-0636 Status: Final
EudraCT No.:2016-000878-38 Page: 3 of 3
1 Introduction including rationale for the protocol amendment
This global protocol amendment is made to accommodate requests from the European regulatory
authorities (Voluntary Harmonised Procedure) received during the approval process.
In this protocol amendment:
!Any new text is written in italics.
!Any text deleted from the protocol is written using strike through.
2C h a n g e s
6.[ADDRESS_1187630] with the site in relation to the trial will be considered as withdrawn from the trial (see Section 6.7).
The subject may be prematurely discontinued from trial products at the discretion of the investigator 
due to a safety concern.
The subject must be prematurely discontinued from trial products if the following applies after 
randomisation:
1. Included in the trial in violation of the inclus ion and/or exclusion criteria and/or randomised in 
violation of the randomisation criterion.
2. Pregnancy 3. Intention of becoming pregnant
4. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product
5. Lack of efficacy defined as fulfilment of all4 below criteria:
âˆ€No reduction in HbA 1cmeasured by [CONTACT_853288] (Visit 1) to visit 18, 
22 or 26 AND
âˆ€A daily average of 4-point SMPG readings (before breakfast, before lunch, before dinner 
and at bed time) on 3 consecutive days higher than 240 mg/dL (13.3 mmol/L) within the lasttwo weeks period AND
âˆ€A confirmatory FPG exceeding 240 mg/dL (13.3 mmol/L) or a confirmatory random PG
exceeding 300 mg/dL (16.7 mmol/L) measured by [CONTACT_853289]
âˆ€No treatable intercurrent cause (e.g. non-compliance) for the hyperglycaemia at the 
investigatorâ€™s judgment
6. Unacceptable adverse event (including toxicity) that cannot be solved by [CONTACT_853290]-acceptable risk at the investigator's judgment.CONFIDENTIAL
Protocol Amendment no 2
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 1.0
     Status: Final
     Page: 1 of 4
Protocol Amendment
no 2
to Protocol, version 3.0
dated 09 June 2017
Trial ID: NN1218-[ADDRESS_1187631]-acting Insulin Aspart Compared to NovoRapidÂ® both in 
Combination with Insulin Degludec with or without Metformin in Adults with Type 2 
Diabetes (onsetÂ®9)
Trial phase: 3b
Applicable to all countries
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment no 2
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 1.0
     Status: Final
     Page: 2 of 4
Table of Contents    
1 Introduction including rationale for the protocol amendment ...........................................................3
Discontinuation of the glycaemic data collection system ........................................................................3
2 Changes ....................................................................................................................... .........................3
2.1 High-level summary of changes: .............................................................................................. .3
2.2 Primary protocol sections affected .............................................................................................3CONFIDENTIAL
Protocol Amendment no 2
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 1.0
     Status: Final
     Page: 3 of 4
1 Introduction including rationale for the protocol amendment
Discontinuation of the glycaemic data collection system
Due to an unusual data reporting pattern of hypoglycaemia and glycaemic values in two ongoing 
randomised clinical trials (NN1250-4252 and NN1218-4113), Novo Nordisk has decided to 
discontinue the glycaemic data collection system (i.e. the combined use of a BG-meter and eDiary) 
in trials using this system to protect the safety  of the trial participants. This affects the 
NN1250-4252, NN1218-[ADDRESS_1187632] the 
electronic glycaemic data collection system with a paper diary solution and a new trial BG meter.
2 Changes
The discontinuation of the glycaemic data collecti on system necessitates update of many sections. 
Therefore, track-changes version of the prot ocol, titration guideline and SI-IC serves as
documentation of the changes.
2.1 High-level summary of changes:
- Replacement of eDiary requirements with paper diary requirements (in alignment with the 
protocol template) including change of trial BG-meter. Throughout the protocol â€œeDiaryâ€
has been replaced with â€œdiaryâ€
- Clarification to titration guideline section 3.[ADDRESS_1187633]
- In agreement with SI-IC SOP author it was decided to include the new statements regarding 
Personal Data Protection in the amended SI-IC according to updated SI-IC template version 10.0
- Minor clarifying updates to protocol text
2.2 Primary protocol sections affected
- 2 Flowchart
- 8.1.2 Run-in- 8.1.9 Premature discontinuation of trial products
- 8.1.11 Review of results
- 8.3.2 Discontinuation of MyGlucoHealth BG-meter and eDiary (new section)- 8.3.3 Self-measured plasma glucose
- 8.3.4 Insulin dose
- 8.4.2 Hypoglycaemic epi[INVESTIGATOR_853248] 2
CONFIDENTIALDate: 23 Fe bruary 2018 1RYR1RUGLVN
Trial ID: NN1218-4113 Version: 1.0
     Status: Final
     Page: 4 of 4
- 8.6.3 Diary
- 9.5 Auxiliary supplies
- 12.4.1 Reporting of technical complaints- 12.4.2 Collection, storage and shipment of technical complaint samples- 13.1 Corrections to case report forms
- 14 Monitoring procedures
- 16 Computerised systemsCONFIDENTIAL